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ABSTRACT  
Inter-individual variation in pharmacokinetic parameters of drugs can 
have profound effects on drug safety in children. Midazolam and 
morphine are among the most commonly used drugs in critically 
children. Theophylline has seen several cycles of enthusiasm and 
unpopularity over the years, although oral theophylline is now rarely 
used, IV aminophylline is still used regularly in severe asthma. These 
drugs are metabolised by hepatic enzymes (CYP3A4, CYP1A2 and 
glucuronidation) which have variable expression. Three systematic 
reviews were conducted in order to explore the inter-individual 
variation of clearance of these drugs in children.  
The first systematic review evaluated the inter-individual variability of 
midazolam clearance in children. Midazolam is predominantly 
metabolised by CYP3A4. Twenty two PK studies were identified. The 
mean clearance of midazolam varied between 0.78 to 3.5 ml/min/kg 
in neonates and 1.1 to 15 ml/min/kg in children. Age was a 
statistically significant predictor of clearance (p<0.05). Critical illness 
was however not a statistically significant predictor of midazolam 
clearance after adjusting for other covariates (p=0.279). There was a 
statistically significant difference between the coefficient of variation 
of midazolam clearance in preterm neonates (91%) and children 
(40%) (p=0.002). However, there was no significant difference 
between the CV in critically ill and non-critically ill children. 
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A second systematic review evaluated the variability of theophylline 
clearance. Theophylline is metabolised by CYP1A2. Twenty nine 
studies were identified. Mean clearance of theophylline varied 
between 0.2 and 2 ml/min/kg. Age was a significant predictor of 
theophylline clearance (p<0.05). There was, however, no significant 
difference between the CV of theophylline in any age group. The CV 
of theophylline clearance was not significantly different between 
critically ill (35%) and non-critically ill (39%) (p=0.403). A sub-
analysis of children also did not show any significant difference 
between critically ill and non-critically ill (p=0.418). 
A third systematic review evaluated the variability of morphine 
clearance in children. Morphine is metabolised by UGT. Twenty 
studies were identified. The mean clearance of the studies identified 
varied between 2 and 16 ml/min/kg in neonates and 19 to 52 
ml/min/kg in children. Critical illness was not a statistically significant 
predictor of morphine clearance. Analyses of the limited data showed 
no statistically significant differences in CV between any age groups. 
There was also no statistically significant difference between the CV 
in critically ill and non-critically ill children. 
In all the studies, a major limitation was the limited number of PK 
studies in children. Invasive studies should be avoided in children 
therefore, a final systematic review evaluated the invasiveness of PK 
studies over two decades. The number of blood samples collected per 
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child was significantly lower in studies carried out between 2004-
2014 than those between 1981-1990 (p=0.013). Furthermore, the 
total volume of blood collected in 24 hours for PK studies was 
significantly lower in new decade than old (p=0.025). However, there 
was no difference in the volume of blood collected per sample. There 
were 35 population PK studies, all of which were new studies. The 
median number of blood samples in population PK studies (median 6, 
[IQR: 4-9]) was significantly lower than non-population PK studies 
(median: 8, [IQR: 6-10]) (p=0.007). 
In conclusion, age is a risk factor for inter-individual variation of 
midazolam clearance in children.  It is also an important predictor of 
midazolam, morphine and theophylline clearance in children. 
Therefore, age appropriate dosing is important. More PK studies are 
required to determine the effect of critical illness on the variability of 
clearance of these drugs. The utilisation of population PK methods 
should be encouraged to minimise invasiveness of PK studies. New 
methodologies for reducing sample volumes and frequency should be 
considered in all studies. 
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1. CHAPTER ONE                                                                               
GENERAL INTRODUCTION AND OVERVIEW 
1.1. Introduction  
Pharmacokinetics (PK) and pharmacodynamics (PD) describe how a 
drug interacts with the human body. PK describes the process of  
absorption, distribution, metabolism and elimination (ADME) of drugs 
(1);while PD is concerned with the relationship between drug 
concentration and its pharmacological response (2). The human body 
handles drugs in different ways; hence, the variability in PK 
parameters for different people. Since individuals may vary in how 
they absorb, metabolise and eliminate drugs, the dosing of some 
drugs should be individualised. This is the core principle of clinical PK, 
which is the application of PK principles for managing patients 
individually (3). These types of practices will improve a drug’s 
efficacy and reduce its toxicity (3). 
1.2. Pharmacokinetic Mechanisms  
1.2.1.  Absorption  
Most drugs prescribed for children are administered by an oral 
formulation. The process of absorption is complex and several factors 
are responsible for the inter-individual variation. Gastric pH is a major 
determinant of drug absorption. Gastric pH determines the degree of 
ionisation and stability of drugs. It is age dependant and usually 
neutral at birth before decreasing to 3 at 24-48h postpartum. It 
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increases to become neutral at about 10 days with subsequent 
decline to acidity at two years (4, 5). There is a gradual decline in 
intestinal permeability, which is initially high at birth. The decline is 
seen in the first week of life possibly due to reduced surface area (6). 
Weakly basic drugs such as Itroconazole tend to dissolve slowly at a 
higher pH (7). Gastric emptying time and intestinal transit time were 
also noted to be the major determinants of absorption and 
bioavailability. For example theophylline is a poorly soluble drug 
therefore its absorption is lower in young children with rapid intestinal 
time (7).  Furthermore, gastric pH in neonates is usually higher than 
the pH in infants and children (5). 
1.2.2.    Distribution  
Drug distribution occurs after absorption when the drug enters the 
systematic circulation. The volume of distribution (Vd) is the apparent 
volume into which the drug would have to distribute to achieve the 
measured concentration (8).  
Distribution is affected by a combination of several factors and varies 
considerably with age, protein binding, body fat, body water and 
differences in membrane permeability. Lipid and water solubility 
affect the volume of distribution (8). It is lower for drugs that are 
water soluble, for example gentamicin. In contrast water soluble  
drugs for example chloroquine have a high volume of distribution (8). 
There is a marked difference in total body water and fat content in 
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neonates and adults (Figure 1.1). Total body water in neonates is 
about 85-90% and fat content is 10-15%, while total body water 
reduces to about 60% in adults (9, 10). Furthermore, extracellular 
water in neonates is higher (45% of body weight) compared to adults 
(20%)(9, 10).  Therefore lipid soluble drugs, such as diazepam, have 
a lower volume of distribution in neonates than adolescents (7). 
 
 
             Figure 1. 1: Developmental Changes in Distribution Sites 
                      This figure adapted from Kearns et al. (2003) (10). 
 
1.2.3.   Metabolism 
1.2.3.1.   The metabolising enzymes 
Several enzymes are involved in drug metabolism (Table 1.1). 
Although the liver is the most important organ for drug metabolism, 
several other organs such as the kidneys and the intestines also 
contribute to the process.  Developmental changes in these organs 
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affect metabolism. While the hepatic metabolising enzymes are 
mainly located in the smooth endoplasmic reticulum of the 
hepatocytes, some are also present in the mitochondria as well as the 
cytosol. Oxidation by the cytochrome P450 (CYP) enzymes contribute 
to the majority of the metabolic process in the liver, accounting for 
up to 75% of drug metabolism (11).  
CYPs are a large family of enzymes with different subfamilies playing 
overlapping and sometimes distinct roles in drug metabolism, as well 
as the metabolism of other endogenous compounds. Other important 
enzymes in the metabolic process include: the reductive enzymes 
(aldo-ketoreductases), hydrolytic enzymes (esterases), N-acetyl 
transferases, methyl transferases, glucronyltransferases, 
sulfotransferases and thiopurine S-methyltransferase (TPMT)(12, 13). 
Genetic influences can also been seen in these enzyme group; 
acetylation by N-acetyltransferase (NAT) depends on two genes, 
NAT1 and NAT2. Fast and slow acetylators can be identified by NAT2 
gene analysis (14).  
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Table 1. 1: Examples of substrate drugs for selected drug-metabolising enzymes   
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4/5 UGT2B7 TPMT NAT2 
Haloperidol Diclofenac Omeprazole Haloperidol Midazolam Morphine Azathioprine hydralazine 
Caffeine Ibuprofen Diazepam Risperidone Alprazolam Chloramphenicol 6-mercaptopurine Isosorbide 
Theophylline Naproxen Phenytoin Amitriptyline Cyclosporine Ketoprofen 6-thioguanine Isoniazid 
Naproxen Celecoxib Phenobarbitone Clomipramine Tacrolimus All- trans retinoic acid Cisplatin - 
Clozapine Phenytoin Cyclophosphamide Desipramine Indinavir - - - 
Duloxetine Tolbutamide Amitriptiylline Imipramine Ritonavir - - - 
Fluvoxamine Losartan Clomipramine Paroxetine Saquinavir - - - 
- Fluvastatin Voriconazole Dextromethorphan Nifedipine - - - 
- Sulfamethoxazole - Flecainide Amlodipine - - - 
- Warfarin - Codeine Verapamil - - - 
- - - Tramadol - - - - 
- - - - - - - - 
- - - - Clarithromycin - - - 
- - - - Erythromycin - - - 
TPMT, thiopurine S-methyltransferase; UGT, UDP-glucuronosyltransferases; NAT, N-acetyltransferases; CYP, cytochrome P450 
This table adapted from de Wildt et al. (2014)(15). 
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1.2.3.2.   CYP drug metabolism 
CYP450 is involved in the metabolism of both endogenous and 
exogenous substances. Hormones, growth factors, prostaglandins and 
bile are all examples of the endogenous substrate of CYP. Although 
there are about 57 functional enzymes in the CYP superfamily, seven 
of the isoenzymes are involved in about 95% of CYP metabolism. 
These isoenzymes are: CYP1A2, CYP1A6, CYP2D6, CYP3A4, CYP2B6, 
CYP2C9 and CYP2C19 (16). These enzymes are mainly localised in 
the liver, the chief organ for drug metabolism.  
There are inter-individual differences in the expression of these 
enzymes, with a resultant effect on drug metabolism and efficacy. 
Furthermore, there are developmental changes in CYP expression 
throughout the course of a human’s lifetime.  
1.2.3.3.   Drug interactions 
CYPs are involved in several clinically important drug-drug 
interactions that can increase the risk of adverse reactions or reduce 
drug efficacy. CYP3A4 is the main enzyme involved in drug-drug 
interaction (Tables 1.2 and 1.3). Several drug interactions have been 
described in the literature. Examples of frequently prescribed enzyme 
inducers include phenobarbital, carbamazepine and phenytoin; while 
enzyme inhibitors include clarithromycin, erythromycin and 
omeprazole.  
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    Table 1. 2: Frequently prescribed CYP inducing drugs used by children 
Inhibitor Enzyme inhibited 
Clarithromycin CYP3A4 
Erythromycin CYP3A4 
Itroconazole CYP3A4 
Ketoconazole CYP3A4 
Voriconazole CYP3A4 
Esomeprazole CYP2C19 
Pantoprazole CYP2C19 
Omeprazole CYP2C19 
Grapefruit juice CYP3A4 
This table adapted from de Wildt et al. (2014) (15).  
 
     Table 1. 3: Frequently prescribed CYP inhibiting drugs used by children 
Inducer Enzyme induced 
Phenobarbital Multiple CYPs 
Rifampin Multiple CYPs 
Dexamethasone CYP2D6 
Carbamazepine Multiple CYPs 
Phenytoin Multiple CYPs 
Ethanol CYP2E1 
St John’s wort CYP3A4s 
CYP,Cytochrom P450 
This table adapted from de Wildt et al.(2014) (15).  
 
CYP3A is the only subfamily of CYP3. It has four different genes, 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43, which are located on 
chromosome 7 (17). They account for the metabolism of up to 50% 
of drugs in clinical use (18). CYP3A4 is the most expressed of the four 
genes; it is preferentially involved in the metabolism of large 
lipophilic drugs, such as midazolam and erythromycin (19). 
Population variability of CYP3A4 has been reported to be more than 
100-fold (20). Multiple of factors such as genetic polymorphism, 
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environmental factors, circulating endogenoeous molecules,  gender, 
induction and age are responsible for this variability (21). Wolbold et 
al. (2003) and Cotreau et al. (2005) reported differences in CYP3A4 
expression in males and females (22, 23). Females usually have 
higher enzyme activity than males (24). 
Therefore, polymorphism in CYP3A4 gene expression is a major cause 
of inter-individual variation. Single nucleotide polymorphism (SNP) in 
the 5І–flanking region of the CYP3A4 gene have been reported (25). 
The most common mutation is CYP3A4*1B, which is frequently 
reported among African-Americans (up to 50%), while it is often 
absent among people of Japanese and Chinese descent (16). CYP3A4 
and CYP3A5 are almost identical, with more than 85% similarity in 
their amino acid sequences. Therefore, these enzymes also share 
similar substrate selectivity (19). The CYP3A5*3 allele is the most 
common type of CYP3A5 mutation, and similar to CYP3A4*1B, it is 
more prevalent among African-Americans (55%). Between 10-20% of 
Caucasians have been reported to have this mutation (21). CYP3A5 
highly expressed in children, its level decreases to about 30% in 
adults (26, 27). Similarly, CYP3A7 is fully expressed in early neonatal 
life but becomes undetectable in adults. However, CYP3A4 is not fully 
expressed until after birth. It reaches 30% of adult levels one month 
after birth and to adult levels within three months of birth (28). 
 
9 
 
There are two subfamilies of CYP1: 1A and 1B. CYP1A has two 
isoforms, 1A1 and 1A2. Age, gender and enzymatic induction are 
common causes of variability in the expression of these enzymes. 
CYP1A2 metabolises several clinically important drugs, such as 
theophylline: acetaminophen, clozapine, propranolol and duloxetine 
(29-31). It is inducible by both phenobarbital and phenytoin (32) and 
for different substrates, including caffeine, the activity of CYP 1A2 has 
been reported to be higher in males than females (33). Although, 
polymorphism is common in the CYP1 family, its effect on drug 
metabolism is still largely unclear. CYP1A is extremely low in the 
neonates, and increases to about 25% of adult levels when the child 
is 1-year old; by the third year of life adult levels are attained (34). 
Theophylline is mainly metabolised by CYP1A2 (31). Therefore, in 
accordance with the level of hepatic expression, and subject to the 
presence of other minor metabolising enzymes, its clearance in 
neonates is about 50% of the adult level, increasing to 150% of adult 
levels by the age of 5 years before subsequently declining to adult 
levels in adolescence (35). 
The two most common genes in the CYP2C subfamily are the CYP2C9 
and CYP2C19. Both of these genes have a similar position on the 
chromosome. CYP2C9 and CYP2C19 are highly polymorphic. 
CYP2C9*2 and CYP2C9*3 are the two most common variants of the 
2C9, with prevalence varying across different ethnicities. CYP2C9*2 is 
extremely rare among Chinese and Japanese people, but seen in 7-
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16% of Caucasians (36). However, CYP2C19 polymorphism is more 
common in the Asian population than Caucasians (37). Despite their 
close genetic similarity, these enzymes have substrate specificity: 
CYP2C9 for weakly acidic molecules, e.g. diclofenac and phenytoin; 
and CYP2C19 for neutral or weakly basic molecules, e.g. proton pump 
inhibitors (19). Poor metabolisers have been reported to have as 
much as 15-fold increase in the omeprazole concentration than 
extensive metabolisers and consequently have a better H.Pylori 
eradication rate (38). Phenytoin is a substrate that is common to 
both enzymes, Odani et al. (1997) found that the elimination rate of 
phenytoin was 33% lower among individuals with CYP2C9*1/*3 
alleles compared with those with homozygous CYP2C9*1. This effect 
was not seen with CYP2C19 polymorphism (39).  
1.2.3.4.   UGT drug metabolism 
UDP-glucuronosyltransferase (UGT) is one of the major drug 
metabolising enzymes. It catalyses the glucuronidation reaction, 
which involves the conjugation of glucuronic acid to substrate drugs 
(40). Glucuronic acid is derived from the cofactor UDP-glucuronic 
acid. UGT enzymes are a superfamily of enzymes, with distinct or 
overlapping substrate specificity. They are located in the smooth 
endoplasmic reticulum and the cell nucleus mainly in the liver, but 
are also expressed in the kidneys and the gastrointestinal tract (GI) 
(41). The majority of UGTs are expressed in the human liver, with 
11 
 
UGT1 and UGT2 being the most important family of enzymes (42). 
There is inter-individual variability in the expression of UGT, although 
the factors responsible for this are mostly unknown. Epigenetic 
regulation has been identified as a cause of variability of UGT1A10 in 
the liver and UGT1A1 in the kidneys (43). Age is also a major 
determinant of UGT expression and the time taken for the different 
forms of the enzymes to attain full maturity varies from 3-6 months. 
The maturation rates also vary between individuals (43). Early 
neonatal UGT deficiency is responsible for the developmental of 
adverse events like the grey baby syndrome, which is associated with 
chloramphenicol (44). 
UGT substrates are as varied as the enzymes. Although the most 
commonly expressed isoforms are UGT2B4 (34-55%) and UGTB10 
(5-19%) (45, 46), several clinically important drugs are metabolised 
by the less predominant forms. UGT1A3 and UGT1A4 metabolises 
lamotrigine (47), UGT1A6 and UGT1A9 metabolises paracetamol and 
propofol respectively (48, 49); morphine and naloxone are substrate 
drugs for UGT2B7 (50). Morphine is glucuronidated to an active 
metabolite (M6G) and an inactive metabolite (M3G) by UGT. Some 
drugs are capable of inducing the enzymes and they are involved in 
clinically relevant drug-drug interactions, such as the interactions 
between valproic acid (an inducer) and lamotrigine (a substrate)(51).  
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1.2.3.5.   Ontogeny of hepatic metabolism  
Hepatic metabolising enzymes undergo developmental transition. 
Several of these enzymes are present in the foetal liver as early as 8 
weeks of gestation and their activity generally increases throughout 
pregnancy and beyond the postnatal period (Figure 1.2)(28). CYP3A7 
is the most common enzyme expressed during the embryonic and 
foetal period. Its expression increases throughout gestation and 
peaks during the perinatal period (28).  
 
        Figure 1. 2: Metabolic capacity in children  
                           This figure adapted from Kearns et al.(2003) (10). 
A shift towards greater CYP3A4 expression also occurs during the 
immediate postnatal period, and the enzyme ultimately becomes the 
most predominant hepatic enzyme expressed postnatally. Lacroix et 
al. (1997) reported that CYP3A4 levels in foetuses of <30 weeks was 
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about 10% of adult levels; while expression increased to 20% of 
adult levels beyond 30 weeks gestational age (28). By 6-12 months, 
CYP3A4 rises to about half the adult levels (28). Delayed CYP3A4 
expression results in decreased clearance of CYP substrates, such as 
midazolam, seen in early infancy (52).  
CYP1A enzymes are expressed at very low levels in the foetal liver.    
Bieche et al. (2007) were unable to demonstrate the expression of 
the enzymes in foetus aged 22-44 weeks (53). Postnatally, CYP1A2 
expression has been shown to increase to 5% of adult levels in 
neonates and rises to 10% of adult levels in infants 1-3 months old; 
25% of the adult levels is attained by 12 months (34). Several 
factors, including nutrition, influence the rate of enzyme maturation 
postnatally. Enzyme activity has been shown to be faster among 
formula fed infants than those receiving breast milk. The half-life of 
caffeine is shorter in formula fed than breast fed infants (54).  
During foetal life, CYP2C19 is the dominant isoform of the CYP2C 
subfamily with 10-20% of adult levels expressed at birth. It increases 
to about 75% of adult levels by 5 months of life (55). CYP2C9 level 
also rises rapidly postnatally and adult levels are attained by 1-6 
months of age. Adult levels are exceeded in children 3-10 years old, 
before returning to adult levels at puberty (56). 
UGT activity is low in foetuses, but increases rapidly postnatally. In 
vitro studies of foetal liver (15-27 weeks) have shown UGT2B7 levels 
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(involved in morphine metabolism) to be up to 20% of adult levels; 
while adult levels are attained by 3 months of life (57). This 
developmental change may be partly responsible for the much lower 
morphine clearance in preterm neonates than children and 
adolescents (58). UGT1A3 levels in the foetus are 30% of adult 
levels; while the expression of UGT1A6 in foetal liver is less than 
10%, reaching 50% at 6 months. UGT1A1, responsible for bilirubin 
conjugation is largely undetectable in the foetal liver (55). 
CYP2D6 is a polymorphic enzyme involved in the metabolism of about 
12% of clinically important drugs (55). Similar to most CYP enzymes, 
there is an age dependent increase in enzyme levels. It is minimally 
expressed in preterm neonates and in early neonatal life. About 1% 
of adult levels seen in foetuses rises to 20% by 28 days (59). By age 
5, 70% of adult levels is attained (60) and full adult levels are seen 
by age 10  (56). Adult levels of CYP2E1 are also attained by the age 
of 10 years up from 10% seen at birth and 30% in infancy  (61).  
1.2.4.   Excretion  
There are three major components of drug excretion. These are the 
glomerular filtration rate (GFR), tubular secretion and passive 
reabsorption. Developmental changes in renal function occur across 
paediatric age groups (62) and these changes may affect plasma 
clearance. Generally, the kidneys are immature at birth but renal 
function improves over time (Figure 1-3)(63). For instance, 50% of 
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adult GFR is attained by 10 weeks of life and about 90% of adult level 
seen by the first year of life (62). Apart from age-related changes in 
GFR, there have also been reports of gender differences in GFR, 
plasma creatinine in male children higher than females (64). 
Changes in tubular secretion also occur with maturity. The renal 
tubules attain full adult capacity by seven months of age (65, 66). 
The tubular secretion of certain drugs, such as imipenem, has been 
reported to exceed adult levels in children and adolescents (67). The 
effects of renal maturation on tubular reabsorption is unclear, 
however, it is believed that it increases with age. Critical illness can 
also worsen renal function in children. For example, hypoxia in 
children with asphyxia can result in renal dysfunction and cortical 
necrosis (68). These three mechanisms involved in drug excretion 
can have a complex relationship on renal clearance of drugs in 
children across the paediatric age groups. 
 
                  Figure 1. 3: Developmental changes in GFR  
                                   This figure adapted from Hines (2008)(55).   
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1.3.   Drug clearance  
Clearance refers to the removal of a drug from the body over time. It 
is usually calculated in relation to the volume of blood or plasma that 
will be totally free of the drug. 
As a major determinant of plasma drug concentration, clearance  is 
one of the most important PK parameters (69). Other important 
factors include the rate of drug administration and the volume of 
distribution. In addition to being a determinant of plasma 
concentration, clearance also determines the half-life of drugs (69). 
Although drug clearance occurs mainly through the liver and kidneys, 
other organs such as the lungs and the GI can also contribute. The 
summation  of clearance from all of the different organs is referred to  
as total body clearance (70). This is represented as: 
 CL tot = CL renal + CL hepatic + CL other 
Others: sites include the lungs, muscle and blood. 
Renal clearance is determined by three major factors: the glomerular 
filtration rate, tubular secretion and tubular reabsorption. Tubular 
reabsorption is dependent on pH and renal tubular urine flow. Hepatic 
clearance refers to the elimination of drugs after transformation in 
the liver.  
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1.4.   The Effect of Critical illness on PK in Children 
1.4.1.   The critically ill child 
Critically ill children are not a homogenous population. Apart from the 
variation in clinical presentations (due to the severity of the disease 
and the presence of end organ failure), there are also differences in 
the types of diseases.  Patients loosely grouped into this category 
would normally be admitted to the Paediatric Intensive Care Unit 
(PICU). However, there is no practical definition for critical illness.  
The most common types of pathology for critically ill children include 
sepsis and respiratory diseases (71). Inter-individual differences in 
pathology have profound implications on the patients’ PK behaviour. 
In addition to intrinsic factors, iatrogenic factors also contribute to 
inter-individual differences in PK behaviour. These extrinsic factors 
include mechanical ventilation, use of vasopressor drugs, intravenous 
fluid administration and extracorporeal membrane oxygenation 
(ECMO)(72). Critical illness may cause hepatic dysfunction, renal 
impairment and cardiac failure, which may lead to alteration in drug 
clearance.  
1.4.2.   Physiological changes during critical illness 
Sepsis is a common reason for PICU admission. Early sepsis is 
characterised by a hyperdynamic state, which may result in increases 
in basal metabolism, cardiac output and oxygen consumption. As a 
result of increased cardiac output, renal and hepatic perfusion is 
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increased during the early phase of sepsis (73), resulting in an  
increase in renal drug delivery and excretion (72). However, in the 
late stages of sepsis, cardiac output decreases and renal perfusion 
and drug clearance are diminished. Furthermore, diminished tissue 
perfusion can also reduce the efficacy of drugs (74).  
1.4.3.   The impact of pro-inflammatory factors on PK  
Critical illnesses, such as sepsis and advanced cancer, are 
accompanied by inflammatory responses. Evidence from both animal 
and human studies have shown significant downregulation of CYP 
activity after inflammatory response. Some of the inflammatory 
mediators associated with these effects include interleukin 1 (IL-1), 
interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis factor (TNF) 
and interferon gamma. These mediators induce the liver’s production 
of acute phase proteins, such as C-reactive protein and fibrinogen, 
while suppressing the production of the normal export proteins, 
including CYP (75). In a study by Morgan (1997), the expression of 
CYP enzymes was shown to be downregulated following the 
exogenous administration of pro-inflammatory cytokines and 
lipopolysaccharides (LPS) (76). In another study, the clearance of 
midazolam declined after proinflammatory LPS was administered to 
rats (77). Other studies have reported the effect of these mediators 
on specific CYPs. For example, in vitro studies on human hepatocytes 
have shown that IL-1, IL-6, interferon gamma and TNF specifically 
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down-regulates CYP3A4, while IL-6 and transforming growth factor β 
are specific to CYP2C9 and CYP2C19 (78).  
Only a few studies have examined the effect of inflammation on PK in 
critically ill children. A study by Petterson et al. (2009) showed a 
significant association between pantoprazole clearance and systemic 
inflammatory response in children (79). Several studies have 
explored this relationship in adults. Jones et al. (2010) showed a 
50% decline in midazolam metabolism in HIV positive adults in 
comparison to healthy adults (80). Another study also showed a 
decrease in midazolam metabolism following advanced cancer (81). A 
decline in CYP1A2 activity with a corresponding increase in IL-6 and 
TNF levels, was similarly observed after caffeine was administered to 
adults with congestive cardiac failure (82).  
1.4.4.   Critical illness and drug absorption 
The extent to which orally administered drugs are absorbed depends 
on the condition of an individual’s GI tract and the chemical 
properties of the drug. GI tract hypomotility is common in critically ill 
patients; moreover, the use of narcotics for pain relief in these 
patients may also impair GI motility. Hypomotility reduces the 
absorption of drugs; therefore, enteral administration of drugs may 
cause variability in drug bioavailability during the acute phase of 
critical illness (83). This challenge is overcome by intravenous drug 
administration in critically ill children, which precludes the absorption 
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of drugs via the intestinal membranes and also prevents first pass 
metabolism (84). 
1.4.5.   Critical illness and drug distribution 
Drug distribution is affected by several factors such as lipid solubility, 
water solubility, protein binding, tissue permeability and pH. These 
factors interact in complex ways to alter drug distribution, which may 
change during critical illness. For example, respiratory failure causes 
pH changes and consequently changes in drug ionisation and tissue 
distribution (12). Endotoxins, such as LPS from gram negative 
bacteria and lipotechoic acid (LTA) from gram positive bacteria during 
sepsis, can result in vascular dilation, endothelial damage and 
increased capillary permeability, which causes a shift of intravascular 
fluids into the interstitium. A fluid shift into the interstitial space 
causes an increase in the volume of distribution of hydrophilic drugs, 
such as β-lactam antibiotics, aminoglycosides and vancomycin (85). 
However, in general the volume of distribution in lipophilic drugs, 
such as macrolide antibiotics is unchanged because they are mainly 
sequestrated in adipose tissue (86). Plasma proteins decrease as a 
result of increased vascular leakage and decreased hepatic 
production. Hypoalbuminemia, increases the level of free unbound 
drugs that normally bind to albumin. Although alteration in plasma 
protein binding of drugs may cause changes in individual PK 
parameters, it does not affect the clinical exposure of the patient. 
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Therefore, changes in drug dosing may not be required (87). 
Interventions, such as fluid replacement and ECMO can also increase 
the volume of distribution. ECMO is the use of pumps to facilitate 
blood circulation via an artificial lung in critically ill children. In two 
separate studies, Mulla et al. (2005 and 2003) reported increased 
volume of distribution and reduced clearance in neonates receiving 
vancomycin and theophylline while on ECMO (88, 89). These changes 
are likely due to increased circulatory volume as a result of ECMO. 
 1.4.6.   Critical illness and drug metabolism 
Critical illness affects the two main physiological processes involved 
in hepatic metabolism: hepatic blood flow and hepatic enzyme 
activity. Hepatic clearance is a function of hepatic blood flow and the 
extraction ratio as follows: 
 ClH = Q x E  
Where CL is the hepatic clearance, Q is the hepatic blood flow and E 
is the extraction ratio.  
 Drugs, such as morphine and midazolam, have high extraction ratios 
(>0.7) thus, their hepatic clearance depends more on hepatic blood 
flow than on how they are metabolised.  In late sepsis, blood flow to 
the liver is significantly reduced leading to a reduction in hepatic drug 
clearance (12). However, for drugs with low extraction ratios <0.3, 
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hepatic clearance depends mainly on hepatic metabolism and the 
level of the unbound fraction of the drug, as follows: 
 CLH =fu x Clint  
Where fu is the unbound fraction and Clint is the intrinsic clearance 
(hepatic metabolism)(85).  
Inflammatory mediators are induced by the stress of a critical illness 
or are released during sepsis, and they decrease the level of the 
metabolising enzymes (90). In addition, hypoxia, which may occur in 
some critically ill children, has been shown to affect CYP, to varying 
degrees. While some studies have reported reduced CYP1A1, CYP1A2 
and CYP3A4 expression, others have reported induced CYP2C9 
expression (91). 
1.4.7.   Critical illness and drug excretion 
Renal dysfunction is common in critically ill children. This can be due 
to acute kidney injury or a pre-existing renal compromise. Renal 
clearance is an important means of drug elimination. The extent to 
which critical illness affects kidney functions varies. Patients with 
renal dysfunction usually have diminished renal clearance; however 
critically ill patients also exhibit augmented renal clearance, which 
decreases the plasma concentration of drugs. For example, septic 
patients without kidney dysfunction initially can have increased 
cardiac output leading to increased renal blood flow (73). Augmented 
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renal clearance has also been reported in patients receiving 
vasoactive drugs, which are commonly used in some critically ill 
children (86). Burns patients have also been reported to have 
increased renal clearance, while those with medical and surgical 
conditions have more variable clearance (12).    
1.5.   Dosing in children  
Dosing of drugs in children is normally based on body weight (92-94). 
It has usually been extrapolated from pharmacokinetic studies in 
adults, initially performed on healthy volunteers. Before a medicine is 
used in children, there has usually been clinical experience in adults, 
alongside scientific studies including pharmacokinetic studies in adult 
patients receiving the medication. These are adults with illnesses who 
may handle the drug differently to healthy adult volunteers. 
Pharmacokinetic studies in children are of benefit in ensuring that 
appropriate doses are given. However, doses are usually calculated 
from mean pharmacokinetic values. It is important to be aware that 
there is often significant inter-individual variation in the 
pharmacokinetics, and in particular the clearance of a medicine, due 
to factors such as age (95), weight (96), disease (97) and 
ethnicity/genotype (98) .  
In early childhood, especially in neonates and infants, physiological 
growth is rapid and pharmacokinetic changes are also rapid.  Hence, 
it is important to adjust drug dosage to reflect these changes (99). 
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Dosing in children is often extrapolated from adult studies and 
paediatric dose scaling by weight and body surface area (BSA) is 
common (94, 99). Adult dose scaling based on BSA predicts a higher 
dose for children than weight based dosing. Weight based dose 
estimation generally underestimates drug clearance in younger 
children, which may result in under dosing. Up to 10% 
underestimation of paediatric clearance values from adult values has 
been reported, hence children often require relatively higher doses 
per kg than adults (94, 100).  
BSA is a surrogate for body size and a commonly used biometric unit 
for the estimation of dose. It is useful for normalising physiologic 
parameters such as, cardiac output, left ventricular mass and renal 
clearance; because they are better correlates than other indices of 
body size (101). While this measure can be used with reasonable 
accuracy for older children, it may also cause excessive dosing in 
neonates and infants (102).  
1.6.  Methods of estimation of PK parameters  
There are two approaches to the estimation of PK parameters. Until 
more recently, the traditional (non-population) PK was the most 
common method. However, population PK is now increasingly utilised.  
Non-population PK relies on the estimation of concentration-time 
profile from each study subject, before the mean estimate is 
calculated for the population. The traditional PK is poor at identifying 
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the effects of covariates like age and weight on inter-individual 
variability. Generally, large numbers of blood samples are required 
per person and it often involves a group of healthy volunteers or 
carefully selected patients. The process is highly standardised and 
participants tend to be homogenous (103). The overall estimates may 
be inaccurate if data is sparse or missing (104). 
Population PK involves PK parameter estimation at the population 
level. This method studies the population and not the individual 
subject. Population PK estimates can be determined with or without 
PK models and the concentration-time profile for each subject can be 
described with a mathematical equation. Pharmacokinetic parameters 
are estimated  for the entire population by collecting samples from 
subjects taking different doses over different periods of time (104). A 
major advantage of population PK modelling is the ability to utilise 
sparse samples (between 2 and 3 samples). A larger number of 
subjects, than non-population PK are however required. The subjects 
are heterogeneous and are generally more representative of the 
general population. Using the appropriate approach, sources of intra 
and inter-individual variability in drug PK as well as the covariates, 
causing the variability can be easily identified (105). 
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1.6.1. PK models 
PK models use data generated from PK studies. They are of value in 
predicting the time concentration profiles of other doses of the drug 
(106). There are three main methods used in modelling data that has 
been collected from patients/volunteers. 
1.6.1.1.   Naïve pooled data approach 
This involves the pooling of time concentration data together. The 
mean plasma concentration of the drug at each time point is used to 
calculate parameter estimates (106). This method is only satisfactory 
if there are extensive data for each subject. It assumes there is minor 
inter-individual variability. It is not useful for determining inter-
individual variability or the cause of such variations (106). 
1.6.1.2.   Standard two-stage approach 
Analysis of individual profiles is undertaken. Individual PK parameters 
are then treated as variables and combined to produce mean values. 
Weighting is required if there are differences in the number of 
measures for each individual or if there is significant inter-individual 
variability (107). It may be possible to identify covariates to explain 
some of the variability (107). This is however dependent upon having 
good independent data to ensure that each individual parameter is 
calculated accurately. 
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1.6.1.3.   Mixed effect model  
These models are called “mixed effects” because they describe the 
data using a mixture of fixed and random effects (106). Fixed effects 
predict the effect of a variable such as weight. Random effects 
describe the remaining variability between subjects that is not 
predictable from the fixed effects average (106). Whereas the naive 
and standard two-stage approaches rely on a large amount of data 
from the small number of subjects, the mixed effects models can be 
used to analyse sparse data from a larger number of subjects (107). 
The most commonly used statistical program is NONMEM (the non-
linear mixed effects model). Such models allow one to study a large 
number of covariates which may affect different PK parameters. 
1.6.1.4.   PK compartments 
The choice of appropriate compartment models that best describe the 
PK behaviour of drugs in the body is essential to the estimation of PK 
parameters. One compartment model is based on the premise that 
the body is a homogenous unit. This model assumes that after 
administration, a drug is instantly distributed inside body tissues; this 
assumption implies that a change in the plasma concentration of a 
drug is accompanied by a commensurate change in tissue 
concentration, and a linear relationship is shown (108). The model 
also assumes that elimination is first order and those pharmacokinetic 
parameters, such as the elimination rate constant (ke) volume of 
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distribution and clearance, are not affected by the drug dose. In 
reality, however, only very few drugs are immediately distributed 
inside the body (108).  
The two-compartment model assumes that the body is divided into a 
central and a peripheral compartment. The central compartment 
consists of the heart, kidneys, brain, lungs and liver (109). The 
assumption of the two-compartment model is that following 
administration, a drug is distributed to both the central and 
peripheral compartments (109). The distribution rate constants out of 
the central compartment to the peripheral compartment (k21) and 
into the central from the peripheral compartment (k12) are slower 
than the elimination rate constant. In this model, the plasma 
concentration–time profile has two phases following intravenous bolus 
injection (109). The first is an initial phase (α- phase), which is the 
distribution phase, and the second is the terminal phase (β- phase), 
which is the post-distribution phase. The terminal phase is longer 
because the drug must first diffuse back from the peripheral 
compartment to the central compartment before it can be eliminated 
(109).  
Pharmacokinetics data can also be summarised without fitting into 
any type of compartment model. An advantage of the non-
compartmental model over the compartmental approaches is the 
requirement of fewer assumptions.  With this method, the area under 
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the concentration curve (AUC), clearance and half-life can be 
calculated from drug plasma concentration data. The AUC is the area 
under the plasma drug concentration versus time curve calculated by 
means of the linear trapezoidal rule or by the log-linear trapezoidal 
rule (110). Drug clearance is calculated from the dose and AUC; while 
the maximum plasma concentration (Cmax) and time to maximum 
plasma concentration (tmax) can also be determined from 
concentrations and their associated time points. Furthermore, the last 
two to four sampling time points can be used to determine the half-
life (111). 
1.6.1.5.   Model validation 
Validation of a model is required. The model should ideally be 
validated on a different group of patients to those from which the 
model was developed. Validation may also be achieved by utilising a 
randomly selected fraction (25%-50%) of the test dataset, while the 
development of the model continues with the remaining dataset. The 
results observed from validation can subsequently be compared with 
those predicted by the model (112). Internal validation is an 
important component of population PK modelling (113). Zhao et al. 
(2013) reported that all population pharmacokinetics model used in 
neonatal vancomycin studies were internally validated (114). In 
addition to internal validation, external evaluation is equally 
important as it examines the modelling procedure as well as identify 
the effect of other study-related factors. 
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1.7   Ethical considerations for invasive PK studies in children 
Like adults, children need to have research performed on the drugs 
they receive to provide a robust evidence base. Many medicines used 
in children are either off-label or unlicensed (115, 116). While it is 
important to perform invasive clinical research with children, this 
should be done in an ethical manner.  
The design  and methods of PK studies should be optimised to allow 
the smallest number of patients to be studied (117). According to the 
Royal College of Paediatric and Child Health (RCPCH) Ethics Advisory 
Committee, clinical research in children must be of a minimal or low 
risk. Research of greater risk may be considered if it involves 
diagnostic procedures or treatment which are important to the child 
and may help with the understanding of the child’s condition. 
Generally the assent of a child, in addition to the consent of their 
parents, over 7 years old should be sought (118).   
 1.7.1.   Blood sampling for PK studies  
The main methods of blood sampling include: venepuncture, arterial, 
finger prick and heel prick. The choice of blood sampling site depends 
on the age, weight and the volume of blood required. Heel prick is 
usually done for infants less than six months old or between 3-10 kg. 
Finger prick is done for children over six months and more than 10kg 
(119). A study involving 100 neonates determined the tolerability of 
both methods using the Facial Coding System (FCS). This study 
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reported greater pain for heel prick (median FCS score of 58) than for 
venepuncture (FCS score 23, p<0.001) (120). However, heel pricks 
are still widely used in neonates. Several other studies have also 
supported that venepuncture is  associated with less pain than heel 
pricks in neonates (120, 121). Drug measurement after venepuncture 
has also been shown to be less prone to errors than finger pricks, due 
to the squeezing associated with sampling and blood specimen 
contamination with extracellular fluid (122). 
 1.7.2.   Blood sampling volume and frequency  
Different institutions have different guidelines on the safe limit for 
blood sampling. The European Medicines Agency (EMA) recommends 
that not more than 3% of the total blood volume (TBV) of neonates 
should be withdrawn during a period of four weeks, and  a single time  
blood draw should not exceed 1% of TBV (123).  
The United States Department of Health and Human Services on the 
other hand, recommend that not more than 3.8% (3ml/kg) of the 
TBV should be withdrawn at one time. In addition, it was 
recommended that not more than 50 ml in total should be withdrawn 
within eight weeks (124)(Table 1.4). The Medical Research Joint 
Ethics Committee (MRC), in partnership with the government in 
Gambia, developed a more age specific guideline (125) which allows 
for up to 5ml of blood to be withdrawn at once in children between 0-
4 years, 10ml for 5-9 years, 15ml for 10-14 years, and 30ml in 
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adolescents over 15 years. There are also recommendations based on 
baseline haemoglobin. For example, the University of California 
guideline recommends that 2.5% of TBV can be withdrawn in a single 
draw only if the child’s haematocrit is at least 7g/dl or between 9-
10g/dl, if cardiorespiratory compromise is present (126).  
The number of samples required for PK studies vary with different 
research methods. There is no standard guideline on the frequency of 
blood sampling in children, some studies have collected as many as 
20 samples (127). Raoof et al.(1995) reported that 11 blood samples 
may be sufficient for the estimation of PK parameters (128), 
however, Long et al.(1987) reported that just three samples may be 
sufficient for practical purposes in neonates (129). 
  Table 1. 4: Guidelines on safe blood sample volume for paediatrics 
           Institution 
 
Maximum volume for a 
single sample 
% TBV 
 
Maximum cumulative 
volume 
% TBV 
US Dept of Health and 
Human Services, Office 
for Human Research 
Protections 
3.8 ≤50ml in eight weeks 
Toronto Hospital for Sick 
Children Research Ethics 
Board 
5 5% in 3 months 
Gambia Government–
MRC Joint Ethics 
Committee 
0.3-2.4 0.3-2.4 in 3 months 
 University of California 2.5 5%  in 1 month 
  This table adapted from Stephen RC Howie,(2011)(125). 
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1.8. Physiological, physical and psychological effect of blood 
sampling in children 
Venepuncture is the most common invasive procedure for PK studies. 
This procedure has been shown to cause both psychological and 
physical pain in children (130). In one study, 58% of children 
considered venepuncture painful while about 25% had some form of 
psychological distress before sampling and 8% afterwards (130). 
Rodin et al. (1983) demonstrated an increased level of anxiety in 
children undergoing invasive procedures without previous 
psychological preparation. As well as the psychological risk, invasive 
procedures may also cause physical risk, such as bruising (131). 
Other risks associated with frequent venous blood sampling include: 
infection, excessive blood loss and possibly anterior intraosseous 
syndrome blood loss (132).  
The EMA recommends that both physical and psychological pain 
should be reduced as much as possible when conducting clinical 
research in children. When pain is unavoidable, it should be 
effectively treated during and after the procedure (123). They also 
recommended that the intensity of pain and distress should be 
monitored and assessed using an appropriate scale (123). An 
example of such scale is the COMFORT scale which is used for 
detection of treatment related change in pain and discomfort intensity 
(133). Furthermore, local anaesthetic agents should be used, 
especially when inserting an indwelling catheter (134). 
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1.8.1.   Physiological effect of blood sampling in neonates 
Besides the psychological and physical effects of drug sampling in 
children, there are also physiological implications. Preterm infants 
generally have a  TBV of about 90-105ml/kg and in term neonates 
the TBV reduces to about 80 ml/kg (135). This implies that a 3kg 
term neonate has a TBV of about 240ml; therefore excessive blood 
sampling may compromise circulation. 
 In a prospective study of 99 preterm infants by Madsen et al. 
(2000), there was a significant correlation between the volume of 
blood sampled and the volume of blood transfused (136). A further 
study of 253 preterm neonates confirmed this (137). A study of 20 
preterm neonates, in which umbilical blood was sampled rapidly (20 
seconds), showed a significant decrease in both oxygenated 
haemoglobin and total oxygenation index, with a corresponding 
increase in oxygenated haemoglobin in the brain (138). Similarly, 
another study of neonates with blood sampled from the umbilical vein 
showed a significant decrease in cerebral oxygenation and cerebral 
blood volume. Acute drop in cerebral oxygenation can lead to brain 
injury such as intraventricular haemorrhage and periventricular 
leukomalacia (139). 
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1.9. Microanalytical methods  
1.9.1   Dried matrix spots (DMS) 
This involves the collection of biological fluid samples on blotting 
paper. Examples of DMS include dried blood spots (DBS), dried urine 
spots (DUS) and dried plasma spots (DPS). Usually, small volume of 
fluids ranging between 5-30µl are collected. The commonest DMS 
method is the DBS which is increasingly being used, in the last 10 
years, in drug development process, therapeutic drug monitoring,  as 
well as PK studies in infants (140). The degree of partitioning of 
drugs into red blood cells determines the differences observed 
between blood and plasma concentrations. In addition to minimal 
samples other advantages of DBS include low cost, potential for 
storage at room temperature and ease of transport (141, 142). A 
major limitation of DBS is that it provides estimates of PK data for 
whole blood, whereas many PK studies estimate plasma or serum 
concentrations. Therefore, DBS drug concentration should be 
corrected in order to obtain an accurate plasma level (143). DBS may 
not be suitable for unstable drugs, which may be degraded during the 
drying process (144, 145). 
1.9.2. Ultra-low volume assays 
This method minimises the volume of blood used for PK studies. 
Plasma volume of <50µl can be used for drug assay compared to the 
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traditional 1-2ml required for PK studies. Several studies have 
reported the use of this method in paediatrics (146, 147). 
 1.9.3. Opportunistic PK studies 
This method can be used for PK studies of drugs that are prescribed 
in routine care. Such samples can be taken when routine laboratory 
blood samples are collected. Therefore, subjects are not subjected to 
further blood collection. Parents are less likely to object to this type 
of study than the traditional PK method. A drawback of this method is 
that samples are sparse and untimed. In order to mitigate the effect 
of sparse sampling, a larger number of subjects are required (147).   
1.9.4.   Alternative biological matrices 
Saliva has been used as an alternative to blood sampling for the PK 
analysis of some drugs. A study of PK profile of voriconazole showed 
a similar PK profile between saliva and plasma (148). Other 
alternatives such as urine or breath samples should be considered 
when suitable (117). A correlation between salivary and plasma 
concentration has been reported for theophylline, phenobarbital and 
phenytoin (149, 150). However, it is difficult to obtain optimally 
sufficient salivary samples from neonates and young children. The 
distribution of drug in the saliva however depends on the 
physiochemical properties of the drug and the characteristics of the 
saliva.  Rapid saliva flow rate lowers the variation in the ratio of drug 
saliva to plasma, hence stimulated saliva is preferred over resting 
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saliva (151). Exhaled breath is another biological matrix that can be 
used for PK analysis. It is however highly dependent on the ability of 
the drug to diffuse across the alveoli (152). 
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1.10. Thesis aims 
It is important to explore the variation in PK of medicines in children. 
Different enzymes are involved in the metabolism of the many 
different medicines used in paediatrics. These drugs can also have 
different PK properties in different age groups. The series of 
systematic reviews performed will explore several different drugs 
which are metabolised by different enzymes.  
The medicines that will be reviewed are; midazolam, theophylline and 
morphine.  
 Midazolam is used as a sedative in paediatrics and CYP3A4 is the 
main metabolic pathway. 
  Theophylline is prescribed mainly as aminophylline, which is the 
intravenous formulation of the drug. It is used in acute asthma 
and is often prescribed in low income countries. It is metabolised 
by CYP1A2.  
 Morphine is a commonly prescribed opiate that is widely used in 
paediatrics. It is glucuronidated to an active metabolite (M6G) and 
an inactive metabolite (M3G) by UGT.  
The aims of the systematic reviews are to: 
 Determine the extent of inter-individual variation of clearance of 
these drugs in children. 
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 Determine the factors such as age, weight or critical illness that 
may be responsible for inter-individual variations of clearance for 
these drugs.  
 
Blood sampling is an important component of PK studies. It is 
however, an invasive process. A systematic review of the frequency 
and volume of blood sampling was conducted in order to determine 
whether PK studies in paediatric patients are becoming less invasive 
by determining the volume and number of samples taken. 
  
40 
 
CHAPTER TWO                                                                         
METHODS FOR SYSTEMATIC REVIEWS OF INTER-INDIVIDUAL 
VARIABILITY OF CLEARANCE  
2.1. Methods  
Systematic reviews of the inter-individual variation in clearance of 
midazolam, theophylline and morphine were conducted.  
2.2. Search strategy  
An electronic search of five databases was conducted. The databases 
were MEDLINE, EMBASE, International Pharmaceutical Abstracts 
(IPA), CINAHL and the Cochrane Library. All studies that involved 
children aged less or equal <18 years that described the 
pharmacokinetics of midazolam, theophylline and morphine were 
included. Paediatric patients were grouped according to the guidelines 
of the International Conference of Harmonization (ICH)(153):  
  Preterm neonates (born at less than 37 weeks of gestation) 
  Term neonates ( born at 37 weeks of gestation  to 27 days old) 
  Infants (28 days to under 2 years old) 
 Children (2 to 11 years old) 
 Adolescents (12 to under 18 years old) 
Paediatric keywords were selected based on the recommendations of  
Kastner et al. (2006)(154). The final PK keywords were selected after 
optimisation to generate the highest number of relevant studies. This 
is because PK systematic reviews in these subjects have not been 
performed before.  
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2.3.  Database and keywords for midazolam 
The following sources of information were utilised: MEDLINE (1946 to 
May 2012), EMBASE (1974 to May 2012), IPA (1970 to April 2012), 
CINAHL and Cochrane library. These databases were searched 
separately, the results were combined and the duplications were 
removed.  
The search strategy included all languages and involved the keywords 
“midazolam” AND “preterm neonate*” OR “term neonate*” OR 
“neonate*” OR “new-born*” OR “child*” OR “children” OR 
“p*ediatric*” OR “infant*” OR “adolescent*” AND “pharmacokinetic*” 
OR “clearance” OR “half-life” OR “absorption” OR “distribution” OR 
“metabolism” OR “elimination” OR “pharmacodynamic*”. 
2.4. Database and keywords for theophylline  
The following sources of information were utilised: MEDLINE (1946 to 
January 2013), EMBASE (1974 to January 2013), IPA (1970 to 
January 2013), CINAHL and the Cochrane Library. These databases 
were searched separately, the results were combined and the 
duplications were removed.  
The search strategy included all languages and involved the keywords 
“theophylline” OR “aminophylline” AND “preterm neonate*” OR term 
neonat*” OR “neonate*” OR “new-born*” OR “child*” OR “children” 
OR “p*ediatric*” OR “infant*” OR “adolescent*” AND 
“pharmacokinetic*” OR “clearance” OR “half-life” OR “absorption” OR 
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“distribution” OR “metabolism” OR “elimination” OR 
“pharmacodynamic*”. 
2.5.  Database and keywords for morphine 
The following sources of information were utilised: MEDLINE (1946 to 
May 2013), EMBASE (1974 to May 2013), IPA (1974 to May 2013), 
CINAHL and the Cochrane Library. These databases were searched 
separately, the results were combined and the duplications were 
removed.  
The search strategy included all languages and involved the keywords 
“morphine” AND “preterm neonate*” OR term neonat*” OR 
“neonate*” OR “new-born*” OR “child*” OR “children” OR 
“p*ediatric*” OR “infant*” OR “adolescent*” AND “pharmacokinetic*” 
OR “clearance” OR “half-life” OR “absorption” OR “distribution” OR 
“metabolism” OR “elimination” OR “pharmacodynamic*”. 
2.6. Exclusion criteria   
 Review articles  
 Editorials  
 Conference abstracts  
 Studies in adults aged over 18 years  
 Studies that involved adults and paediatric patients but did not 
present the paediatric data separately. 
  Studies in which the drug of interest (midazolam, theophylline 
or morphine) was not administered intravenously. 
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2.7. Inclusion criteria  
 Inclusion criteria were original research studies assessing the 
pharmacokinetics of the drug of interest in children up to the 
age of 18 years. 
2.8. Quality assessment  
There is no formal quality assessment for use in PK studies. Therefore 
the quality of papers was assessed using the following criteria 
include: 
 Studies with ≤ 2 patients or with number of patients not stated 
were excluded. 
 Studies with ≤2 samples or with the number of samples not 
stated were excluded. 
2.9. Data extraction 
All relevant articles were read carefully and the required data were 
extracted onto tables. A second reviewer independently verified the 
eligibility of 25% of randomly selected studies. The data extracted 
include: 
 Number of patients 
 Age  
 Weight  
 Study year and reference 
 Dose (single, multiple or continuous infusion) 
 Drug-drug interaction 
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 Single or multi-site  
 Medical condition  
 Number of blood samples 
 Blood, plasm or serum    
 PK analysis method 
 Clearance  
 Values of mean/median clearance and the minimum and 
maximum clearance. 
The variation ratio was calculated from the range of clearance 
maximum clearance divided by the minimum clearance. The 
coefficient of variation (CV) was extracted from the paper if given. If 
individual data were presented, then the CV was calculated using the 
formula CV= √ ((e SD2) -1)(155), which allows for the fact that 
clearance usually display a lognormal distribution in children. We 
contacted original authors by email if their paper did not provide 
individual data of clearance.  If individual data were not available, 
then the CV was estimated by dividing the standard deviation by the 
mean of clearance, i.e., normal distribution was assumed. Patients 
were divided into two groups: (1) critically ill if they were in an 
intensive care unit and (2) non-critically ill, which included other 
groups. 
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2.10.  Statistical Analysis 
The coefficients of variation between studies in critically and non-
critically ill patients were compared using Students t-test (or Mann-
Whitney test, if not normally distributed). Differences in CV for 
different age groups were also determined using ANOVA. The mean 
drug clearance of studies in all patients was pooled, in a meta-
analysis (StataSE14). For each population, the extent of association 
between the CL values and differences between the primary studies 
was assessed by conducting a heterogeneity test, using the Q 
statistic (156). A non-significant result (P > 0.1) indicated lack of 
significant difference between the studies (157). Additionally, I-
squared statistic, which measures the percentage of the variability in 
effect estimates due to heterogeneity rather than sampling error was 
carried out. Where the I-squared was low (i.e. < 40%), the fixed-
effect model was deemed suitable. The random effect model was 
utilised for heterogeneous data.   
To identify potential influences on the CL, a meta-regression was 
conducted, utilising age group, weight, study type (i.e. whether it 
was population PK-based or not) and sample size as covariates. The 
random effects model was also used so as to account for possible 
heterogeneity.  
The correlation between weight and CV was evaluated and the effect 
of all covariates was evaluated with multiple linear regression. 
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CHAPTER THREE                                                                                    
A SYSTEMATIC LITERATURE REVIEW OF INTER-INDIVIDUAL 
VARIATION IN MIDAZOLAM CLEARANCE IN CHILDREN 
3.1. Introduction 
Midazolam is a 1, 4-benzodiazepine derivative that was first 
synthesized in 1975 by Walser and Fryer (158). It is a short acting 
benzodiazepine that is used as a central nervous system depressant 
(CNS)(158). It reversibly potentiates the effects of gamma-amino 
butyric acid (GABA) receptors in the central nervous system (159). As 
a result of this characteristic, it exhibits sedative, anxiolytic, 
anticonvulsive, muscle relaxant and amnesic effects, which can be 
seen in both adults and children (158). Midazolam can be 
administered via different routes: IV, intramuscular (IM), buccally, 
intranasally (IN), and orally (160). 
Following IM injection, more than 90% of midazolam is absorbed. 
However, oral bioavailability is only about 27% in children (161). The 
lower oral bioavailability is due to first pass metabolism in the liver 
and small intestine. Its Vd varies between 0.95 and 6.6L/kg, and is 
generally higher in females than males (161). Obese children also 
have a higher Vd. A significant decrease in central and peripheral Vd 
has been reported after weight loss in morbidly obese adults (162).  
Midazolam is metabolised by the cytochrome P450 isoforms such as 
CYP3A4, CYP3A5, and CYP3A7 to a major hydroxylated metabolite (1-
OH-midazolam) and several minor metabolites (163). 1-OH-
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midazolam is equipotent to midazolam and is metabolised to 1-OH-
midazolam-glucuronide by UGTs. 1-OH-midazolam-glucuronide is 
subsequently excreted via the kidneys (163).  
Therefore developmental differences in CYP3A activity may alter the 
pharmacokinetics of midazolam in paediatric patients of different 
ages (28). Clearance is reduced in neonates and infants under 6 
months of age. Thereafter, it is similar to that in adults. In addition, 
the pharmacokinetics of midazolam can be altered by dysfunction of 
the kidneys or the liver (164, 165). 
The dose of midazolam used varies with the indication, route of 
administration and age. For sedation in stable patients, IV midazolam 
is given at an initial dose 25-50 µg/kg in those aged 12-18 years 
(166). This may be increased gradually if necessary. However, higher 
doses are needed for sedation in intensive care unit and this varies 
according to the age of the patients. Preterm neonates less than 32 
weeks require about 30 µg/kg, IV for sedation in intensive care unit, 
while a much higher IV dose of 60 µg/kg is recommended for patients 
> 32 weeks to 6 months (166). Children 6 months-12 years require 
up to 200 µg/kg while the dose in adolescents can be as higher as 
300 µg/kg given by slow IV injection (166). Dose also varies 
according to route of administration with a lower dose  required for 
the IV route whereas oral, rectal and buccal require higher doses 
(166). 
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Prolonged administration of midazolam has been shown to result in 
tolerance and the development of withdrawal symptoms such as 
hypertension, tachycardia and seizures (167). 
Some studies have suggested that  factors such as age (95), route of 
administration (168), gender and weight (169), and critical illness 
(170) may affect the pharmacokinetics of midazolam in children.  
3.2.  Aims  
The purpose of this systematic review is to determine the variability 
of midazolam clearance in children and establish the factors which are 
responsible for this variability. 
3.3. Objectives  
 Determine the extent of inter-individual variation in midazolam 
clearance by estimating the CV. 
 Evaluate the effect of factors such as age, birth weight and 
critical illness that may be responsible for the inter-individual 
variation in midazolam.  
3.4. Methods 
The methods for this chapter are described in chapter two. 
3.5. Results  
A total of 1,654 articles were short listed by five search engines 
(Figure 3.1). Only 26 articles (including two identified by manual 
search) met the inclusion criteria. Table 3.1 shows the details of 
papers excluded from the systematic review. 
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               Table 3. 1: Details of excluded articles from systemic review  
Exclusion Reason 
Review studies 245 
Editorials 8 
Conference abstracts 16 
Studies in which midazolam was not administered intravenously  3 
Studies in adults aged  over 18 years  123 
Combined adult and paediatric studies where paediatric data was not 
presented separately 
1 
Studies where data for midazolam was not presented 614 
Studies that did not evaluate the pharmacokinetics of midazolam 358 
 
Total 
 
1,368 
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Figure 3. 1: Search strategy of midazolam 
 
 
  
Cochrane 
47 
 
41 non-human   
studies           
221 Duplicates 
                1,392 Studies  
 
 
2 Manual search articles 
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322 
EMBASE 
882 
CINAHL 
378 
IPA 
25 
 
                                                1,654 Studies 
 
1,368 Studies excluded  
 
             1,613 Studies 
 
 
51 
 
3.5.1. Quality assessments  
Four studies were excluded after quality assessment, described in 
section (2.8) of chapter 2. Two studies were excluded because of the 
small number of blood samples (171, 172). One study was excluded 
because of lack of information on the number of blood samples (173) 
and one study was excluded because of the small number of patients 
(174) (Table 3.2).  
 
 
 
 
 
 
 
 
 
52 
 
      Table 3. 2:  Quality assessment of midazolam PK studies in paediatric 
Study Age group †Number of 
patients 
+Number of blood 
samples collected 
Verdict 
Jacqz-Aigrain et al.(1992)(175) Preterm 
neonates 
15 7* Included  
Jacqz-Aigrain et al.(1990) (176) 5 6* Included 
de Wildt et al.( 2001) (177) 24 8* Included 
Harte et al.(1997) (178) 9 4* Included 
Lee et al. (1999)(179) 60 4‡ Included 
Jacqz-Aigrain et al. (1990) (176)  
Term neonates 
5 6* Included 
Mulla et al. (2003)(180) 11 7* Included 
de Wildt et al. (2003)(164) 5 3* Included 
Burtin et al. (1994)(181) 187 3-6* Included 
Ahsman et al.(2010)(182) 20 5-9* Included 
Mulla et al.(2003)(183) 19 7 Included 
de Wildt et al.(2003)(164)  
Infants 
5 3* Included 
Hughes et al.(1996)(171) 25 1 Excluded 
Peeters et al.(2006)(184) 24 7-10* Included 
Minagawa (2006)(174) 2 3 Excluded 
Mathews et al.(1988)(185) 5 12-14* Included 
Reed et al.(2001)(186) 5 12* Included 
de Wildt et al. (2003)(164)  
2-11 years 
6 3* Included 
Minagawa (2006)(174) 2 3 Excluded 
Roberts et al.(2009)(187) 5 5* Included 
Muchohi et al.(2008)(188) 12 13* Included 
Hughes et al. (1996)(171) 12 1 Excluded 
Mathews et al. (1988)(185) 12 12-14* Included 
Reed et al. (2001)(186) 14 12* Included 
Rey et al.(1991)(189) 6 10* Included 
Jones et al. (1993)(190) 12 9* Included 
Kraus et al.(1989)(191) 6 13* Included 
Payne et al.(1989)(192) 8 9* Included 
Salonen et al.(1987)(193) 21 12* Included 
Tolia et al.(1991)(194) 12-18 years 20 7* Included 
Vet et al.(2012)(173) 2 dy to 17 yrs 21 NA Excluded 
Nahara et al.(2000)(97) 2dy-16yrs 22 5* Included 
Hartwig et al.(1991)(172) 26 dy to 5  yrs 24 1‡ Excluded 
†Studies with ≤ 2 patients or with number of patients not stated are excluded; +Studies with ≤2 samples or with the number 
of samples not stated are excluded, *plasma, ‡serum  
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3.5.2. Clearance of midazolam in neonates (0 - 27 days) 
Ten studies reported midazolam clearance in 360 critically ill 
neonates undergoing sedation for mechanical ventilation (175-179, 
181-183, 195). All were single centre studies. The number of 
participants varied between 5 and 181 (Tables 3.3 and 3.4). The 
number of collected blood samples was between 3 and 8.  
Six of the studies were 2 compartment studies; there were 2 one 
compartment studies and 1 non-compartment study. In the one other 
study, one, two and three compartment models were used. 
Midazolam loading dose varied between 0.03 and 0.2 mg/kg and 
maintenance dose between 0.01 and 0.6 mg/kg/h (Table 3.5).   Age 
and weight were covariates in half of these studies. Other important 
covariates were route of administration and co-medication. None of 
the studies reported the effect of drug-drug interaction. 
The CV in the four studies of preterm neonates ranged from 78% to 
109% (Table 3-6). The CV in the four studies of term neonates 
ranged from 18% to 77%. Five studies gave data regarding the range 
of clearance values for individual neonates (175-177, 183, 195). The 
three studies in preterm neonates suggested a 4.5 fold, 5-fold and 
10-fold variation in clearance in 15 and 5 and 24 neonates 
respectively. One study involving five term neonates reported a 2-
fold variation in clearance. The mean clearance in preterm neonates 
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ranged from 0.78 to 1.7 ml/min/kg and in term neonates ranged 
from 1.17 to 3.5 ml/min/kg.   
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                Table 3. 3:  Characteristics of studies in preterm neonates  
Study 
Number 
of 
patients 
Gestational 
age 
(weeks) 
Postnatal 
age 
(days) 
Range of 
weight 
(kg) 
Type of patients Covariates Comments 
Jacqz-Aigrain 
et al. 
(1992)(175) 
15 
29-41 
(32)* 
NA 
1-3 
(1.9)* 
Mechanical 
ventilation 
NA 
Liver and renal function normal. 
Period of illness NA. 
Jacqz-Aigrain 
et al. 
(1990)(176) 
5 
34-37 
(35)‡ 
NA 
2-3.6 
(2.8)* 
Respiratory distress 
syndrome or 
infection 
Gestational age and 
weight 
Liver and renal function normal. 
Period of illness NA. 
 
de Wildt et al.      
(2001)(177) 24 
 
26-34 
(29)* 
 
3-11 
(5.5)* 
0.8-1.6 
(1)* 
ICU 
Age, co-medication 
(indomethacin and 
caffeine) and 
mechanically 
ventilated 
Excluded patients receiving morphine, dobutamine, 
dopamine or those with primary renal, hepatic, 
hemodynamic, or neurologic dysfunction. 
Period of illness NA. 
Harte et al.          
(1997)(178) 9 
25-30 
(28)* 
NA 
0.7-1.4 
(1)* 
Mechanical 
ventilation 
NA 
Excluded patients with cardiovascular instability, 
neurologic, hepatic or renal dysfunction. 
Period of illness was over two months. 
Lee et al.               
(1999)(179) 
33 
27 
24-31 
(27)* 
2-15 
<1kg 
>1kg 
Mechanical 
ventilation 
Single/multiple birth 
pregnancy and birth 
weight 
Excluded patients with cardiovascular instability, 
neurologic, hepatic or renal dysfunction. 
Period of illness NA. 
 *Mean, ICU, intensive care unit, NA, not available 
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    Table 3. 4: Characteristics of studies in term neonates  
Study 
Number of 
patients 
Gestational age 
(week) 
Postnatal age 
(days) 
Range of 
weight 
(kg) 
Type of 
patients 
Covariates Comments 
Jacqz-Aigrain 
et al. 
(1990)(176) 
5 
38-41  
(39)* 
NA 
3-3.9 
(3.5)* 
Neonatal 
infection or 
respiratory 
distress 
syndrome 
Gestational age and 
weight 
Liver and renal function was normal. 
Period of illness NA. 
Mulla et al.            
(2003)(180) 
11 
38–41.6  
(40)* 
0.5-16  
(3.6)* 
 (3.6)* 
ECMO 
 
Route of 
administration 
(IV vs. 
extracorporeal) 
Patients were diagnosed, MAS, PPHN, CDH, Sepsis, 
post cardiac surgery and metabolic. 
Period of illness NA. 
de Wildt et al. 
(2003) (164) 
5 NA 
1-16 
(9)* 
2.8-3.8 Cardiac Age and disease Duration of illness ranged from 3.8 hours to 25days. 
Burtin et al.           
(1994)(181) 
 
181 
 
 
7 
 
 
 
< 39/40  
 
 
>39/40  
 
 
NA 0.7-5.2 ICU 
Gestational age, birth 
weight 
and co-medication 
138 patients received aminoglycosides, 135 
aminopenicillins,91 third generationcephalosporins,34 
sympathomimetic amines,31 opioids,20 fentanyl,6 
received nalbuphine,5 phenoperidine,12 colfibrate,10 
neuromuscular blocking agents and 6 other 
benzodiazepines . 
Period of illness NA. 
Ahsman et 
al.(2010) (182) 
20 
37-42  
(40)* 
0.17-5.6 
2.7-3.9  
(3)* 
ECMO 
 
Weight, PNA, time 
after cannulation, and 
concomitant inotrope 
use 
 
10 patients with MAS,7-CDH,2 respiratory 
insufficiency,1-sepsis 
Duration of ECMO ranged from 70-275h. 
Mulla et al.            
(2003)(183) 
19 39.5* 
0.5-18  
(3.8)* 
3.4* 
ECMO 
 
Route of 
administration (IV vs. 
extracorporeal) and 
time dependency 
12 patients with MAS, 1 sepsis, 4 CDH, 2 post cardiac 
surgery and 1 metabolic. 
Length of ICU stay 6 ±8.6 days 
*Mean, ECMO, extracorporeal membrane oxygenation, MAS ,Meconium aspiration syndrome, PPHN, Persistent pulmonary hypertension of the newborn, CDH, congenital  
diaphragmatic hernia , PNA, postnatal age, NA, not available, 
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           Table 3. 5:  Midazolam doses in neonates  
Age 
group 
Loading dose or 
Single dose (SD) 
Mg/kg 
Midazolam 
infusion 
Mg/kg/h 
Number of 
blood 
samples 
collected 
Method Study 
 
 
Preterm 
neonates 
0.2 0.06 7 Two compartment 
Jacqz-Aigrain et 
al.(1992)(175) 
0.2 NA 6 Two compartment 
Jacqz-Aigrain et 
al.(1990)(176) 
NA 0.1 8 Non-compartmental 
de Wildt et al. 
(2001)(177) 
0.1 NA 4 Two compartment 
Harte et al. 
(1997)(178) 
0.1* NA 4 Two compartment 
Lee et al.(1999) 
(179) 
 
 
Term 
neonates 
0.2 NA 6 Two compartment 
Jacqz-Aigrain et 
al.(1990)(176) 
0.05-0.1 0.05-0.25 7 One compartment 
Mulla et al.  
(2003)(180) 
NA 0.05-0.4 3 Two compartment 
de Wildt et al. 
(2003)(164) 
0.03-1.6 0.01-0.6 3-6 
One and two 
compartment 
Burtin et al. 
(1994)(181) 
NA 
0.1† (0.10-
0.30) 
5 One compartment 
Ahsman et 
al.(2010)(182) 
0.05-0.1 0.05-0.25 7 
One, two and three 
compartment 
Mulla et al. 
(2003)(183) 
                           * Single dose or multiple doses when necessary, †Median (range), NA, not given  
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Table 3. 6: Midazolam clearance in critically ill neonates   
Age 
group 
Number 
of 
patients 
Mean 
Clearance 
(ml/kg/min) 
SD 
Coefficient of 
variation 
(CV %) 
Range of 
clearance 
(ml/kg/min) 
Variation ratio 
in clearance 
Comments Study 
Preterm 
neonates 
15 
 
1.7 1.8 106 0.6-2.7 4.5 
Non-pop-Pk Jacqz-Aigrain et al.(175) 
5 1.6 0.9 109 0.74-3.5 5 
Individual data available ,Non-pop-Pk Jacqz-Aigrain et al.(176) 
24 1.8* NA NA 0.7 - 6.7 10 
Non-pop-Pk de Wildt et al. (177) 
9 
 
1.7 1.4 81ƒ NA NA 
Pop-PK  Harte et al. (178) 
33 
 
0.78 0.6 83ƒ NA NA 
The only population PK study with 
omega2 /eta values, Pop-PK 
Lee et al. (179) 
27 
 
1.24 0.9 78ƒ NA NA 
Term 
neonates 
5 2.5 0.75 30 1.8-3.7 2 
Two stage PK study Individual  data 
available, Pop-PK 
de Wildt et al. (164) 
5 
 
2.5 1.2 77 0.86-3.7 4 
Individual data available Non-pop-Pk, Jacqz-Aigrain et al. (176) 
20 
 
2.6 NA 18ƒ NA NA 
Pre-ECMO , Pop-PK Ahsman et al. (182) 
19 
 
1.4 1 73ƒ NA NA 
Post –ECMO, Pop-PK Mulla et al. (183) 
11 
 
3.5 4.9 71ƒ 0.4–17.5 44 
Post –ECMO, Pop-PK Mulla et al. (180) 
181 
 
6 
1.17 
 
1.84 
0.7 
 
1.2 
65ƒ NA NA 
 
 
 
Pop-PK 
 
 
Burtin et al.(181) 
                                         *Median, SD, standard deviation, CV, Coefficient of variation, POP-PK, population pharmacokinetics study, non-pop-Pk, non-population pharmacokinetics study,ƒ, CV provided by  
 author, NA, not available 
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3.5.3. Clearance of midazolam in infants (>28 days -23 months) 
Four studies reported midazolam clearance in 40 infants (177, 184-
186). Three of these studies were in critically ill infants. There were 3 
single and 1 multicenter study. The number of participants varied 
between 5 and 24 (Table 3.7). The number of collected blood 
samples was between 3 and 14. 
 Two of the studies were 2 compartment studies and there was 1 
non-compartment studies. In 1 other study, one and two 
compartment models were used. Midazolam loading dose varied 
between 0.05 and 1 mg/kg and maintenance dose between 0.05 and 
0.4 mg/kg/h.  Age was a covariate in 3 of these studies. Other 
covariates were weight and disease condition. None of the studies 
reported the effect of drug-drug interaction. 
The CV ranged from 31% to 89%. The CV was lowest in the study 
where the infants were not ventilated (184).  Two studies gave the 
full range of clearance values for individual infants. There was a 6 to 
9 fold variation in clearance values. 
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Table 3. 7: Characteristics of studies in infants  
Study 
Number 
of 
patients 
Loading dose or 
Single dose 
(SD) 
Mg/kg 
Midazolam 
infusion 
Mg/kg/h 
Number of 
blood 
samples 
collected 
Method 
Type of 
patients 
Covariates Comments 
de Wildt et al. 
(2003)(164) 6 
NA 0.05-0.4 3 Two compartment 
ICU 
Age and 
disease 
1 Patient With respiratory insufficiency, 3 upper 
airway infection,1 meningitis and 1 pneumonia.  
Duration of illness (3.8 hours to 25days). 
Peeters et al.  
(2006)(184) 
24 
0.1 0.05 7-10 Two compartment 
Surgical Age 
Major craniofacial surgery. 
Period of illness NA. 
Mathews et 
al.(1988)(185) 
5 
0.05 0.05 12-14 Non-compartment 
Cardiac 
Intra and 
post-
operative 
treatment 
No patients prescribed benzodiazepines. No 
liver dysfunction. 
3 patients with transposition of great vessels, 1 
AV canal defect, 1 mitral stenosis. 
Period of illness NA. 
Reed et al. 
(2001) (186) 
5 
0.25-1 NA 12 
One and two 
compartment 
Minor 
surgery 
Age and 
weight 
Exclusion of any patients with upper airway 
disease, CNS dysfunction, gastroesophageal 
dysmotility, or taking hepatic inducer, inhibitors 
or substrate. 
ICU, intensive care unit, AV, atrioventricular, CNS, central nervous system, NA, not available
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3.5.4. Clearance of midazolam in children (2-11 years) 
Ten studies reported midazolam clearance in 102 children. Four 
studies reported clearance values in critically ill children (164, 185, 
187, 188). All but one of the studies were single center studies. The 
number of children participating in each study varied between 5 and 
21 (Table 3.8). The number of blood samples taken between 3 and 
14. 
The majority of the studies (6 studies) utilised non-compartment 
models. Two studies were two compartment and 1 three 
compartment study. In 1 other study, one and two compartment 
models were used. Midazolam loading dose varied between 0.05 and 
1 mg/kg and maintenance dose between 0.01 and 0.4 mg/kg/h 
(Table 3.10). Age was a covariate in half of the studies. In 3 studies, 
weight and route of administration were covariates. Drug-drug 
interaction was not reported in any of the studies. 
The CV ranged from 21% to 72% (Table 3.11).  Three studies gave 
full range of values for individual children. There was a 2 to 5 fold 
variation in clearance (164, 187, 188). Six studies were in non- 
critically ill children (186, 189-193). Their CV ranged from 13% to 
54%.  Four of these studies provided data regarding the full range of 
clearance values and the degree of inter-individual variation was 
between 2 to 10.5 fold (189-191, 193).  
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3.5.5. Clearance of midazolam in adolescents (12-18 years) 
Only one study reported midazolam clearance in 20 non-critically ill 
adolescents (Table 3.12). This was a non-compartmental study 
involving 20 patients receiving midazolam maintenance dose of 0.1 
mg/kg/h. No loading dose or covariates were reported in this study.  
The CV for this study was 50%.  
3.5.6. Clearance of midazolam in paediatric patients of mixed ages 
Only one study reported midazolam clearance in 22 critically ill 
paediatric patients across all age groups (196)(Table 3.11). This was 
a non-compartmental study. This study did not report neither mean 
or the CV of clearance.  
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Table 3. 8: Characteristics of studies in children 
Study 
Number of 
patients 
Type of patients Covariates Comments 
de Wildt et al.        
(2003)(164) 6 ICU Age and disease 
1-Empyema ,1-Acute bronchitis ,2-Pulmonary hypertension 
1-Staphylococcal and1-Measles pneumonia.  
 Duration of illness ranged from 3.8 hours to 25days. 
Roberts et al.     
(2009)(187) 
5 ICU Age 
1-severe head injury, 1-sepsis, 1-meninigitis, 1-alveolar haemorrhage, 1-addisonian crisis. 
Exclusion of patients with hepatic impairment, renal impairment or co-medication with 
CYP3A4 or CYP3A5 inducer or inhibitor. 
Period of illness NA. 
Muchohi et al.    
(2008)(188) 12 High dependency unit 
Route of administration 
(IV,IM and buccal) 
Severe malaria and convulsion.  
Patients who received diazepam were excluded. 
Period of illness NA. 
Mathews et al.   
(1988)(185) 12 Cardiac 
Intra and post-operative 
treatment 
None prescribed benzodiazepines and no liver dysfunction.  
5 coarctation of aorta,1 tricuspid valve shunt, 3 Fallot's tetralogy,1 atrial septum defect, 1 
mitral valve stenosis, 1 Pulmonary valve infundibular stenosis. Period of illness NA. 
Reed et al.  
(2001)(186) 
14 
Minor in –hospital or 
day procedures 
Age and weight 
Exclusion of upper airway disease, CNS dysfunction, gastroesophageal dysmotility, or taking 
hepatic inducer, inhibitors or substrate. 
Rey et al.    
(1991)(189) 
6 Healthy children 
Route of administration 
(IV,IN) 
Mino genito- urinary  
Jones et al. 
(1993)(190) 12 Healthy children NA 
Children undergoing circumcision. Exclusion for hepatic, renal, respiratory, cardiac or 
haematological disease.  
Period of illness NA. 
Kraus et al. 
(1989)(191) 
6 
Minor elective 
surgery 
Age and weight 
- 
Payne et al.    
(1989)(192) 
8 Minor surgery 
Route of administration 
(IV,IM,rectal and oral) 
Minor inguinal area surgery. 
 
Salonen et al. 
(1987)(193) 
21 Minor surgery Age and weight 
- 
   ICU, intensive care unit, IN, intranasal, CNS, central nervous system, NA, not available, 
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 Table 3. 9: Characteristics of studies in adolescents and mixed age groups  
Study 
Number of 
patients 
Type of 
patients 
Covariates Comments 
Tolia et al. (1991) 
(194) 20* Endoscopy NA 
Esophagogasterodudenal endoscopy. 
Children with cardiac, renal, liver or neurologic disease were excluded.  
  
Nahara et al. (2000) 
(97) 
22 ICU NA 
Period of illness NA. 
*Adolescents, ICU, intensive care unit, NA, not available 
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       Table 3. 10:  Midazolam doses in children  
Age group 
Loading dose or 
Single dose (SD) 
Mg/kg 
Midazolam 
infusion 
Mg/kg/h 
Number 
of blood 
samples 
collected 
Method Study 
2-11 yrs  NA 0.05-0.4 3 Two compartment de Wildt et al.(2003)(164) 
0.1-0.5 0.01-0.06 5 Two compartment Roberts et al. (2009)(187) 
0.3 NA 13 Non-compartment Muchohi et al.(2008)(188) 
0.05 0.05 12-14 Non-compartment 
Mathews et 
al.(1988)(185) 
0.25-1 NA 12 
One and two 
compartment 
Reed et al.(2001)(186) 
0.2 NA 10 Non-compartment Rey et al.(1991)(189) 
NA 0.5 9 
Three-
compartment 
Jones et al.(1993)(190) 
NA 0.1 13 Two compartment Kraus et al.(1989)(191) 
NA 0.15 9 Non-compartment Payne et al.(1989)(192) 
NA 0.15-0.45 12 Non-compartment Salonen et al.(1987)(193) 
12-18yrs NA 0.1 7 Non-compartment Tolia et al.(1991)(194) 
6dys-16yrs NA NA 5 Non-compartment Nahara et al.(2000)(97) 
                               NA, not given  
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 Table 3. 11: Midazolam clearance in critically ill children 
Age 
group 
Number 
of 
patients 
Range of 
age 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/kg/min) 
SD 
Coefficient 
of variation 
(CV %) 
Range of 
clearance 
(ml/kg/min) 
Variation ratio 
in clearance 
Comments Study 
>28 dy-23 
Mos 6 
1-8mos 
(3)* 
4-20 
(8) * 
4.8 5 89 1.8 - 16 9 
Two stage PK study, Individual  
data available, Pop-PK 
de Wildt et al. (164) 
5 1.3* yrs 8.8* 9 3.4 37 NA NA Non-pop-Pk Mathews et al. (185) 
24 
3-24.7mos 
(11) * 
5-12 16.7 5.2 31ƒ 0.1-0.6 6 
Not ventilated, ml/min 
(not kg-1),CV Pop-PK 
Peeters et al. (184) 
2-11 yrs 
 5† 
7-14 
(8) * 
13-88 
(38)* 
1.1 NA NA 0.9-3.8 4 
Individual  data available, Non-
pop-Pk 
Roberts et al. (187) 
6 
2.8-9 
(7)* 
13-25 
(20)* 
6 3.8 72 2.3-11 5 
Two stage PK study, Individual  
data available, Pop-PK 
de Wildt et al.(164) 
12 
7-39mos 
(27)* 
8.7-12 
(10)* 
14 NA NA 9.2-19.7 2 Non-pop-Pk Muchohi et al. (188) 
6 5* 18* 12 6.6 55 NA NA Non-pop-Pk 
Mathews et al. (185) 
6 4.7* 16* 8.5 1.8 21 NA NA - 
8 dy to 16 
yrs 
22 8dys-16yrs NA NA NA NA 1.6-51.6 32 Non-pop-Pk Nahara et al. (97) 
    *Mean,†only one patient with 14 years old, SD, standard deviation, CV, Coefficient of variation, POP-PK, population pharmacokinetics study, non-pop-Pk, non-population              
  pharmacokinetic study, ƒ,CV provided by authors,  NA, not available. 
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Table 3. 12: Midazolam clearance in non-critically ill children 
Age group 
Number 
of 
patients 
Range of 
age 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/kg/min) 
SD 
Coefficient 
of variation 
(CV %) 
Range of 
clearance 
(ml/kg/min) 
Variation 
ratio 
in clearance 
Comments Study 
>28 dy-23Mos 
5 6mos-<2yrs 3-13 11 6 53 NA NA Two stage PK study, Pop-PK 
Reed et al. (186) 
 
2-11 yrs 6 
 
1.8-4 
(2.5) 
11-17 
(15)‡ 
13 4 41 9.5-17.8 2 Individual  data available Rey et al.  (189) 
12 
 
5-9 
(6.5)‡ 
14-39 
(22)‡ 
15 3 20 11-23 2 Non-pop-Pk Jones et al. (190) 
6 3-7 15-30 3.2 1.1 54 1.1-6.5 6 
Individual  data available, 
Non-pop-Pk 
Kraus et al. (191) 
21 6‡ 23‡ 7 3 42 1.3-13.7 10.5 Non-pop-Pk 
Salonen et al. (193) 
 
14 2-<12 19.5‡ 10 3.8 38 NA NA Two stage PK study, Pop-PK 
Reed et al. (186) 
 
8 5.5‡ 17‡ 9 1.2 13 NA NA Non-pop-Pk 
Payne et al. (192) 
 
12-18 yrs 
20 
8-17 
(13.5)* 
NA 10 5 50 NA NA Non-pop-Pk 
Tolia et al. (194) 
 
         ‡Mean;*Median, SD, standard deviation, CV, Coefficient of variation, POP-PK, population pharmacokinetics study, non-pop-Pk, non-population pharmacokinetic study, NA not available, 
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              Table 3. 13: Coefficient of variation for midazolam clearance in paediatrics  
Age 
Critically ill % 
(n) 
Non-critically ill % 
(n) 
Preterm neonates 78-109 
(113) 
- 
Term neonates 18-77 
(247) 
- 
Infants 31-89 
(35) 
53 
(5) 
Children 21-72 
(35) 
13-54 
(67) 
Adolescents 
- 
50 
(20) 
(n), number of patient 
3.5.7. Effect of covariates on midazolam clearance and variability 
All studies in neonates were performed in those that were critically ill. 
It was therefore not possible to compare the effect of critical illness. 
Also, there was only one study performed in 20 adolescents who were 
not critically ill (194), so it was not possible to compare the effect of 
critical illness in this age group either.  
Three studies were performed in 34 critically ill infants (164, 184, 
185), but only one study in those not critically ill. (186). This study 
only included five infants and so it was therefore felt inappropriate to 
try and perform statistical comparison. 
Statistical comparison was therefore only performed between children 
aged 2-11 years, who were critically ill and those who were non-
critically ill. The coefficient of variation between these studies was 
compared using Students t-test. Mean CV for critically ill children was 
49% while the mean CV from non-critically ill children was 35%. 
However, this difference was not statistically significant p=0.261. 
Meta-analysis is inappropriate to compare coefficient of variations. 
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Mean CV of midazolam clearance in preterm neonates 91% was 
significantly higher than children 40% (p=0.002). There were no 
significant differences between other age groups. 
A total of 17 PK studies across all age groups were identified. The 
mean clearance for these studies was 5.89 ml/min/kg (95% CI 4.69-
6.67). The effect of covariates, such as age, critical illness, weight and 
sample size on midazolam CL was evaluated in a meta-regression. 
Weight, age and critical illness were statistically significant co-variates 
(p=0.007, 0.001 and 0.016 respectively). Sample size and study type 
were not significant. Critical illness was however not a statistically 
significant predictor of midazolam clearance after adjusting for age and 
weight (p=0.279). After adjusting for critical illness and weight, age 
remained a statistically significant predictor of midazolam clearance 
(Table 3.15). 
              Table 3. 14: Unadjusted meta-regression for covariates 
Covariates 
 
P value 
Age  
 
 
Term neonates 
 
Infants 
 
Children 
 
Adolescents 
 
 
0.737 
 
< 0.001 
 
< 0.001 
 
0.016 
Critical illness 0.007 
Weight  <0.001 
Study type  0.156 
Sample size  0.295 
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As a result of the heterogeneity of midazolam clearance for preterm 
and term neonatal studies, meta-analysis using the random effect 
model was performed. Pooled mean clearance were 1.25 (95% CI 
0.83-1.67) and 1.75 (1.2 -2.29) respectively for critically ill preterm 
and term neonates (Figures 3.2 and 3.3). 
 
Figure 3. 2: Mean CL and CIs for preterm neonates 
 
 
   
Figure 3. 3: Mean CL and Cls for term neonates 
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The mean clearance from studies involving infants and children was 
highly heterogeneous (I square>80%); therefore the mean clearance 
was not pooled.  
Multiple factors such as age (p=0.003), weight (p=0.002) and critical 
illness (p=0.031) are significantly associated with CV. A multiple linear 
regression analysis of the effects of these covariates however shows 
that age group alone is independently associated with the CV 
(p<0.05). 
3.6.  Discussion 
This systematic review shows that the CV of midazolam clearance 
varied between 13% and 109% across all age groups. In neonates, it 
ranged between 78% and 109% and in children CV was between 21% 
and 72%. Critical illness significantly increased the variability of 
midazolam in all pediatric studies. However, after adjusting for weight 
and age, this was not significant. There was no significant difference in 
variability between critically ill and non-critically ill children (2-11years 
old) and the relationship between critical illness and variability in other 
age groups (neonates, infants and adolescents) could not be 
determined due to the non-availability of data for non-critically ill 
patients.  
A study by Ince et al. (2012) had previously demonstrated the effect 
of critical illness on the clearance of midazolam. They reported 93% 
and 86% reduction in CYP3A4/5 mediated midazolam clearance among 
72 
 
ICU patients when compared with non-critically ill patient groups 
(197). Critical illness is however a broad categorisation including, 
diverse disease states such as sepsis, renal failure, respiratory failure. 
It was impossible to determine the effect of specific disease conditions 
on midazolam clearance due to the limited number of studies and the 
clinical details provided about the patients they included. Van den 
Anker (2003) have however previously shown that  covariates such as 
renal failure, hepatic failure, and concomitant administration of CYP3A 
inhibitors affect midazolam PK among critically ill children (198). 
However, many of the studies in this review excluded patients on co-
medication, as well as hepatic and renal failure. 
Age was a significant predictor of CV and clearance. Clearance is 
generally lower in neonates than older children and adolescents (199) 
due to the immaturity of drug metabolism process in neonates (176, 
181). The CV was greater in preterm neonates (78%-109%) than term 
neonates (18%-77%), probably due to the developmental changes in 
metabolising enzymes, which is more prominent during this stage of 
life. The major pathway of midazolam metabolism is oxidation which 
involves the cytochrome P450 dependent (CYP) enzymes (200) and 
the enzymes involved are CYP3A4, CYP3A5 and CYP3A7 (175, 200). 
CYP34A activity is significantly reduced in early neonatal life, but 
gradually increases as the liver matures (Figure 1.2) (26-28). CYP3A7 
has greatest activity in the neonatal period (28). This variability in 
maturation will account for some of the variability in PK. 
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A limitation of this review is the lack of sufficient studies involving non-
critically patients. Thus, it was impossible to establish the relationship 
between critical illness and CV or clearance, for the different age 
categories. Furthermore, some studies did not report the CV and some 
others did not provide the required details, such as the standard 
deviation and individual clearance values, for the calculation of CV.  
Midazolam is administered by a continuous intravenous infusion in 
critically ill children and the dose is titrated in relation to the response. 
With about 44-fold variability in clearance in children, the development 
of dosing strategies based on midazolam plasma concentrations in 
critically ill patients may be difficult (201). Therefore, midazolam 
dosing should be individualised. This is particularly important in 
neonates with high inter-individual variation during the first few days 
of life. Therefore, after the initial dosing of midazolam, maintenance 
dosing should be based on the  individuals response (5). An approach 
to achieving this is by therapeutic drug monitoring (5, 201). This 
involves the measurement of drug concentration at designated 
intervals to maintain a constant concentration in a patient's 
bloodstream, in order to optimise individual dosage regimens and 
efficacy (202). 
Furthermore, optimisation of dosing can also be achieved by PK/PD 
modelling, which links dose-concentration relationship (PK) with 
concentration-effect relationship. The effect of inter-individual 
variability and other covariates can be established by utilising  the 
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population PK approach (203, 204). Such studies have been used to 
predict the disposition of midazolam and theophylline in paediatrics 
(205). 
Overall, it is important clinicians are aware of this variation and should 
titrate dose based on clinical response and adverse effects. 
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CHAPTER FOUR                                                               
 A SYSTEMATIC LITERATURE REVIEW OF INTER-INDIVIDUAL 
VARIATION IN THEOPHYLLINE CLEARANCE IN CHILDREN 
 
4.1. Introduction 
Theophylline is 1, 3-dimethylxanthine; it was first used clinically in the 
early 20th century (206). Although its mechanism of action is not fully 
known, it has been hypothesised that its bronchodilator effect is due to 
phosphodiesterase inhibition, which causes an increase in cyclic 
adenosine monophosphate (cAMP) (207). Other possible mechanisms 
include inhibition of adenosine receptors (208), interleukin-10 release 
(209) and prevented transport of proinflammatory transcription factor 
(KB) into the nucleus (210) . 
Theophylline can be administered IV or orally. For the treatment of 
acute asthma in children, theophylline is administered as IV 
aminophylline which is a combination of theophylline and 
ethylendiamine (211). For chronic asthma in children, oral theophylline 
may be used. 
After IV administration, theophylline is rapidly distributed throughout 
the extracellular fluid. Its volume of distribution is between 0.4 to 0.7 
L/Kg (212). Theophylline reversibly binds to plasma proteins, with 
about 40% bound (212). It is metabolised in the liver by CYP1A2, 
CYP2E1 and CYP3A3 to an active metabolite (3-methylxantheine) 
(212). The half-life of theophylline varies with age. In preterm 
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neonates it ranges between 14 to 58 hours. In children (1-4 years old) 
half-life varies between 2 to 5 hours while in adults it is between 3 to 9 
hours (213).   About 10% is excreted unchanged in the urine (214). 
Theophylline has a narrow therapeutic range. As result, patients on the 
drug may require monitoring of theophylline plasma concentration 
(213). Generally, a plasma concentration of 10-20 mg/L is required to 
produce a therapeutic effect (213). 
Theophylline is currently not licensed for neonatal use. It can, 
however, be given to neonates for apnoea as an aminophylline 
intravenous injection. The dose varies according to age. In chronic 
asthma, infants between 6 months and two years require 12mg twice 
daily orally, children between 2 and 6 years can receive up to 120mg 
twice daily and children of 6-12 years can be given up to 250mg twice 
daily. A dose of up to 500mg twice daily is recommended for 
adolescents (215). 
Common side effects in children include tremor, insomnia, nausea 
vomiting, abdominal distension, dyspepsia, palpitations (216, 217). 
Factors such as age , diet , disease , obesity  and other drugs  can 
influence the clearance of the drug and contribute to the extensive 
inter-individual variability of theophylline clearance (211, 218). 
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4.2.  Aims  
The purpose of this systematic review is to determine the variability of 
theophylline clearance in children and establish the factors which are 
responsible for this variability. 
4.3. Objectives  
 Determine the extent of inter-individual variation in theophylline 
clearance by estimating the CV. 
 Evaluate the effect of factors such as age, birth weight and 
critical illness that may be responsible for the inter-individual 
variation in theophylline. 
4.4. Methods  
The methods for this chapter are described in chapter two. 
4.5. Results 
A total of 2,663 articles were short listed by five search engines 
(Figure 4.1). Only 48 articles (including 9 identified by manual search) 
met the inclusion criteria. Table 4.1 shows the details of papers 
excluded from the systematic review. 
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Figure 4. 1: Search strategy of theophylline 
  
CINAHL 
96 
IPA 
159 
         
 
MEDLINE 
703 
EMBASE 
1,606 
2,663 Studies 
                                            
 
2,295 Studies 
 
 
  1,568 Studies excluded  
 
           48 Studies Included 
          
 
 
689 duplicates 
Cochrane 
99 
 
 368 non-human studies           
                1,606 Studies 
 
 
10 Manual search articles 
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Table 4. 1: Details of excluded articles from systemic review 
Exclusion Reason 
Review studies 383 
Editorials 5 
Case reports 12 
Conference abstracts 4 
Studies in adults aged over 18 years  180 
Combined adult and paediatric studies where paediatric data was not 
presented separately 
5 
Studies where data for theophylline was not presented 442 
Studies in which theophylline not administered intravenously 51 
Studies that did not evaluate the pharmacokinetics of theophylline 486 
Total 1,568 
 
4.5.1  Quality assessments 
Twenty nine studies were included after excluding 19 studies. Eleven 
of these did not report the number of blood samples collected (219-
229) and 8 studies collected less than three samples (230-237)(Table 
4.2).  
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            Table 4. 2:  Studies excluded after Quality assessment  
Study Age group 
†Number 
of 
patients 
+Number of 
blood 
samples 
collected 
Method 
Robert et al. (1990)(219) Preterm 
neonates 
12 NA Non-compartmental 
Nahata  et al. (1989)(230)     9 1 Non-compartmental 
Narui et al. (2003) (220)      24 NA Non-compartmental 
Lowry et al. (2001) (221)     3 NA One compartment 
Bonati et al. (1981) (222) 9 NA Non-compartmental 
Samira  et al. (2004)(231)   50 2 Non-compartmental 
Gilman et al. (1986)(223)    179 NA Non-compartmental 
Gal et al. (1982)(232)       Term neonates 30 1 Non-compartmental 
Imai et al. (2012) (233) Infants  30 1 Non-compartmental 
Igarashi  et al. (2009)(224)  69 NA Non-compartmental 
Mayo  (2001) (234) Children  31 2‡ Non-compartmental 
Odajima (225) 33 NA Non-compartmental 
Yano et al. (1993) (226) 66 NA Non-compartmental 
Slotfeldt et  al.(1979) (235) 3 1 ‡ Non-compartmental 
Ginchansky et al.(1977) (227) 23 NA Non-compartmental 
Weinberger et al. (1976)(236) Adolescents  6 1‡ Non-compartmental 
Reiter et al. (1992)(228) 3mos-14yrs 61 NA Non-compartmental 
Muslow et al.  (1992) (229) 6mos-4yrs 58 NA One compartment 
Itazawa et al. (2006) (237) 0-6yrs 21 2 Non-compartmental 
†Studies with ≤ 2 patients or with number of patients not stated are excluded; +Studies with ≤2                             
samples or with the number of samples not stated are excluded, ‡serum 
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Table 4. 3:  Studies included after Quality assessment 
Study Age group 
Number of 
patients 
Number of 
blood samples 
collected 
Method 
Latini et al. (1978)(238)  
 
 
 
 
 
 
Preterm 
neonates 
7 8-10 One compartment 
Aranda et al. (1976)(239) 6 10 Two compartment 
Stile et al. (1986)(240) 9 8 One/Two compartment 
Jones and Baillie. (1979) 
(241)  
12 >2 One compartment 
Dothey  et al. (1989) (242) 9 6 Non-compartmental 
Moustogiannis et al. (1997) 
(243) 
15 6 Non-compartmental 
Kraus et al. (1993) (244) 52 7‡ Non-compartmental 
Ahn et al. (1999) (245) 7 5‡ Non-compartmental 
Ni Y et al. (2009) (246) 11 5‡ Non-compartmental 
Bolme et al. (1979) (247)  
 
 
Infants 
5 12‡ Two compartment 
Simons et al.  (1978) (248) 13 6‡ One compartment 
Franko et al. (1982) (249) 12 6‡ One compartment 
Eriksson et al.(1983)(250) 6 6* Non-compartmental 
Desoky et al. (1997)(251) 
 
 
 
 
 
Children 
15 3* One compartment 
Hill  et al. (1988) (252) 7 11 Two compartment 
Scott et al. (1989) (253) 7 8‡x Non-compartmental 
Loughnan et al.(1976) (254) 10 7* Two compartment 
Uematsu  (1993) (255) 16 6‡ One compartment 
Arnold et al. (1981) (256) 8 9* Non-compartmental 
Vichyanond et al. 
(257)(2011)   
13 11‡ One compartment 
Leung et al. (1977) (258) 8 3*x Non-compartmental 
Prats (1991) (259) 16 3 Non-compartmental 
Principi et al. (1987) (260) 5 8‡ One/Two compartment 
Kubo et al. (1986)(261) 13 3*x Non-compartmental 
Eriksson et al.(1983)(250)  25 6* Non-compartmental 
Larsen et al. (1980)(262) 
Adolescents 
18 14‡ Two compartment 
Leung et al. (1977) (258) 22 3*x Non-compartmental 
LaForce et al. (1981)(263) 9-19 Yrs 14 3‡x Non-compartmental 
Walson et al. (1977) (264) 7-16 Yrs 7 5‡x Non-compartmental 
Ellis et al. (1976)(265) 6-18 Yrs 30 9 * Two compartment 
Wells et al. (1984)(266) 1-14yrs 29 3‡x One compartment 
 *plasma, ‡serum, x, at steady state 
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4.5.2. Clearance of theophylline in neonates (0 - 27 days) 
Ten studies reported theophylline clearance in 131 neonates. All were 
single centre studies and involved critically ill neonates (238-246, 
259). The majority treated apnoeic neonates. The number of 
participants varied between 3 and 20. Age and weight were the most 
common covariates (Table 4.4). The number of collected blood 
samples was between 3 and 10. Theophylline loading dose varied 
between 5 and 7 mg/kg and maintenance dose between 1 and 6 
mg/kg/h (Table 4.5).  
Seven of the studies were non-compartment studies; there were 2 one 
compartment studies and 1 two compartment studies. None of the 
studies reported the effect of drug-drug interaction. 
The mean clearance from all preterm neonatal studies ranged between 
0.2 and 0.9 ml/min/kg. 
The CV ranged between 9% and 58% in studies involving preterm 
neonates. The lowest of these values was reported in a study involving 
6 preterm neonates receiving aminophylline for apnoea (239). The 
highest was recorded for a study involving 5 preterm neonates treated 
for apnoea.   
Eight studies provided data regarding the range of clearance values for 
individual neonates. The variation ratio of clearance in preterm 
neonatal studies ranged between 1.5-7 fold. 
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Table 4. 4: Characteristics of studies in preterm  
Study 
Number 
of 
patients 
Gestational 
age 
(weeks) 
Postnatal 
age 
(days) 
Range of 
weight 
(kg) 
Type of 
patients 
Covariates Comments 
Latini et al. 
(1978)(238) 7 
26-33 
(31)* 
4-8 
(7)* 
0.87-2.7 
(1.66)* 
Severe 
apnea 
Age 
Patients with hypoglycemia, CNS infection or sepsis were 
excluded. Duration of illness was 13 days. 
 
Aranda et al. 
(1976)(239) 
6 
 
25-32 
(27)* 
NA 
0.6-1.2 
(0.9)* 
Apnea Age Duration of illness between 3-15 days. 
Stile et al. 
(1986)(240) 
9 
 
25-30 
(28)* 
NA 
0.8-1.5 
(1)* 
Apnea Age and weight - 
Jones and 
Baillie 
(1979)(241) 
12 
25-30 
(28)* 
1-3 
0.7-1.4 
(1.1)* 
Apnea NA 
Any patient with infection was excluded. 
Duration of illness NA. 
Dothey  et al. 
(1989)(242) 9 
25-30 
(28)* 
12-191 
(57)* 
0.9-2.4 
(1.3)* 
Apnea Age and weight 
Patient who received drugs such as phenobarbital or cimeditine 
as well as patients with cholestatic hepatitis were excluded. 
Duration of the illness NA. 
Ahn et al. 
(1999)(245) 
7 
28.5-34 
(32)* 
2-26 
(8)* 
0.6-1.5 
(1.2)* 
NICU NA 
Patients were apnea and/or bradycardia. 
The neonates with hypoxemia, patent ductus arteriosus, 
anemia, infection, metabolic abnormalities, or abnormal liver 
and kidney functions were excluded. Duration of illness NA. 
 
Moustogiannis 
et al. 
(1997)(243)  
 
5 
5 
5 
 
33* 
33* 
34* 
 
 
10* 
9* 
9* 
 
 
1.55* 
1.6* 
1.7* 
Apnea 
Fluid and calorie 
intakes 
Neonates with perinatal asphyxia, respiratory distress 
syndrome, hemodynamic instability or hepatic or renal failure 
were excluded. Nine patients were given ampicillin and 
gentamicin while sepsis and /or necrotizing enterocolitis were 
evaluated as secondary causes of apnea no other medications 
were given. Duration of illness NA. 
Kraus et al. 
(1993)(244)  
20 
15 
17 
29* 
30* 
31* 
2-9 
NA 
NA 
NA 
Apnea 
Age, weight, co-
medication and race 
Patients with known bleeding abnormalities, renal and hepatic 
impairment were excluded. Duration of illness NA. 
 
Ying-hua et al. 
(2009)(246) 11 
 
30-33 
(31)* 
NA 
1.1-2  
(1.5)* 
Apnea Age Duration of illness NA. 
Prats (1991) 
(259) 
 
3 NA 
6-20 
(12)* 
1-3 
(1.7)* 
NICU Age Duration of illness NA. 
                *Mean ,NICU, neonatal intensive care unit, NA, not available
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            Table 4. 5: Theophylline doses in neonates  
Loading dose or 
Single dose (SD) 
Mg/kg 
Theophylline 
infusion 
Mg/kg/h 
Number of blood 
samples collected 
Study 
NA 3.3-6 4-8 Latini et al. (1978) (238) 
5.5 2.5-5 10 Aranda et al. (1976) (239) 
5.5 2.5 8 Stile et al. (1986) (240) 
5-7 4.4 >2 Jones and Baillie (1979)(241)  
NA NA 6 Dothey  et al. (1989) (242) 
5 NA 6 Moustogiannis et al. (1997)(243) 
NA 2.1-26.4* 7 Kraus et al. (1993) (244) 
5 1 5 Ahn et al. (1999 (245) 
NA 5 5 Ying-hua et al. (2009)(246) 
5* 1.4* 3 Prats (1991 (259) 
        *Mean, NA, not given  
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             Table 4. 6: Theophylline clearance in critically ill preterm neonates 
Number of 
patients 
Mean Clearance 
(ml/min/kg) 
SD 
Coefficient of 
variation 
(CV %) 
Range 
(ml/min/kg) 
Variation Ratio Comments Study 
7 0.2 NA NA 0.11-0.49 1.5 Individual data available  Latini et al. (238) 
6 1.1 0.1 9 0.7-1.5 2 - Aranda et al. (239) 
9 0.7 0.23 45 0.5-1 2 Individual data available  Stile et al. (240) 
12 0.3 0.08 25 0.2-0.5 2.5 Individual data available  Jones and Baillie (241) 
9 0.4 0.23 50 0.15-0.98 6 Individual data available  Dothey  et al. (242) 
7 0.4 0.1 25 NA NA - Ahn et al. (245) 
11 0.23 0.1 10 0.1-0.4 4 Individual data available  Ying-hua et al. (246) 
20 0.3 0.1 33 NA NA - 
Kraus et al. (244) 15 0.5 0.2 40 NA NA 
17 1.1 0.2 18 NA NA 
a
5 0.3 0.07 23 0.23-1.6 7 - 
Moustogiannis et al. (243) b5 0.5 0.25 50 - - 
c
5 0.9 0.53 58 - - 
3 0.5 0.1 11 0.4-0.7 2 Individual data available  Prats (1991) (259) 
SD, standard deviation, CV, Coefficient of variation, all studies were non-population pharmacokinetics ,Categorized according to caloric intakes, a) 150 Kcal, b) 98 kcal, c) 38  
Kcal, NA, not available
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4.5.3. Clearance of theophylline in infants (>28 days -23 months) 
Four studies reported theophylline clearance in 37 infants (247-250). 
All were single centre studies involving between 6 to 13 participants. 
The most common covariate was age. The number of blood samples 
varied between 6 to 12 (Table 4.7). There were two 1 compartment 
and 1 two compartment studies.  
All studies were in non-critically ill infants. The mean clearance in 
these infants varied between 0.6 and 2 ml/min/kg. All studies gave 
data regarding the range of clearance values for individual infants. 
The variation ratio ranged between 3-10 fold. The CV ranged from 
22% to 52% (Table 4.8). 
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Table 4. 7: Characteristics of studies in infants  
Study 
Number of 
patients 
Loading dose or 
Single dose (SD) 
Mg/kg 
Theophylline 
infusion 
Mg/kg/h 
Number of 
blood samples 
collected 
Type of 
patients 
Covariates Comments 
Simons  et al. (1978)(248) 13 NA 0.65 6 Asthma  Age 
Duration of illness was between 
24-192h. 
Franko et al. (1982)(249) 12 5-8 2.5-5 6 Bronchiolitis Age Duration of illness NA. 
Bolme et al. (1979)(247) 6 5-6 NA 12 Asthma 
Route of 
administration 
Duration of illness NA. 
Eriksson et al.(1983)(250) 6 NA 5 6 Asthma 
Nutritional 
status 
6 underweight patients.  
        NA, not given  
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 Table 4. 8: Theophylline clearance for infants (>28 days-23 months)  
Number 
of 
patients 
Range of age 
 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient of 
variation 
(CV %) 
Range 
Variation 
Ratio 
Comments Study 
12 
3wks-6.5mos 
(3.6mos)* 
2.6-10 
(5)* 
0.6 0.23 22 0.3-1 3 Individual data available 
Franko et al. (249) 
6 
2-14mos 
(8)* 
NA 2 0.9 45 0.3-3 10 Individual data available 
Bolme et al. (247) 
13 
3-20mos 
(10)* 
NA 1.07 0.55 52 0.47-2.4 5 Individual data available 
Simons et al. (248) 
6 1.9 yrs 
7-11 
(8)* 
1 0.15† NA NA NA - Eriksson et al.(1983)(250) 
           *Mean, †SE, slandered error, SD, standard deviation, CV, Coefficient of variation, all studies were non-population pharmacokinetics study, NA, not available
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4.5.4. Clearance of theophylline in children (2-11 years) 
Twelve studies reported theophylline clearance in 143 children (250-
253, 255-261, 267). All studies were single centre studies. The 
number of participants in each study varied between 5 to 25. The 
most common covariate was age (Table 4.9). Maintenance dose 
varied between 1-13.6 mg/kg/h (Table 4.10).  
The number of blood samples collected was between 3 to 11. The 
majority (5 studies) were non compartment. There were 3 and 2 one 
and two compartment studies respectively. Drug-drug interaction was 
not reported in any of the studies (Table 4.3). 
The mean clearance from all these studies ranged between 1 and 2 
ml/min/kg. The CV ranged between 20% and 50% in studies 
involving non-critically ill children (Table 4.11). The lowest CV was 
reported in a study involving 7 patients who received treatment for 
moderate to severe asthma. The highest value was documented in a 
study involving 7 patients who received theophylline for chronic 
asthma (253). Four studies involved critically ill children with acute 
asthma, and the CV in those studies ranged between 29% and 72%. 
Nine studies gave data regarding the range of clearance (Table 4.12). 
The variation ratio of theophylline clearance in all children involved in 
these studies ranged between 1.3 and 5 fold.  
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 Table 4. 9: Characteristics of studies in children  
Study 
Number of 
patients 
Type of patients Covariates Comments 
Scott et al. (1989) 
(253) 
7 Asthma NA Duration of treatment NA. 
Loughnan et al. 
(1976)  (254) 
10 Chronic asthma Age 
Other drugs prednisone, orciprenaline, phenobarbital, ephedrine, penicillin and 
erythromycin. 
Desoky et al. 
(1997)(251) 
15 
Acute asthma with 
dyspnoea and cough 
NA 
Normal liver and kidney function. 
Duration of treatment NA. 
Hill  et al. (1988) 
(252) 
7 
Moderate to severe 
asthma 
NA 
All patients were free of cardiac, renal and hepatic disease. 
Duration of treatment NA. 
Uematsu  (1993) 
(255) 
16 Asthma Age 
No patents showed hepatic or renal dysfunction also No patents’s body temperature 
exceeded 37.5 °C. 
Arnold et al. 
(1981)(256) 
8 Acute asthma NA All patients were with normal hepatic and renal function  
Vichyanond et al. 
(257) (2011)   
13 Asthma NA 
Patients with upper respiratory tract infection and acute asthma were excluded. 
Duration of illness NA. 
Leung et al. 
(1977)(258) 
8 Severe asthma Age - 
Prats (1991) (259) 16 ICU Age 
Duration of illness NA. 
 
Principi et al. 
(1987)(260) 
5 Chronic asthma NA The clearance was not altered by miocamycine administration.  
Kubo et al. (1986) 
(261) 
13 Severe asthma NA 
Exclusion patients with viral infection, hepatic or renal disease also patients who 
received β2- adrenergic agonists or hydrocortisone were excluded. 
Duration of illness NA. 
Eriksson et 
al.(1983)(250) 
25 Asthma 
Nutritional 
status 
12 patients were normal, 8 Marasmus and 5 Kwashiorkor. 
            ICU, intensive care unit, NA, not available 
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Table 4. 10: Theophylline doses in children  
Loading dose or 
Single dose (SD) 
Mg/kg 
Theophylline 
infusion 
Mg/kg/h 
Number of 
blood samples 
collected 
Study 
6 1 3 Desoky et al. (1997)  (251) 
NA 4-6 11 Hill  et al. (1988)  (252) 
NA 13.6 8 Scott et al. (1989) (253) 
4* 0.9* 3 Prats  (1991) (259)    
NA 3 7 Loughnan et al. (1976) (254) 
NA 3-4 6 Uematsu  (1993) (255) 
NA 2-4 9 Arnold et al. (1981) (256) 
NA 5 11 Vichyanond et al. (2011) (257)  
NA 1 3 Leung et al. (1977) (258) 
NA 4.5 8 Principi et al. (1987) (260) 
NA 5-7 3 Kubo et al. (1986)(261) 
NA 5 6 Eriksson et al.(1983)(250) 
        *Mean, NA, not given  
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Table 4. 11: Theophylline clearance for non-critically ill children (age 2-11 years) 
Number 
of 
patients 
Range of 
age  
(year) 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient 
of variation 
(CV %) 
Range 
(ml/min/kg) 
Variation 
Ratio 
Comments Study 
15 
2-12 
(6.4)* 
12-30 
(20)* 
1 0.20 46 0.7-1.5 2 
Individual data available 
Pop-PK 
Desoky et al. (251) 
7 2-7 NA 2 0.44 20 1.5-3 2 
Individual data available, 
Non-PK 
Hill et al. (252) 
7 7-11 NA 1.5 0.43 50 0.9-2 2 
Individual data available, 
Non-PK 
Scott et al. (253) 
10 
1.3-4 
(2.5)* 
9-16 
(13)* 
1.6 0.6 38 0.95-3 3 Non-Pop PK Loughnan et al. (254) 
16 
6-11 
(8.7)* 
15-45 
(28)* 
1 0.4 38 0.5-1.8 3.5 
Individual data available 
Non-pop-PK 
Uematsu (255) 
8 
7-12 
(10)* 
NA 1 0.55 45 0.6-2.3 4 
Individual data available 
Non-pop-PK 
Arnold et al. (256) 
13 
7-12 
(9)* 
29* 1.5 NA NA 0.6-3 5 Non-pop-PK Vichyanond et al. (257) 
12‡ 2.7* 13* 1.2 0.2† NA NA NA - 
Eriksson et al. (1983)(250) 8‡ 4.4* 7* 1.45 0.17† NA NA NA - 
5‡ 2.4* 9.5* 1.49 0.22† NA NA NA - 
 *Mean, ‡ three different groups, normal, Marasmus and Kwashiorkor, †SE, slandered error, SD, standard deviation, CV, Coefficient of variation, POP-PK, population                                              
pharmacokinetics    study, non-pop-Pk, non-population pharmacokinetics study, NA, not available  
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Table 4. 12: Theophylline clearance for critically ill children (age 2-11 years) 
Number 
of 
patients 
Range of 
age 
(year) 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient of 
variation 
(CV %) 
Range 
(ml/min/kg) 
Variation 
Ratio 
Comments Study 
8 
6-12 
(8)* 
19-48 
(34)* 
1.3 0.4 29 1.18-1.5 1.3 
Individual data available, 
Non-Pop PK 
Leung et al.(258) 
16 
3-11 
(6)* 
14-49 
(30)* 
1 0.4 44 0.68-1.6 2.5 
Individual data available 
Non-Pop PK, 
Prats  (259) 
5 7-10 NA 1.7 0.3 72 0.36-2 2 
Individual data available, 
Non-Pop PK 
Principi et al.(260) 
13† 
4-12.8 
(7.5)* 
15-40 
(24)* 
1 0.6 60 0.79-3 4 
Individual data available, 
Non-Pop PK 
Kubo et al. (261) 
*Mean, †,Only one patient with 12.8 years old, SD, standard deviation ,CV, Coefficient of variation, non-pop-Pk, non-population pharmacokinetics study, NA, not  
available 
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4.5.5. Clearance of theophylline in adolescents (12-18 years) 
Two studies (1 critically ill and 1 non-critically ill) reported 
theophylline clearance in 30 adolescents. Age was a covariate in one 
study while the other did not report any covariate. Theophylline 
infusion dose was 1 and 4 mg/kg/h for critically and non-critically 
patients respectively (Table 4.13). None of the studies reported the 
effect of drug-drug interaction. 
The CV of these patients was 29% and 43% (Table 4.14). Both 
studies gave the range for theophylline clearance. The variation ratio 
in critically ill adolescents was 1.4 and 5-fold.  
Table 4. 13: Characteristics of studies in adolescents   
Study 
Number 
of 
patients 
Loading dose or 
Single dose(SD) 
Mg/kg 
Theophylline 
infusion 
Mg/kg/h 
Number 
of blood 
samples 
collected 
Type of 
patients 
Covariates 
Larsen et al. 
(1980)(262) 
8 NA 4 14 
Cystic 
fibrosis 
NA 
Leung et al. 
(1977)(258) 
22 NA 1 3 
Severe 
asthma 
Age 
NA, not given 
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             Table 4. 14: Theophylline clearance for adolescents (age 12-18 years)  
Number 
of 
patients 
Range of age 
(Year) 
Range of 
weight 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient 
of variation 
(CV %) 
Range 
(ml/min/kg) 
Variation 
ratio 
Comments Study 
8‡ 
12-18 
(14.5)* 
26-53 
(45)* 
1.5 0.5 29 0.9-2.5 3 
Individual data 
available 
Larsen et al. (262) 
22† 12-17 31-61 1.3 0.6 43 0.60-2.93 5 
Individual data 
available 
Leung et al. (258) 
              ‡Non-critical, †Critical ill, *mean, SD, standard deviation, CV, Coefficient of variation, all studies were non-population pharmacokinetics 
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4.5.6. Clearance of theophylline in paediatric patients of mixed ages 
Four studies reported theophylline clearance in 80 children across all 
age categories. These involved a combination of different age groups. 
All were single centre studies and the number of participants varied 
between 7 to 30. Covariates in these studies included age, sex and 
weight. Maintenance dose varied between 4 to 30 mg/kg/h and the 
number of blood samples collected was between 3 to 9 (Table 4.15). 
None of the studies reported the effect of drug-drug interaction. 
All studies except one were conducted with non-critically ill patients. 
The mean clearance for these studies ranged between 0.8 and 1.5 
ml/min/kg (Table 4.16). 
The CV ranged between 5% and 45% in all studies. The lowest CV of 
5% was reported in a study involving 29 patients (aged 1 - 14 years), 
while the highest CV of 45% was documented in a study involving 7 
patients (aged 7-16years)(264, 266). 
All studies documented the range of clearance values. The variation 
ratio of theophylline clearance ranged between 2 to 8 fold. 
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 Table 4. 15: Characteristics of studies in mixed age groups  
Study 
Number 
of 
patients 
Loading dose or 
Single dose (SD) 
Mg/kg 
Theophylline 
infusion 
Mg/kg/h 
Number of 
blood samples 
collected 
Type of 
patients 
Covariates Comments 
LaForce et al. 
(1981) (263) 
14 NA 16-30 3 Asthma 
Age, sex and 
weight 
Duration of illness NA. 
Walson et al. 
(1977) (264) 
7 NA 4-6 5 
Moderate to 
severe asthma 
NA Duration of illness NA. 
Ellis et al. 
(1976) (265) 
30 NA 4 9 Asthma Age Duration of illness NA. 
 
Wells et al. 
(1984) (266) 
29 4.56* 0.86* 3 Acute asthma NA 
Patients with hepatic, renal or cardiovascular 
diseases were excluded. Duration of treatment NA.  
                                                                                   *Mean, NA, not given
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 Table 4. 16: Theophylline clearance for paediatric patients with unspecified age groups  
Number of  
patients 
Age Range 
(Year) 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient 
of variation 
(CV %) 
Range 
(ml/min/kg) 
Variation 
Ratio 
Comments Study 
14 
9-19 
(14.5)* 
30-73 0.8 0.18 43 0.48-1.1 2 
Individual data 
available Non-
PK 
LaForce et al. (1981)(263) 
7 7-16 NA 1.8 0.8 45 0.95-3 3 
Individual data 
available 
Walson et al. (1977) (264) 
30 
6-16 
(11)* 
NA 1.5 0.58 39 0.5-4 8 - Ellis et al. (1976) (265) 
29‡ 1-14 NA 1.5 0.08 5 0.8-2.4 3 - Wells et al. (1984) (266) 
                                *Mean,‡ critical ill, SD, standard deviation ,CV, Coefficient of variation ,all studies were non-population pharmacokinetic, NA, not available  
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           Table 4. 17: Coefficient of variation for theophylline clearance in paediatrics 
Age 
Critically ill % 
(n) 
Non-critically ill % 
(n) 
Preterm neonates 9-58  
(131) 
- 
Infants - 22-52 
(37) 
Children 29-72  
(42) 
20-50 
 (101) 
Adolescents 43  
(22) 
29 
 (8) 
(n) Number of patients 
 
4.5.7. Effect of covariates on theophylline clearance and variability 
The mean clearance of theophylline in all patients was 1 ml/min/kg. A 
meta regression analysis was performed to determine the effect of 
covariates on theophylline clearance. Covariates including weight 
(p<0.001), age (infants, children and adolescents (p<0.05)) and 
critical illness (p<0.001) were independent predictors of theophylline 
clearance. However, sample size did not significantly affect clearance 
(Table 4.18). After adjusting for confounding covariates, critical 
illness did not significantly affect clearance (p=0.768). The mean 
clearance from studies involving neonates, infants and children was 
highly heterogeneous (I square>80%); therefore the mean clearance 
was not pooled.  
The CV of theophylline clearance was not significantly different 
between the critically ill with a mean CV of 35% (95% CI 26-43) and 
the non-critically ill patients with a mean CV of 39% (95% CI 33-
45)(p=0.403). A sub-analysis of children also did not show any 
statistically significant difference between critically ill and non-
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critically ill (p=0.418). Subgroup analysis in neonates was not carried 
out because all neonatal studies were in the critically ill. There was 
insufficient data on critically ill infants and adolescents, hence 
comparison of CV within this age group was also not performed. 
Table 4. 18: Unadjusted meta-regression for covariates 
 
Covariates 
 
P value 
Age  
 
 
Infants 
 
Children 
 
Adolescents 
 
 
 
0.021 
 
< 0.001 
 
0.002 
 
Critical illness <0.001 
Weight  <0.001 
Sample size  0.803 
 
4.6. Discussion  
Theophylline is used mainly for the treatment of apnoea in neonates 
and asthma in children and adolescents. This systematic review 
suggests that age, weight and critical illness are independent 
predictors of theophylline clearance. However, critical illness did not 
significantly affect clearance after adjusting for confounding factors.   
The CV in preterm neonates was higher than in children and 
adolescents. Theophylline clearance is significantly reduced in 
neonates, but increases rapidly in the first year of life  and reaches its 
peak value by age 1-2 years, when clearance is twice that of the 
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adult level (34). The major factor responsible for age-related 
differences in the pharmacokinetics of theophylline is the altered 
metabolism of the drug across paediatric age groups. Studies have 
shown differences in the oxidising capacity of CYP in neonates, 
infants, and children. CYP1A2 synthesis is very negligible in utero and 
very low in neonates before rising to adult level by 4 months 
postpartum (56). Furthermore, CYP1A2 activity is very highly variable 
between individuals because of difference in genetic constitution, with 
up to 15 alleles identified (16). 
The effect of critical illness in all the age categories could not be 
determined. All studied neonates were critically ill, all studies in 
infants were in the non-critically ill and there were too few adolescent 
studies for comparison. Although CV varied more among critically ill 
children (29%-72%) than non-critically ill (20-50%), there was no 
significant difference in the CV of theophylline between the two 
patient groups. The major indication for theophylline is airway 
obstruction, which may be accompanied by hypoxia and/or 
hypercapnia, both of which have  been shown to reduce the clearance 
of theophylline in vivo (268). Hypoxia alters expression of CYP1A1 
and CYP1A2, thereby affecting theophylline clearance (269). Similar 
to CYP3A4, CYP1A2 can also be down-regulated by inflammatory 
mediators such as interleukin and interferon gamma, which are 
produced in inflammatory airway disease (270-272). 
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Theophylline has a narrow therapeutic index; hence, an increase in 
plasma concentration beyond therapeutic range can result in toxicity. 
Extensive variation in metabolism among patients also increases the 
risk of fluctuation in plasma concentration. To avoid toxicity, 
therapeutic monitoring of theophylline concentration in plasma is 
therefore necessary (273). 
This study is limited by insufficient studies in non-critically ill 
subjects. Therefore, the relationship between critical illness and CV in 
the different age categories could not be determined. Studies 
involving patients with renal and hepatic failure were not identified 
and it was impossible to establish how these conditions influenced 
theophylline clearance. Similarly the effect of drug interaction on 
theophylline CV could not be determined. Similar to midazolam 
studies, CV or individual clearance values were not reported in some 
studies.  
In conclusion, age and weight are the most important covariates of 
theophylline PK and these should be considered when treating 
children.  
  
103 
 
CHAPTER FIVE   
A SYSTEMATIC LITERATURE REVIEW OF INTER-INDIVIDUAL 
VARIATION IN MORPHINE CLEARANCE IN CHILDREN 
  
5.1. Introduction 
Morphine is a naturally occurring opioid alkaloid. It was first isolated 
in 1805 and synthesized in 1952 (274, 275). The World Health 
Organization (WHO) recommends morphine as the first choice 
analgesic for cancer pain (276). It is also one of the most commonly 
used analgesics in neonates (277). Apart from its analgesic effect, 
morphine can also be used for preoperative sedation. Studies have 
suggested that morphine binds to specific µ opioid receptors in the 
brain to exert its analgesic effect. µ1 receptors mediate analgesic 
effect while µ2 is involved in gastrointestinal and respiratory adverse 
effects (278). 
Morphine can be administered via different routes IV, IM, SC, orally 
and rectally. Dosing varies according to age and route of 
administration. Intravenous morphine is administered to neonates at 
an initial dose of 100µg/kg six hourly, initially by slow bolus over five 
minutes then by continuous intravenous infusion of 10-20µg/kg. The 
subcutaneous dose of morphine is 100 µg/kg. Oral, rectal and IM 
morphine are not recommended for neonates. Dosing for children and 
adolescents can be up to 200 µg/kg (maximum 10mg ) four hourly 
(279). Since patients’ responses to pain vary, the morphine dose is 
usually titrated according to clinical response.    
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Oral morphine undergoes first pass metabolism and extensive inter-
individual variation in metabolism. Its bioavailability is approximately 
20-30% (278). The volume of distribution is 2.8 ±2.6 L/kg and 
protein binding about 15-35% (278, 280).  
It is metabolised primarily in the liver by UGT to M3G and MG6. M3G 
is an inactive metabolite while M6G is very active and more potent 
than morphine itself. MG6 is responsible for the opioid effects 
observed during treatment. M3G however, does not have any effect 
on opioid receptors (281). Hence, it does not have analgesic 
properties. Some studies have reported its anti-analgesic and 
respiratory depressant effect (282). Plasma concentrations of both 
metabolites are usually higher than morphine itself and are  mainly 
excreted via the kidneys (58, 280). About 10% is excreted 
unchanged and only a small amount is excreted as glucuronide in bile 
(283). 
The elimination half-life in preterm neonates and term neonates is 9 
±3.4 and 6.5 ±2.8 hours respectively. The half-life in infants and 
children is 2 ±1.8 hours (280). 
Some studies have suggested that age contributes to the variability 
of morphine pharmacokinetics in children. Clearance of the drug in 
neonates increases with age and reaches adult levels at three month 
(57). The rate of glucuronidation is also affected by age (284). 
Critically ill neonates have also been shown to have inter-individual 
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variation of morphine clearance (285). There is also evidence to 
suggest that there may be a racial difference in morphine clearance 
(286, 287).  
Common side effects associated with morphine include, nausea, 
vomiting, constipation, sedation and respiratory depression. Less 
common side effects include  hyperalgesia delayed gastric emptying 
and muscle rigidity (288). 
5.2. Aims  
The purpose of this systematic review is to determine the variability 
of morphine clearance in children and establish the factors which are 
responsible for this variability. 
5.3. Objectives  
The purpose of this systematic review is to: 
 Determine the extent of inter-individual variation in morphine 
clearance. 
 Evaluate the effect of factors such as age, birth weight and 
critical illness that may be responsible for the inter-individual 
variation in morphine PK.  
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5.4. Methods 
The methods for this chapter are described in chapter two. 
5.5. Results 
A total of 2,040 articles were short-listed from five search engines 
(Figure 5.1). Only 28 articles met the inclusion criteria. Table 5.1 
shows the details of papers excluded from the systematic review. 
Table 5. 1: Details of excluded articles from systematic review 
Exclusion Reason 
Review articles 590 
Editorials 33 
Case report 32 
Conference abstracts 23 
Studies in adults aged over 18 years  284 
Combined adult and paediatric studies where paediatric data was not 
presented separately 
26 
Studies where data for morphine was not presented 312 
Studies that did not evaluate the pharmacokinetics of morphine 424 
Studies in which morphine not administered intravenously 6 
Total 1,730 
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Figure 5. 1: Search strategy of morphine 
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5.5.1. Quality assessments  
Twenty eight studies were identified, however only twenty studies 
fulfilled the inclusion criteria. Three studies were excluded for 
collecting less than 3 blood samples (289-291) and another three for 
not reporting number of blood samples (58, 292, 293). One study 
involving less 3 participants was therefore excluded (294) (Table 
5.2). 
Table 5. 2: Studies excluded after quality assessment   
Study Age group 
†Number of 
patients 
+Number of blood 
samples collected 
Method 
Hartley et al. (1993)(292) 
Preterm 
neonates 
10 NA Non compartment 
Lynn et al. (1998)(289) 
Term 
neonates 
and Infants 
26 2 Non compartment 
Choonara et al. (1992) 
(290) 
8 1 Non compartment 
Lynn et al.(2003)(295) 
10 
10 
2 Non compartment 
Shelly et al.(1986)(294) Children 2 9 Non compartment 
Robie et al. (1992)(293) 3-18yrs 24 NA Non compartment 
Choonara et al. (1989) (58) 
Preterm 
neonates 
and children 
17 NA Non compartment 
Mashayekhi et al. 
(2009)(291) 
2.5-16 yrs 7 2 One compartment 
   †Studies with ≤ 2 patients or with number of patients not stated are excluded   
+Studies with ≤2 samples or with the number of samples not stated are excluded 
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Table 5. 3: Studies included after quality assessment  
Study Age group 
Number 
of 
patients 
Number of 
blood samples 
collected 
Method 
Hartley et al. (1993) (296) 
 
Preterm 
neonates 
9 6*x Non compartment 
Mikkelsen et al. (1994) (297) 8 5-7 Non compartment 
Barrett et al. (1991) (298) 24 12-15*x Non compartment 
Chay et al. (1992) (299) 10 4-19* Non compartment 
Saarenmaa et al. (2000)(300) 31 5‡x Non compartment 
Barrett et al. (1996)  (301) 18 4-9*x Non compartment 
Pokela et al. (1993)  (302) 4 14 x Non compartment 
Bhat et al. (1990)(303) 
10 
7 
8 x Non compartment 
Scott et al. (1999) (304) 
9 
13 
13 
3 
6‡x Non compartment 
Geiduschek et al. (1997) (305) 
Term neonates 
 
11 4‡x Non compartment 
Bouwmeester et al. (2003) (306) 52 4 x Non compartment 
Lynn et al. (1987) (307) 6 11*x Non compartment 
McRorie et al. (1992) (308) 14 10*x Non compartment 
Mikkelsen et al. (1994) (297) 5 5-7*x Non compartment 
Chay et al. (1992) (299) 5 4-19* Non compartment 
Koren et al. (1985) (309) 12 3-5* Non compartment 
Bhat et al.  (1990)(303) 3 8 Non compartment 
Pokela et al. (1993) (302) 16 14 x Non compartment 
Roka et al. (2008) (310) 16 5‡x Non compartment 
Olkkola et al. (1988)(311) 
Infants 
5 11* Non compartment 
Lynn et al. (1987) (307) 3 11 Non compartment 
Bouwmeester et al.(2003)(306) 97 4 x Non compartment 
Pokela et al. (1993) (302) 5 14
 x Non compartment 
Olkkola et al. (1988) (311) 
2-11 yrs 
9 11* Non compartment 
Nahata et al. (1985) (312) 3 3 Non compartment 
Nahata et al. (1985) (312) 12-18 yrs 3 3 Non compartment 
McRorie et al. (1992) (308) 31dys-2.5yrs 35 10 Non compartment 
Collins et al. (1996)(313) 1-15yrs 10 3 Non compartment 
Dagan et al. (1993)(314) 7mos-7yrs 
8 
8 
5 Non compartment 
Dampier et al. (1995)(315) 6-19 yrs 18 13* Two compartment 
          *plasma, ‡serum, x, at steady state 
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5.5.2. Clearance of morphine in neonates (0 - 27 days) 
Fourteen studies reported morphine clearance in 247 neonates (Table 
5.2) (292, 296-305, 307-309). Only one study, involving 52 
neonates, reported M6G/M ratio but did not report clearance (306). 
All were single centre studies. The number of participants varied 
between 3 and 52. Age and weight were the most common covariates 
(Table 5.4 and 5.5). The number of collected blood samples was 
between 3 and 19. Morphine loading dose varied between 50 and 200 
µg/kg and maintenance dose between 5 and 100 µg/kg/h (Table 5.6). 
All studies were non-compartment studies. None reported the effect 
of drug-drug interaction. 
All studies, except two, involved critically ill neonates who were 
receiving treatment in a NICU. The mean clearance for all preterm 
neonatal studies ranged between 2 and 10 ml/min/kg and the mean 
clearance for term neonates varied between 2 and 12 ml/min/kg. 
The CV ranged between 16% and 97% in studies involving preterm 
neonates. The lowest CV of 16% was recorded in a small study 
involving 9 preterm neonates receiving morphine to encourage 
synchronisation of their respiratory effort with the ventilator, as well 
as for analgesia (296). The highest CV of 97% was documented in a 
study involving 10 postoperative preterm neonates during the first 
week of life (303). 
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The range of CV was similar in term neonates, (24%-75%) to 
preterm neonates (16%-97%). The variation ratio of clearance was 
also similar in term neonatal studies (2-20 fold) and preterm neonatal 
studies (2-14 fold). 
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 Table 5. 4: Characteristics of studies in preterm neonates  
Study 
Number 
of 
patients 
 
Gestational 
age 
(weeks) 
 
Postnatal 
age 
(days) 
Range of 
weight 
(kg) 
Type of patients Covariates Comments 
Hartley et al.  
(1993) (296) 
9 
26-34 
(29.6)* 
<1 
0.9-2 
(1)* 
RDS Age Duration of illness NA. 
Mikkelsen et al. 
(1994) (297) 
8 
25-32 
(25)* 
NA 
2-4 
(1)* 
RDS Age Duration of illness NA. 
Barrett et al. 
(1991) (298) 
24 
26-36 
(30)* 
1-37 
0.7-4 
(1.4)* 
The majority of 
patients with RDS 
Age 
20 Patients with RDS, 2 pneumothorax, 1 
apnea, 1 perforated caecum. 
Duration of illness NA. 
Chay et al.(1992)             
(299) 
10 
28-36 
(33)* 
>2 
1-3.5 
(2)* 
RDS 
Age and 
weight 
Duration of illness NA. 
Saarenmaa et al.  
(2000) (300) 
31 30† NA 1† Ventilator-treated 
Age and 
weight 
27 Patients with RDS and other patients with 
infection, hypertension and intraventricular 
hemorrhage. 
Duration of illness NA. 
Barrett et al.  
(1996) (301) 
18 
24-35 
(29)* 
<1 
0.8-3 
(1.5)* 
Ventilated 
Age and 
dose 
Duration of illness NA. 
Pokela et al.  
(1993) (302) 
4 
28-36 
(33)* 
1-3 
2-3 
(2)* 
Surgery Age Duration of illness NA. 
Bhat et al.  
(1990) (303) 
10 
7 
28* 
33* 
NA 
1† 
2† 
Ventilated Age Duration of illness NA. 
Scott et al.  
(1999) (304) 
9 
13 
13 
3 
24-27(27)* 
28-31(30)* 
32-35 (32.5)* 
36-39 (35)* 
1.1* 
1.3* 
6.1* 
16* 
1* 
1* 
2* 
3* 
Mechanical 
ventilation 
Age Duration of illness NA. 
               *Mean, †Median, RDS, Respiratory distress syndrome, NA ,not available   
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 Table 5. 5: Characteristics of studies in term neonates  
Study 
Number 
of 
patients 
 
Gestational 
age 
(weeks) 
 
Postnatal 
age 
(days) 
 
Range of 
weight 
(kg) 
Type of patients Covariates Comments 
Geiduschek et 
al. (1997) (305) 
11 
36-41 
(40)* 
NA 
2-4 
(3)* 
ECMO ECMO 
5 patients with MAS, 2sepsis, 3 CDH and 1 PPHN. 
Duration of ECMO from 4-19 days. 
Bouwmeester et 
al. (2003) (306) 
52 38* 0-28 2.9 
Mechanical 
ventilation 
Age, sex 
and weight 
Patients with hepatic or renal dysfunction were 
excluded. Duration of illness NA. 
Lynn et al. 
(1987) (307) 
6 NA 
2-4 
(2)† 
3-4 
(3)* 
Ventilated Age 
3 patients with RDS, 2 MAS and 1 resection lung 
malformation.  All patients were normal cardiovascular 
and renal function. Duration of illness NA. 
McRorie et al. 
(1992) (308) 
14 >36 1-19 2-5 Cardiac surgery Age 
All patients undergo cardiac surgery and all were with 
normal hepatic and renal function. 
Duration of illness NA. 
Mikkelsen et al. 
(1994) (297) 
5 
37-40 
(39)* 
NA 
2-4 
(3)* 
Mechanical 
ventilation 
Age 
2 patients with congenital heart disease,1 neonate of 
diabetic mother,1 persistent foetal circulation and 1 
asphyxia 
Chay et al. 
(1992) (299) 
5 
37-41 
(39)* 
<4 
3-4 
(4)* 
Mechanical 
ventilation 
Weight 
3 patients with RDS, 2paients MAS  
Duration of illness NA. 
Koren et 
al.(1985) (309) 
12 
35-41 
(39)* 
1-49 
2-4 
(3)* 
Postoperative NA 
3 patients with total anomalous pulmonary drainage,3  
duodenal atresia and down syndrome, 2 complex 
cyanotic heart disease 1  transposition of great 
arteries,1  pulmonary arteries, 1 tracheoesophageal 
fistula and 1 omphalocoele. 
Duration of illness NA. 
Bhat et 
al.(1990)(303) 
3 40* NA 3* Ventilated Age Duration of illness NA. 
Pokela et 
al.(1993) (302) 
6 
38-42 
(40)* 
3-35 
3-5 
(4)* 
Surgery Age Duration of illness NA. 
Roka et al. 
(2008)(310) 
16 
36-40 
(38)† 
≤3 
2-4 
(3)† 
Asphyxia and 
hypothermia 
Disease Duration of illness NA. 
*Mean, †median, ECMO, extracorporeal membrane oxygenation, MAS, meconium aspiration syndrome, CDH, congenital diaphragmatic hernia, PPHN, persistent pulmonary   
hypertension, ICU, intensive care unit, NA, not available 
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 Table 5. 6: Morphine doses in neonates 
 
Loading dose or 
Single dose (SD) 
µg/kg 
Morphine infusion 
µg/kg/h 
Number of blood 
samples collected 
Study 
100 12.5 6 
Hartley et al.  (1993) (296) 
200 50 6 
150 NA 5-7 Mikkelsen et al. (1994) (297) 
50 15 12-15 Barrett et al .(1991) (298) 
10-100 7.5-30 4-19 Chay et al. (1992 (299) 
140 20 5 Saarenmaa et al. (2000)(300) 
50 or 200 15 4-9 Barrett et al. (1996) (301) 
100 10-20 4 Geiduschek et al. (1997)(305) 
100 NA 8 Bhat et al. (1990 (303) 
50 20-30 6 Scott et al. (1999) (304)  
100 10-30 4 Bouwmeester et al. (2003) (306) 
NA 20-100 11 Lynn et al. (1987) (307) 
NA 20 10 McRorie et al. (1992) (308) 
150 NA 5-7 Mikkelsen et al. (1994) (297) 
10-100 7.5-30 4-19 Chay et al. (1992) (299) 
100 NA 14 Pokela et al. (1993 )(302) 
50-100 6-40 3-5 Koren et al. (1985)(309) 
100 NA 8 Bhat et al. (1990) (303) 
50 20-30 6 Scott et al. (1999) (304) 
50-150 5-30 5 Roka et al. (2008) (310) 
                     NA, not given
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 Table 5. 7: Morphine clearance in critically ill neonates  
Age 
group 
Number of 
patients 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient of 
variation 
(CV %) 
Range of 
clearance 
(ml/min/kg) 
Variation 
ratio 
in clearance 
 
Comments 
Study 
Preterm 
neonates 
9 2 0.4 16 2-3 2 Individual data available Hartley et al. (296) 
8 5 1.8 47 2-6 3 Individual data available Mikkelsen et al. (297) 
24 3 0.8 26 2-6 3 Individual data available Barrett et al. (298) 
10 3 1.8 96 0.5-7 14 Individual data available Chay et al. (299) 
31 2 1 50 0.8-6 8 - Saarenmaa et al. (300) 
18 5 3 71 1-14 14 Individual data available Barrett et al. (301) 
4 2 0.7 35 1-2 2 Individual data available Pokela et al. (302) 
10‡ 
7‡ 
3 
10 
3 
4 
97 
42 
NA NA - Bhat et al. (303) 
9‡ 
13‡ 
13‡ 
3‡ 
2 
3 
5 
8 
1 
2 
2 
3 
47 
66 
40 
37 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
- Scott et al. (304)  
Term 
neonates 
11 12 9 75 3-35 12 - Geiduschek et al. (305) 
6 6 2 35 4-10 3 Individual data available Lynn et al. (307) 
14 7 NA NA 3-14 5 - McRorie et al. (308) 
5 5 1.8 55 2-7 4 Individual data available Mikkelsen et al. (297) 
5 2 1.4 74 0.8-4 5 Individual data available Chay et al. (299) 
6 8 2.5 30 4-13 3 Individual data available Pokela et al. (302) 
12 8 2 24 2-39 20 - Koren et al. (309) 
3 16 10 65 NA NA - Bhat et al. (303) 
10 0.7* NA NA 0.6-1 2 - Roka et al. (310) 
               ‡, Two or four groups of preterm neonates, *median, SD, standard deviation, CV, Coefficient of variation, all studies were non-population pharmacokinetics, NA, not available 
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5.5.3. Clearance of morphine in infants (>28 days -23 months) 
Three studies reported morphine clearance in 13 infants (302, 307, 
311). One study, involving 110 infants,  reported M6G/M ratio but did 
not report clearance (306). All were single centre studies. The 
number of participants varied between 3 and 97 (306). Age and 
weight were the most common covariates (Table 5.8). The number of 
collected blood samples was between 4 and 14. Morphine loading 
dose varied between 50 and 150µg/kg and maintenance dose 
between 5 and 100 µg/kg/h. All studies were non-compartment 
studies. None of the studies reported the effect of drug-drug 
interaction. 
Two studies involved critically ill infants (307, 311) and one non-
critically ill (302). The mean morphine clearance for these infants 
varied between 21 and 24 ml/min/kg (Tables 5.10 and 5.11).  
The CV varied between 35% to 134%. The highest CV of 134% was 
documented for a study involving 5 patients who received morphine 
after thoracic and orthopedic surgery (311). Only one study in non-
critically infants reported the CV (44%) (302). Variability of morphine 
clearance in critically ill infants was 3 to 11 fold (Table 5.10).  
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            Table 5. 8: Characteristics of studies in infants 
Study 
Number 
of 
patients 
Loading dose or 
Single dose (SD) 
µg/kg 
Morphine 
infusion 
µg/kg/h 
Number of 
blood samples 
collected 
Type of patients Covariates Comments 
Olkkola et al. 
(1988)(311) 
5 NA 50 11 
Thoracic or orthopedic 
surgery 
NA Duration of illness NA. 
Lynn et al.  
(1987) (307) 
3 NA 20-100 11 Ventilated Age 
2 patients with viral pneumonia and 
1 VSD. Duration of illness NA. 
Bouwmeester et 
al. (2003)(306) 
97 100 10-30 4 Mechanical ventilation 
Age, sex and 
weight 
Patients with hepatic or renal 
dysfunction were excluded. 
Pokela et al.  
(1993) (302) 
5 100 NA 14 Surgery  Age Duration of illness NA. 
              VSD, ventricular septal defect, NA, not given   
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5.5.4. Clearance of morphine in children and adolescents 
Two studies reported morphine clearance in critically ill children aged 
2-12 (311, 312). These studies involved a total of 12 children. Both 
were non-compartmental studies (Table 5.9). The mean clearance 
was 32 and 52 ml/min/kg. The CV of clearance was 39% and 55% 
(Table 5.10). 
Only one small study involving 3 adolescents with malignancy aged 
12-18 was identified (312). The mean clearance was 19 ml/min/kg.  
In this study the CV was 74%.   
5.5.5. Clearance of morphine in paediatric patients of mixed ages 
Four studies reported morphine clearance in 79 critically ill paediatric 
patients across all age groups (291, 293, 313-315). All were single 
centre studies. The number of participants in each study varied 
between 10 to 35. The number of blood samples collected was 
between 3 to 13.  All but one study were non-compartmental studies. 
Two of these studies were in patients with cardiac surgery, one study 
was in patients with sickle cell disease and the last was in patients 
with malignancy. Mean clearance varied between 14 and 36 
ml/min/kg. The highest CV of 39% was reported in a study of 18 
patients between 6 and 19 years old (315). The lowest CV of 25% 
was reported in 8 patients who received morphine after cardiac 
surgery (314). The CV was not documented in two studies. Four 
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studies reported the range of morphine clearance. The variation ratio 
was between 2-10 fold. 
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             Table 5. 9: Characteristics of studies in paediatric groups 
Study 
Number 
of 
patients 
Loading dose or 
Single dose (SD) 
µg/kg 
Morphine 
infusion 
µg/kg/h 
Number of 
blood samples 
collected 
Type of patients Covariates Comments 
Nahata et al.  
(1985) (312) 
3* 90-150 NA 3 
Hematologic-oncologic 
disorder 
Age and 
disease 
Liver and renal function was normal. 
Olkkola et al.  
(1988) (311) 
9* NA 50 11 
Thoracic or orthopedic 
surgery 
NA Duration of illness NA. 
Nahata et al. 
(1985) (312) 
3† 90-150 NA 3 
Hematologic-oncologic 
disorder 
Age and 
disease 
Liver and renal function was normal. 
McRorie et al. 
(1992) (308) 
35‡ NA 30 10 Cardiac surgery Age 
All patients undergo cardiac surgery and all 
were with normal hepatic and renal function. 
Duration of illness NA. 
Collins et al. 
(1996) (313) 
10‡ 28-100 10 3 
Hematologic 
malignancy 
NA Duration of illness NA. 
Dampier et al.  
(1995) (315) 
18‡ NA 35-195 13 Sickle cell disease NA Duration of illness NA. 
Dagan et al. 
(1993) (314) 
16‡ NA 20-40 5 Cardiac surgery NA 
8 patients with Fontan repair and 8 tetralogy 
of Fallot. Duration of illness NA. 
 
                *Children, †adolescents, ‡mixed age, NA, not given 
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Table 5. 10: Morphine clearance in critically ill paediatric patients 
Age group 
Number 
of 
patients 
 
Range of 
age 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient 
of variation 
(CV %) 
Range of 
clearance 
(ml/min/kg) 
Variation 
ratio 
in clearance 
 
Comments 
Study 
Infants  
5 
1-6mos 
(3)* 
4-8 
(5)* 
22 17 134 4-45 11 
Individual 
data available 
Olkkola et al. (311) 
3 
17-65dys 
(42)* 
3-6 
(4)* 
24 14 35 13-39 3 
Individual 
data available 
Lynn et al. (307) 
2-11yrs 
9 
2-7 
(5)* 
13-26 
(19)* 
52 18 39 26-76 3 
Individual 
data available 
Olkkola et al. (311) 
3 
11-12 
(12)* 
21-40 
(31)* 
32 18 55 21-53 3 
Individual 
data available 
Nahata et al. (312) 
12-18yrs 3 
13-16 
(15)* 
50-60 
(56)* 
19 8 74 9-24 3 
Individual 
data available 
Nahata et al. (312) 
31dys-2.5yrs 35 31dys-2.5yrs 3-14 NA NA NA 6-29 5 - McRorie et al.(308) 
1-15yrs 10 14* NA 34 NA NA 19-58 3 - Collins et al. (313) 
6-19yrs 18 15* NA 36 14 39 6-59 10 - Dampier et al. (315) 
8mos-7yrs 
8† 
8‡ 
8mos-7yrs NA 
14 
23 
5 
6 
37 
25 
8-22 
18-33 
3 
2 
Individual 
data available 
Dagan et al. (314) 
                   *Mean, †Fontan repair;‡ Tetralogy of Fallot (TOF), SD, standard deviation, CV, Coefficient of variation, all studies were non-population pharmacokinetics ,NA; not available   
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 Table 5. 11: Morphine clearance in non-critically ill paediatric patients  
Age 
group 
Number 
of 
patients 
 
Range of age 
Range of 
weight 
(kg) 
Mean 
Clearance 
(ml/min/kg) 
SD 
Coefficient 
of variation 
(CV %) 
Range of 
clearance 
(ml/min/kg) 
Variation 
ratio 
in clearance 
 
Comments 
Study 
Term 
neonates 
10 
38-42wks 
(36)* 
3-5 10 3.5 37 6-16 3 
Individual data 
available 
Pokela et al. (302) 
6 
36-40wks 
(39)† 
2-4 1† NA NA 0.6-1 2 - 
Roka et al.   (310) 
Infants 5 
2-6mos 
(1.5)* 
4-8 21 8 44 10-31 3 
Individual data 
available 
Pokela et al. (302) 
               *Mean, †median, SD, standard deviation, CV, Coefficient of variation, all studies were non-population pharmacokinetics, NA, not available 
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5.5.6. M6G/M ratio in paediatric patients  
Three studies reported the ratio of M6G to morphine in 188 patients.  
(Table 5.12) (301, 306, 313) . One of these studies involved preterm 
neonates, with mean plasma M6G/M of 0.8 and the variation ratio 
was 29 fold. The variation ratio of M6G/M was between 2 and 29 fold 
(306).  
 
There was only one infant study. This involved 110 infants and 
provided the plasma M6G/M range (0.9-2.3) from which a variation 
ratio of 3 fold was estimated. A further study involved 10 mixed aged 
children from 1 to 15 years and the variation ratio was 2 fold. The 
difference in the variation of M6G/M for the different age groups 
could not be established due to insufficient number of studies in each 
age categories. 
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 Table 5. 12: Range and variation ratio of critically ill patients in relation to M6G/M 
 
 
Age group 
 
Number of 
patients 
 
Mean plasma concentration 
(ng mlˉ¹) 
 
Morphine                    M6G 
 
Mean Plasma 
M6G/M 
 
Range 
(M6G/M) 
 
Variation 
Ratio 
(M6G/M) 
 
Study 
Preterm neonates 19 86 48 0.8 0.1-2.9 29 Barrett et al.(301) 
Term neonates 52 NA NA NA 0.5-1.7 3 Bouwmeester et al. (306) 
Infants  110 NA NA NA 0.9-2.3 3 Bouwmeester et al. (306) 
1-15 yrs 10 NA NA 2.5 1.44-3.3 2 Collins et al. (313) 
           NA, not available 
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          Table 5. 13: Coefficient of variation for morphine clearance in paediatrics 
Age Critically ill % 
(n) 
Non-critically ill % 
(n) 
Preterm neonates 16–97  
(159) 
- 
Term neonates 24–75  
(72) 
37  
(16) 
Infants 35–134 
(8) 
44  
(5) 
Children 39–55  
(12) 
- 
Adolescents 74  
(3) 
- 
(n) Number of patients 
5.5.7. Effect of covariates on morphine clearance and variability 
The mean clearance of morphine is 7ml/min/kg (95% CI: 5.97-7.92). 
Age is an independent predictor of morphine clearance. Neonates (p= 
0.027), infants (p=<0.001), children (p=<0.001) and adolescents 
(p=0.017) have significantly higher clearance values than preterm 
neonates (Table 5.14). Similarly, weight is also a significant predictor 
of clearance (p=0.009). However, critical illness did not significantly 
affect the morphine clearance. There was no significant difference 
between the mean CV of morphine clearance in critically ill (52.4%) 
and non-critically ill patients (40.5%) (p=0.538). Subgroup analysis 
of the CV for the different age groups was not performed because of 
insufficient number of studies. 
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            Table 5. 14: Unadjusted meta-regression for covariates 
 
Covariates 
 
P value 
Age  
Term neonates 
Infants 
Children 
Adolescent  
 
0.027 
<0.001 
< 0.001 
 0.017 
Critical illness 0.566 
Weight  0.009 
Sample size  0.338 
 
5.6. Discussion  
Morphine is one of the most commonly prescribed drugs for pain 
management in children. This systematic review has identified age 
and weight as predictors of morphine clearance in paediatric patients. 
A large inter-individual variation in the ratio of M6G to morphine in 
neonates and infants was also observed. 
At birth, the renal clearance of drugs is generally underdeveloped and 
inefficient. Generally, this maturation (glomerular, filtration and renal 
tubular function) occur at different rates. However, by the first year 
of life, renal function matures to adult levels (316). Term neonates 
can have about three times preterm neonatal clearance rate (304).  
Morphine is extensively metabolised by UGT2B7, to M3G and M6G, 
which is developed early in neonatal life. This isoform of UGT 
develops rapidly and reaches adult level by three months (57).  
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Generally, neonates and infants have relatively immature and 
inefficient glucuronidation compared with older children, adolescents 
and adults (57, 58). In addition, UGT expression is highly variable 
among paediatric patients (317) with consequent effect on morphine 
clearance (318). African American children have been reported to 
have higher morphine clearance than Caucasian children and this has 
been attributed to variability in UGT expression and increased M3G 
formation (287). 
In this study, neonates and infants had a very high variation ratio of 
M6G/M clearance. In four neonatal studies, which reported M6G/M, 
variation ranged between 2-29 fold. M6G is an active metabolite of 
morphine. Studies have shown that factors such as age (304, 308) 
and disease (312), may affect the variability in the pharmacokinetics 
of morphine and its metabolites. A systematic review by Faura et al. 
(1998) showed that morphine glucuronide formation was much lower 
in neonates than children and adults. They also reported higher 
metabolite ratios in patients with renal impairment (319). The 
determination of relationship between M6G and morphine and the 
degree of variability in the plasma concentration is important in order 
to avoid morphine toxicity. 
The CV of morphine clearance was not significantly different between 
critically ill and non-critically ill patients. All studies involving children 
and adolescents were in critically ill patients and only one study 
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involved neonates and infants, hence it was impossible to compare 
inter-individual variability between critically ill and non-critically ill 
patients in these age groups. Due to this limitation, the effect of 
critical illness on variability of morphine clearance could not be 
adequately explored. Furthermore, the effect of hepatic and renal 
impairment could not be determined, because most of the studies 
excluded patients with hepatic and renal impairment.  
In conclusion, age is an important determinant of morphine 
clearance. It also determines the rate of metabolite formation which 
may influence morphine toxicity and tolerance.   
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CHAPTER SIX  
 A SYSTEMATIC LITERATURE REVIEW OF INVASIVENESS OF 
PHARMACOKINETIC STUDIES IN CHILDREN 
 
 6.1. Introduction  
Pharmacokinetic studies require the collection of multiple blood 
samples, most commonly venous blood. Venous blood sampling is 
however invasive. In the previous chapters it was observed that the 
frequency of blood sampling varied considerably in paediatric PK 
studies. There should be a limit to the frequency and volume of blood 
sampling in children. Although, several institutions have proposed 
guidelines for the maximum acceptable volume of blood for PK 
studies (125), these guidelines are highly varied.  Furthermore, there 
are no guidelines for the frequency of blood sampling in children.  
Invasive PK methods can cause pain in children and reduce their level 
of cooperation in clinical research (130). Pain should be avoided if 
possible and intensity and level of distress should be monitored. 
Over the years, less invasive techniques have been developed for PK 
studies, such as the collection of micro samples (141, 320). Other 
methods, such as the use of scavenged clinical samples have also 
been encouraged. When possible, alternative non-invasive methods 
like the use of saliva, urine and breath samples have been utilised. 
6.2. Aims  
 To determine whether PK studies in paediatric patients are 
becoming less invasive  
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 To determine the number of samples and volume of blood 
collected in two decades of practice (1981-1990 and 2005-
2014).  
6.3. Objectives  
 To determine the number of blood samples collected in PK 
studies over two decades and make statistical comparison. 
 To determine and statistically compare the volume of blood 
samples per child and total volume of blood over two decades 
(1981-1990 and 2005-2014).  
 6.4. Methods 
A systematic literature review was conducted electronically to identify 
papers describing the invasiveness of pharmacokinetic studies in 
children (defined as aged less than 18 years or paediatric age as 
defined by the authors). Paediatric patients were grouped according 
to the guidelines of the ICH (153) as follows:  
 Preterm neonates (born at less than 37 weeks of gestation) 
  Term neonates ( born at 37 weeks of gestation  to 27 days old) 
  Infants (28 days to under 2 years old) 
 Children (2 to 11 years old) 
 Adolescents (12 to under 18 years old) 
Paediatric keywords were selected based on the recommendations of  
Kastner et al. (2006)(154). The final blood samples/PK study 
keywords were selected after optimisation to generate the highest 
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number of relevant studies, as a systematic review on invasiveness of 
PK has never been conducted before. 
The following sources of information were utilised: MEDLINE (1946 to 
May 2014), EMBASE (1974 to May 2014), IPA (1970 to May 2014), 
CINAHL (1937 to May 2014) and the Cochrane Library. These 
databases were searched separately and combined together to 
remove duplications. The search strategy included all languages. The 
keywords “preterm neonate*” OR term neonate*” OR “neonate*” OR 
“new-born*” OR “child*” OR children OR “p*ediatric* OR “infant*” OR 
“adolescent*” (154) AND “pharmacokinetic*” OR blood OR plasma OR 
specimen OR serum OR blood sampling OR blood sample*” were 
used.  
 6.4.1. Inclusion Criteria 
Inclusion criteria were original PK studies with documented number of 
blood samples in children up to the age of 18 years. 
 6.4.2. Exclusion Criteria 
 Review articles 
 Editorials  
 Conference abstracts 
 Studies in adults aged over 18 years  
 Studies where data for blood sampling was not presented 
 Observational studies   
 Therapeutic drug monitoring studies 
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 6.4.3. Data extraction 
All relevant articles were read carefully and the required data were 
extracted onto tables. The data extracted include: 
 Number of patients in PK studies 
 Age group  
 Mean weight 
 Total number of blood samples taken  
 Volume of blood per sample over 24 hours 
 Total volume of blood for whole study 
 Name of drug  
 Year of study 
 Country  
 Sampling methods 
 6.4.4. Statistical analysis  
The samples and volume for the two decades under consideration 
were not normally distributed for some age groups. Therefore, the 
number of samples and the volume for two decades were compared 
with the use of Mann–Whitney U test. A significance level of P< 0.05 
was considered significant for all tests. Missing data were accounted 
for with complete case analysis. Data were summarised with the use 
of median and interquartile range. 
133 
 
6.5. Results 
A total of 3,994 articles were identified from five search engines 
(Figure 6.1). Only 473 articles met the inclusion criteria 82 studies 
were between 1981-1990 and 152 studies between 2005-2014. Table 
6.1 shows the details of papers excluded from the systematic review. 
Table 6. 1: Details of excluded articles from systematic review 
Exclusion Reason 
Reviewed articles 1,429 
Editorials 170 
Case report 147 
Conference abstracts 225 
Studies in adults aged over 18 years 1,352 
Studies where data for blood sample was not presented 170 
 
Observational studies   15 
Therapeutic drug monitoring studies 13 
Total 3,521 
 
The most common drugs studied were antibiotics and analgesics. 
There were more studies involving children (114, 49%) than any 
other age group. Seventy two studies (31%) involved paediatric 
patients across the whole age spectrum. The number of studies in 
neonates and infants were lower in the later decade however, the 
number of patients were higher. In contrast, the number of studies in 
children and mixed ages were considerably higher in the later decade 
(Table 6.2). 
134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 1: Search strategy of blood sampling 
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                                    4,764 Publications 
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                3,994 Studies 
 
 
1981-1990 
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2005-2014 
152 Studies included 
                                         473 Studies included 
 
3,521 Studies Excluded  
 
 
18 
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             Table 6. 2: Pharmacokinetic studies in the two decades 
 
Age group 
 
Number of studies 
(number of cannula studies) 
 
Number of patients 
 
1981-1990 
 
2005-2014 
 
1981-1990 
 
2005-2014 
Neonates 13 (3) 10 (1) 193 300 
Infants 9 (3) 8 (1) 184 365 
Children 45 (18) 69 (25) 668 4,243 
Adolescents 4 (2) 4 (1) 25 45 
Mixed age 11 (5) 61 (12) 280 3,503 
Total 82 (31) 152 (40) 1,350 8,456 
 
In total 9,806 patients were enrolled in the PK studies. Eighty six 
percent of participants were in new decade. The lowest number of 
participants in a single study (1987) was 3 patients, in a study of 
hydrocortisone (321); while the largest study (2009) involved 690 
children in a PK study of amodiaquine (322). 
The route of blood collection was documented in 23% of the studies 
in the old decade and 35% of the new decade. For both periods, 
intravenous blood collection was the preferred method by 
investigators. Sixteen percent of studies in new decade and 24% in 
old decade used an indwelling catheter, while 22% in new decade and 
17% in old decade used venous blood samples. Other sampling 
methods in both decades included arterial sampling (1%), heel prick 
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(1%) and finger prick (2%).  In 42% of studies the method was not 
stated.  
The majority of the studies (40%) were conducted in the United 
States of America (US). Other studies originated from France (8%), 
United Kingdom (UK) (7%), Japan (4%) and Canada (4%). Some 
studies were multinational and this accounted for (13%) of all 
studies. 
Thirty five of the studies were population PK studies (Table 6.3). The 
number of blood samples varied between 1 and 15 samples; while 
the number of samples in non-population PK studies ranged between 
2 to 20. The median number of samples collected in all population PK 
studies (median: 6, IQR [4-9]) was significantly lower than non-
population PK studies (median: 8, IQR [6-10]) (p=0.007) (Figure 
6.2).  
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            Table 6. 3: Blood samples in population pharmacokinetic studies 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total 
vol of 
blood 
(ml) 
Drug 
Study 
 
28 1* 3 0.2 0.6 
Amphotericin 
B 
Wurthwein et al. (2005) (323) 
 
24 NA 
5 
 
0.2 1 
Ganciclovir 
 
Acosta et al. (2007) (324) 
20 3 5-9 0.5 7 Midazolam 
Ahsman et al. (2010) (182) 
 
58 10 5 2 10 Desloratadine 
Gupta et al. (2007)(325) 
 
104 20 3 2 
 
6 
Tramadol Garrido (2006)(326) 
79 25 1 NA NA Methotrexate 
Piard  et al.(2007)(327) 
 
53 46 9 NA 
 
NA 
Clofarabine Bonate et al.(2011)(328) 
34 18 5 3 15 Artemisinin 
Salman et al.(2012)(329) 
 
53 22* 2-7 3 6 - 21 Naproxen 
Valitalo et al.(2012)(330) 
 
70 11 4 1.5 6 Artesunate 
Hendriksen et al.(2013)(331) 
 
23 11 6 1.8 11 
Tranexamic  
acid 
Goobie  et al.(2013)(332) 
 
28 16 8 2.5 20 Primaquine 
Moore  et al.(2014)(333) 
 
123 NA 11 NA NA Azithromycin 
Zhao et al.(2014)(334) 
 
105 28 4 0.1 0.4 Abacavir 
Jullien et al.(2005)(335) 
 
76 NA 8 0.3 - 0.4 2.4 – 3.2 Sotalol 
Laer et al.(2005)(336) 
 
24 16 10 0.5 5 Midazolam 
Peeters et al. (2006)(184) 
 
99 17 2 NA NA Meropenem 
Du et al.(2006)(337) 
 
73 52 4 0.5 2 Amlodipine 
Flynn  et al.(2006(338) 
 
59 19 15 5 75 Melphalan 
Nath et al.(2007)(339) 
 
34 8 4 0.5 2 Gentamicin 
Seaton et al.(2007)(340) 
 
72 36 7 NA NA Micafungin 
Hope et al.(2007)(341) 
 
162 22 10 1 10 Ciclosporin 
Fanta et al.(2007) (342) 
 
128 37 3 2 6 Abulterol 
Maier et al.(2007)(343) 
 
24 23 2-8 NA NA Busulfan 
Booth et al.(2007)(344) 
 
33 30 8 NA NA 
Actinomycin-
D 
Mondick et al.(2008) (345) 
 
50 30 7 NA NA Tacrolimus 
Zhao et al.(2009)(346) 
 
50 NA 7 2 14 Lopinavir 
Rakhmanina et al. (2009) 
(347) 
22 34 6 0.5 3 Valganciclovir 
zhao et al.(2009)(348) 
 
217 18 1 NA NA Tebipenem 
Sato et al.(2008) (349) 
 
20 NA 10 0.5 4.5 Pantoprazole 
Pettersen et al.(2009) (79) 
 
         *Median, NA, not available  
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          Table 6.3 continued: Blood samples in population pharmacokinetic studies 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol of 
blood (ml) 
Drug 
Study 
 
189 NA 10 1 10 
Tamsulosin  
hydrochloride 
Tsuda et al.(2010) (350) 
50 15 2 - 4 NA NA Meropenem 
Ohata et al.(2011) (351) 
 
94 NA 5 NA NA Busulfan 
Trame et al.(2011)(352) 
 
67 15* 2-6 NA NA Busulfan 
Michel et al. (2012)(353) 
 
236 18 10 NA NA Piperaquine 
Tarning et al.(2012)(354) 
 
          *Median, NA, not available 
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           Figure 6. 2: Number of blood samples in population PK and non-population 
PK studies (p=0.007) 
 
6.5.1. Blood samples in neonates  
In the two time periods, 23 neonatal studies were identified. There 
were thirteen studies in old decade (1981-1990) involving 193 
neonates; while 10 studies in the new decade (2005-2014) involving 
300 neonates were identified (Tables 6.4 and 6.5). Seventy eight 
percent (18 studies) provided information on the volume of blood 
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collected from each subject. Similar volumes per sample were 
collected from studies in the old decade (median: 0.7ml, IQR: [0.2-
1]) than the new (median: 0.3ml, IQR: [0.2-0.8ml])(p=0.283). The 
maximum volume of blood sampled at a single time in old studies 
was 2ml (355); while the minimum was 0.2ml . The range in the 
studies in the new decade was between 0.15ml-2ml.  
Between 3-10 blood samples were collected in the old decade; while 
2-9 samples were collected in the new (Figure 6.3). The median 
frequency of blood sampling in the new studies was slightly lower 
(median=4.5, IQR [3-7.2]) than the old studies (median=7, IQR [5-
8]), but there was no statistically significant difference (P=0.054). 
During old studies, the highest volume of blood obtained from 
neonates over a 24 hour period was 16ml and this was a study 
conducted in the United States (US) in 1989 (355). In the new 
decade the highest volume collected within 24 hours was 7ml (182). 
The total volume of blood ranged from 1.4-16ml (old) and 0.6-7ml 
new.  
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Table 6. 4: Blood samples in preterm neonates 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(1981-1990) 
28 NA 8 0.5 4 Cefoperazone 
Rosenfeld et al. (1983)  
(356) 
9 
 
NA 8 NA NA Theophylline Stile et al.(1986) (240) 
9 
 
1 6 NA NA Theophylline 
Dothey  et al. (1989)    
(242) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
sample 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(2005-2014) 
 
28 
 
1* 
 
3 
 
0.2 
 
0.6 
Amphotericin B 
Wurthwein et al. (2005) 
(323) 
55 2 3 NA NA 
Cefepime 
 
Capparelliet al. (2005) (357) 
24 
 
 
NA 
5 
 
0.2 1 
Ganciclovir 
 
Acosta et al. (2007) (324) 
35 NA 7 0.3 2 
PK study 
 
Heidmets et al. (2011) (358) 
42 3 8 0.15 1 Dexmedetomdine 
Chrysostomou et al. (2014) 
(359) 
           *Median, NA, not available   
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                                     Figure 6. 3 : Number of samples collected from each neonate 
during old and new periods (P=0.054) 
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        Table 6. 5: Blood samples in term neonates 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(1981-1990) 
16 3 5 0.3 1.5 phenytoin Bourgeois et al. (1983) (360) 
12 2 8 0.2 1.6 Cefotaxime Lambert et al. (1984) (361) 
12 3 3-5 1 3-5 Morphine Koren et al. (1985)(309) 
10 2 7 0.8 5.6 Cilastatin Gruber et al. (1985) (362) 
41 2 7 0.2 1.4 Ceftazidime Mulhall &Louvois (1985) (363) 
4 3 5 NA NA Teicoplanin Tarral et al. (1988) (364) 
21 NA 10 NA NA Immunoglobuline Noya et al. (1989) (365) 
10 4 8 2 16 Gentamicin Southgate et al. (1989) (355) 
11 3 9 0.5-1 4.5-9 Bupivacaine Bricker et al. (1989)(366) 
10 3 6 0.7 4.2 Midazolam 
Jacqz-Aigrain et al.(1990) 
(176) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(2005-2014) 
14 3.2 4 1.4 5.6 Morphine Peters et al. (2005) (367) 
20 3 5-9 0.5 7 Midazolam Ahsman et al. (2010) (182) 
15 1.8 7 0.2 0.6 Anidulafungin Wolkowiez et al. (2011) (368) 
36 3* 4 0.6 2.4 Cefazolin Cock et al. (2014) (369) 
31 3 2 0.5- 1 1-2 Amikacin Vucicevic et al. (2014) (370) 
      *Median (range), NA, not available 
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6.5.2. Blood samples in infants  
There were 8 studies in the new decade and 9 in the old involving 
365 and 184 infants respectively (Table 6.6). Only one old study 
provided information on the volume of blood, 0.5ml of blood was 
obtained six times in each of 12 infants (249). The volume of blood 
collected at a single time in the new decade varied from 0.5ml-2.5ml; 
with the frequency of blood sampling 4-10 times. The median 
frequency in both decades was similar for the new (median=7, IQR 
[4-8]) and old (median=7, IQR [5.5-7.5]) (p=0.999) (Figure 6.4). 
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Table 6. 6: Blood samples in infants 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug Study 
(1981-1990) 
 27 11 7 NA NA Amoxicillin Ginsburg et al. (1981)(371) 
10 12 8 NA NA Ceftriaxone Schaad et al. (1982)(372) 
34 NA 7 NA NA 
Potassium 
clavulanate 
Nelson et al. (1982) (373) 
19 10 7 NA NA Ceftriaxone Rio et al. (1982) (374) 
12 6 6 0.5 3 Theophylline Franko et al. (1982) (249) 
29 12 5 NA NA Aztreonam Stutman et al. (1984) (375) 
20 15 7 NA NA Sultamicllin Ginsburg  et al. (1985)(376) 
13 24 3-4 NA NA Theophylline Kubo et al. (1986)(261) 
20 NA 10 NA NA Sufentanil Davis et al. (1987)(377) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug Study 
(2005-2014) 
58 10 5 2 10 Desloratadine Gupta et al. (2007)(325) 
13 10 8 NA NA Levetiracetam Glauser et al. (2007)(378) 
24 16 10 0.5 5 Midazolam Peeters et al. (2006)(184) 
107 9 4 1.5 6 Esmolol Tabbutt et al. (2008)(379) 
13 12 8 2 16 Clonidine Almenrader et al.(2009)(380) 
5 11 8 2 16 Carvedilol Leucuta et al. (2010)(381) 
114 14 6 1.5 9 Amodiaquine Tekete et al. (2011)(382) 
31 NA 4 2.5 10 Topotecan Park et al. (2011)(383) 
          NA, not available  
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                                   Figure 6. 4: Number of samples collected from each infants  
during old and new periods (p=0.999) 
 
6.5.3. Blood samples in children  
There were 45 studies in the old decade involving 668 children (Table 
6-7). The total volume of blood collected during the course of a study 
ranged between 2.8-55ml and the number of samples between 4-20 
times. The lowest frequency of blood collection, reported in several 
studies, was 4 times from each patient. However, the highest number 
of blood samples of 20, was collected in a 1985 French study of 
bupivacaine (384). 
There were 69 studies in the new decade involving 4,243 children 
(Tables 6.7 and 6.8). The number of blood samples collected ranged 
between 1-13 times. The lowest volume of blood collected at a single 
time was 0.2ml, in a 2007 multicentre US study of zolpidem 
pharmacokinetics involving 67 children (385). The highest volume of 
blood was 7ml, in a PK study involving 18 children receiving 
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methylphenidate (386). The total volume across all study periods 
varied between 2-77ml. 
Significantly more samples were collected during the old (median=9, 
IQR [7-12]) than new decade (median=8, IQR [5-9.5]) (P=0.006) 
(Figure 6-5). Similarly, there was significant (P=0.014) difference 
between the total volume of blood (median= 24ml, IQR [12-33ml]) 
vs. (median=15ml, IQR [8-18ml]). However, there was no significant 
difference between the volume of blood collected for a single sample 
(P=0.942), (median=2ml, IQR [1-3ml]) vs. (median=2ml, IQR [1.5-
3ml]).  
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                                      Figure 6. 5: Number of samples collected during two periods 
in children (p=0.006) 
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             Table 6. 7: Blood samples in children (1981-1990) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(1981-1990) 
18 20 7 NA NA Amikacin Lanao et al. (1981)(387) 
7 NA 6 NA NA Co-trimoxazole Beachet al. (1981)(388) 
8 19 7 NA NA Netilmicin 
Michalsen & bergan (1981) 
(389) 
28 NA 7 NA NA Cefadroxil Windorfer et al.(1982)(390) 
13 NA 5 NA NA Moxalactam 
Romagnoli  et al. (1982) 
(391) 
8 NA 6 NA NA Theophylline Eriksson et al. (1983)(250) 
25 NA 13 NA NA Valproic acid Otten et al. (1983)(392) 
15 NA 9 NA NA Methotrexate Balis et al. (1983) (393) 
12 NA 8 NA NA Amoxicillin Schaad et al. (1983)(394) 
31 29 6 NA NA Mezlocillin Kramer et al. (1984)(395) 
11 20 18 0.5 9 Lignocaine Ecoffey et al. (1984)(396) 
10 21 8 NA NA Flunitrazepam Iisalo et al. (1984)(397) 
9 32 6 5 30 Prednisone Gatti et al. (1984)(398) 
8 NA 8 NA NA Etoposide Sinkule et al. (1984)(399) 
6 23 20 1 20 Bupivacaine Ecoffey et al. (1985)(384) 
17 NA 13 NA NA Tiazofurin Bails et al. (1985)(400) 
16 19 12 2 24 Midazolam Maurice  et al. (1986)(401) 
29 NA 11 5 55 6-mecaptopurine Lennard  et al. (1986)(402) 
11 NA 8 NA NA Amoxcycillin Schaad et al. (1986)(403) 
20 22 12 3 36 Morphine Attia et al. (1986)(404) 
   NA, not available  
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                       Table 6.7 continued: Blood samples in children (1981-1990) 
Number of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total 
vol of 
blood 
(ml) 
Drug 
Study 
(1981-1990) 
9 19 12 2 24 Midazolam Saint et al.(1986)(405) 
20 NA 12 2 24 Alfentanil Roure  et al.(1987)(406) 
10 NA 8 NA NA Rimantadine Anderson  et al.(1987)(407) 
5 32 17 2 34 Bupivacaine Murat et al.(1987)(408) 
8 21 16 2 32 Alfentanil Meistelman et al.(1987)(409) 
5 NA 8 2 16 Theophylline Principi et al.(1987)(260) 
21 22 12 NA NA Midazolam Salonene et al.(1987)(193) 
7 NA 11 NA NA Theophylline Hill  et al.(1988)(252) 
17 16 12 1 12 Midazolam Mathews et al.(1988)(185) 
9 38 10 NA NA Lithium  Vitiello et al.(1988)(410) 
13 21 6 3 18 Teicoplanin Terragna et al.(1988)(411) 
60 NA 4 1 - 2 4 - 8 Methohexitone Forbes et al.(1989)(412) 
7 NA 8 NA NA Theophylline Scott et al.(1989)(253) 
6 NA 11 NA NA Prednisolone Choonara et al.(1989)(413) 
10 17 11 3 33 Dantrolene Lerman et al.(1989)(414) 
32 17 9 3 27 Midazolam Payne et al.(1989)(192) 
6 15 7 0.4 2.8 Midazolam Kraus et al.(1989)(191) 
16 NA 9 3 24 Fazarabine Heideman et al.(1989)(415) 
12 22 8 0.5 4 Amphotericine B Benson et al.(1989)(416) 
15 NA 12 NA NA Amoxicillin Jones et al.(1990)(417) 
20 34 4 1 4 Esmolol Wiest et al.(1991)(418) 
12 26 18 NA NA Propofol Jones et al.(1990)(419) 
19 23 4 3 12 Deferoxamine Bentur et al.(1990)(420) 
6 15 9 0.5 4.5 Vigabatrin Rey et al.(1990)(421) 
21 NA 9 4 36 Idarubicin Reid et al.(1990)(422) 
       NA, not available        
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Table 6. 8: Blood samples in children (2005-2014) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(2005-2014) 
62 57 8 1.5 12 Paroxetine Findling et al.(2005)(423) 
20 24 9 5 45 Levobupivacain Kokko et al.(2005)(424) 
15 NA 6 NA NA Levocetirizine Cranswick et al 2005.(425) 
25 NA 9 3 27 Montelukast Ramakrishan et al. (2005)(426) 
14 30 12 2.5 30 Levocetirizine Simons  et al.(2005)(427) 
20 27 12 NA NA Amprenavir 
Yogev et al.(2005)(428) 
 
41 34 3 2 6 Levofloxacin Chien et al.(2005)(429) 
35 NA 5 NA NA Tinzaparin kuhle et al.(2005)(430) 
31 NA 8 2 16 Dactinomycin Veal et al.(2005)(431) 
19 NA 10 NA NA Ifosfamide Willits et al.(2005)(432) 
6 NA 6 3 18 Topotecan Freeman  et al.(2006)(433) 
11 36 8 NA NA Hydroxurea Montalembert et al.(2006) (434) 
24 20 7 1 7 Rocuronium Gebicka et al.(2006)(435) 
104 20 3 2 6 Tramadol Garrido (2006)(326) 
17 NA 12 NA NA Quetiapine Findling et al.(2006)(436) 
24 43 9 2 18 Ziprasidone Sallee et al.(2006)(437) 
48 38 2 - 3 3-5 6-15 Valproate Herranz et al.(2006) (438) 
19 NA 13 5 65 Temozolomide Baruchel et al.(2006)(439) 
128 37 3 2 6 Abulterol Maier et al.(2007)(343) 
15 16 10 NA NA Meglumine Cruz et al.(2007)(440) 
5 NA 12 1 12 Treosulfan Glowka et al.(2007)(441) 
79 25 1 NA NA Methotrexate Piard  et al.(2007)(327) 
     NA, not available                
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                       Table 6. 8 Continued: Blood samples in children (2005-2014) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total 
vol of 
blood 
(ml) 
Drug 
Study 
(2005-2014) 
43 25 9 2 18 Paracetamol kulkarni et al.(2007)(442) 
9 43 5 NA NA Risperidone Aman et al.(2007)(443) 
18 28 11 7 77 Methylphenidate Quinn et al.(2007)(386) 
71 21 7 4 28 Mefloquine Ramharter et al.(2007)(444) 
49 33 9 2 18 
Sodium ferric 
gluconate 
Warady et al.(2007)(445) 
21 NA 7 NA NA Levtiracetam Fountain et al.(2007)(446) 
67 35 10 0.2 2 Zolpidem Blumer et al.(2007)(385) 
26 11 12 0.75 9 Lorazepam Muchohi et al.(2008)(447) 
77 17 2 NA NA 
Fenoldopam 
mesylate 
Hammer et al.(2008)(448) 
30 32 7 2.5 17.5 
Eslicarbazepine 
Acetate 
Almeida et al.(2008)(449) 
30 41 10 1.5 15 Gadoversetamide Wible et al.(2009)(450) 
22 46 11 0.5 5.5 Doxorubicin Thompson et al.(2009)(451) 
44 12 5 1 5 Rifampin Schaaf et al.(2009)(452) 
37 NA 13 NA NA Growth hormone Peter et al.(2009)(453) 
5 13 5 3 15 Midazolam Roberts et al.(2009)(187) 
690 NA 5 3 15 Amodiaquine Mwesigwa et al.(2010)(322) 
52 16 8 NA NA 
Recombinant 
factor VIII 
Bjorkman et al.(2010)(454) 
16 NA 11 3 33 Cediranib Fox et al.(2010)(455) 
39 43 9 NA NA Lithium  Findling et al.(2010)(456) 
15 15 9 2 18 Micafungin Metha et al.(2010)(457) 
41 20 7 NA NA Efavirenz Fillekes et al.(2011)(458) 
899 14 5 1.5 7.5 Lumefantrine Djimde et al.(2011)(459) 
                         NA, not available  
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                          Table 6. 8 Continued: Blood samples in children (2005-2014)                        
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total 
vol of 
blood 
(ml) 
Drug 
Study 
(2005-2014) 
40 NA 7 1 – 2 7 - 14 Voriconazole Driscollet al.(2011)(460) 
20 NA 5 NA NA Isoniazide Thee et al.(2011)(461) 
47 48 8 NA NA Tenofovir king et al.(2011)(462) 
87 NA 7 2 - 3 14 - 21 Hydroxyurea Ware et al.(2011)(463) 
19 13 7 1.5 10.5 Lopinavir Kasirye et al.( 2011)(464) 
53 46 9 NA NA Clofarabine Bonate et al.(2011)(328) 
53 22* 2-7 3 6 - 21 Naproxen Valitalo et al.(2012)(330) 
31 49 12 1 12 Rizatriptan Fraser et al.(2012)(465) 
34 18 5 3 15 Artemisinin Salman et al.(2012)(329) 
46 18 7 2.5 17.5 Napthoquine Batty et al.(2012)(466) 
25 34 8 1 8 Roxatidine Nakamura  et al.(2012)(467) 
21 54 4 2 8 Fesoterodine Malhotra et al.(2012)(468) 
58 36 5 3 15 Tigecycline Purdy et al.(2012)(469) 
236 18 10 NA NA Piperaquine Tarning et al.(2012)(354) 
15 NA 9 1 9 Sulphadoxine Ademisoye et al.(2012)(470) 
27 NA 7 1.5 10.5 Beclomethasine Chawes et al.(2013)(471) 
40 35 8 0.5 - 1 4 - 8 Sirolimus Goyal et al.(2013)(472) 
70 11 4 1.5 6 Artesunate Hendriksen et al.(2013)(331) 
23 11 6 1.8 11 
Tranexamic  
acid 
Goobie  et al.(2013)(332) 
23 38 9 5 45 Aerosol particle 
Bonnelykke  et al.(2013) 
(473) 
23 50 3 NA NA Lyophilisate Bruyne  et al.(2014)(474) 
28 16 8 2.5 20 Primaquine Moore  et al.(2014)(333) 
22 NA 6 NA NA Ofloxacin Thee et al.(2014)(475) 
123 NA 11 NA NA Azithromycin Zhao et al.(2014)(334) 
16 36 4 1.2 4.8 
Liposomal 
cytarabine 
Peyrl et al.(2014)(476) 
            *Median, NA, not available 
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6.5.4. Blood samples in adolescents  
There were 8 studies involving 70 adolescents (Table 6.9). Four of 
these studies were from the new and 4 from old decade. There was 
no difference in the median number of blood samples collected 
(median: 9, IQR [5-11] vs. old (median: 7.5, IQR [5-8.7] 
(p=0.571)(Figure 6.6). The lowest frequency of blood sampling in the 
new decade was four, reported in a study conducted in Greece (477), 
and the largest was 11 times (478). Most studies did not provide 
details of volume of blood collected.  
          Table 6. 9: Blood samples in adolescents 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol of 
blood (ml) 
Drug Study 
(1981-1990) 
9 NA 5 5 - 7 25 - 35 Metoclopramide Bateman  et al.(1983) 
(479) 
3 Na 8 Na Na Hydrocortisone Iwasski (1987)(321) 
5 48 7 NA NA Aminosalicylic 
acid 
Tolia et al.(1989)(480) 
8 34 9 NA NA Theophylline Agbaba et 
al.(1990)(481) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol of 
blood (ml) 
Drug Study 
(2005-2014) 
24 42 10 NA NA Agalsidasealfa Ries et al. (2007)(482) 
10 41 4 NA NA Voriconazole Markantonis et al. 
(2011) (477) 
5 53 8 NA NA Ketorolac Mohammed et al.(2013) 
(483) 
6 NA 11 1 11 Cisatracurium Gao et al.(2014)(478) 
       NA, not available 
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                                      Figure 6. 6: Number of samples collected during two periods 
in adolescents (P=0.571) 
 
 
6.5.5 Blood samples in mixed age groups 
Some studies involved patients across the whole paediatric age 
spectrum. There were a total of 72 studies, 61 of these were from 
new and 11 from old decade, involving 3,503 and 280 patients 
respectively (Tables 6.10 and 6.11). The median number of blood 
samples was similar, 7 in the new decade, IQR [6-9], compared to 8, 
IQR [6-11] (p=0.384) (Figure 6.7). The range of samples collected in 
the new decade was 1-15 samples compared to 2 -18 samples.  
At each time point a median volume of 1ml, IQR [0.5-2ml] compared 
to 2ml in the older decade, IQR [1-3ml], was collected, there was no 
significant difference (p=0.234). During the course of study, there 
was a trend towards collection of a larger volume of blood in the old 
decade (median=16.5ml IQR [11-25ml]) than the new 
(median=9.5ml, IQR [3-15ml]) (p=0.062). 
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              Table 6. 10: Blood samples in mixed age groups (1981-1990) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood (ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
 (1981-1990) 
46 NA 9 2 
 
18 
Ceforanide 
Dajani  et al.(1982) 
(484) 
15 25 6 NA NA Piperacillin 
Wilson et al.(1982) 
(485) 
30 NA 8 NA NA Ceftriaxone 
Steele et al.(1983) 
(486) 
16 23 18 0.5- 1.5 9 - 27 Thiopental 
Sorbo et al.(1984) 
(487) 
13 12 11 0.7 8 Cefotaxime Trang et al.(1985)(488) 
50 20 5 3 15 Methohexitone 
Quaynor  et al. (1985) 
(489) 
27 19 8 1.5 12 Bupivacaine 
Rothstein et al.(1986) 
(490) 
10 14 2 NA NA 
Amphotericin 
B 
Starke et al.(1987) 
(491) 
40 NA 13 NA NA Trimetrexate Bails et al.(1987)(492) 
18 12.3 7 NA NA Acyclovir 
Sullender et al.(1987) 
(493) 
15 NA 8 2-3 16 - 24 Idarubicin Pui et al.(1988)(494) 
                       NA, not available 
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              Table 6. 11: Blood samples in mixed age groups (2005-2014) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
 (2005-2014) 
105 28 4 0.1 0.4 Abacavir Jullien et al.(2005)(335) 
76 NA 8 0.3 - 0.4 2.4 – 3.2 Sotalol Laer et al.(2005)(336) 
25 NA 5 3 15 Anidulafungin Benjamin et al.(2006)(495) 
99 17 2 NA NA Meropenem Du et al.(2006)(337) 
73 52 4 0.5 2 Amlodipine Flynn  et al.(2006(338) 
19 20* 8 NA NA Lopinavir Lee et al.(2006)(496) 
35 19 12 0.5 6 Propofol ShanGuanet al.(2006)(497) 
59 19 15 5 75 Melphalan Nath et al.(2007)(339) 
34 8 4 0.5 2 Gentamicin Seaton et al.(2007)(340) 
46 NA 9 0.7 - 1.5 6.3 - 13.5 Lisinpril Hogg et al.(2007)(498) 
72 36 9 NA NA Micafungin Hope et al.(2007)(341) 
15 NA 9 2 18 Tanespimycin Bagatell et al.(2007)(499) 
16 NA 8 2 16 Temozolomide Horton et al.(2007)(500) 
33 28 7 2 14 Itraconazole 
Abdel-Rahman et al.(2007) 
(501) 
24 23 2-8 NA NA Busulfan Booth et al.(2007)(344) 
31 NA 10 0.1 1 Pemetrexed Malempati et al.(2007)(502) 
18 17* 7 NA NA Busulfan Hempel et al.(2007)(503) 
53 NA 6 NA NA Lonafarnib kieran et al.(2007)(504) 
162 22 10 1 10 Ciclosporin Fanta et al.(2007)(342) 
50 28 7 NA NA Efavirenz Fletcher et al.( 2007)(505) 
64 30 7 2 14 Nevirapine Kabamba et al.( 2008)(506) 
21 NA 4 3 12 Bevacizumab Bender et al. (2008) (507) 
        *Median, NA, not available   
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                       Table 6-11 Continued: Blood samples in mixed age groups (2005-2014) 
Number 
of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood 
(ml) 
Total 
vol of 
blood 
(ml) 
Drug 
Study 
 (2005-2014) 
33 30 8 NA NA Actinomycin-D 
Mondick et al.(2008)   
(345) 
217 18 1 NA NA Tebipenem 
Sato et al.(2008)       
(349) 
15 NA 6 NA NA Flomoxef 
Masuda  et al.(2008) 
(508) 
33 11 13 0.5 6.5 Midazolam 
Muchohi et al.(2008)  
(188) 
25 46 10 2 20 Roflumilast 
Neville et al.(2008)    
(509) 
30 9 8 0.1 0.8 Rifampicin Ren et al.(2008)(510) 
97 NA 10 5 50 Temozolomide 
Meany et al.(2009)     
(511) 
50 30 7 NA NA Tacrolimus 
Zhao et al.(2009)      
(346) 
50 NA 7 2 14 Lopinavir 
Rakhmanina et al. (2009) 
(347) 
22 34 6 0.5 3 Valganciclovir zhao et al.(2009)(348) 
24 56 3 NA NA Montelukast 
Friesen et al.(2009)     
(512) 
22 8 4 1.2 4.8 Nevirapine Oudijk et al.(2009)(513) 
20 NA 10 0.5 4.5 Pantoprazole 
Pettersen et al.(2009) 
(79) 
189 NA 10 1 10 
Tamsulosin  
hydrochloride 
Tsuda et al.(2010)    
(350) 
71 26 4 5 20 Busulfan 
Gaziev et al.(2010)   
(514) 
11 NA 7 NA NA Valproate 
Visudtibhan  et al.(2011) 
(515) 
15 49 7 3 21 Cyclophosphamide 
Chinnaswamy  et al. 
(2011) (516) 
165 39 7 NA NA Lopinavir 
Rakhmanina et al.(2011) 
(517) 
31 NA 6 0.1 0.6 Ethionamide Thee et al.(2011) (518) 
50 15 2 - 4 NA NA Meropenem Ohata et al.(2011)(351) 
38 14 6 0.75 4.5 Azithromycim Liu et al.(2011)(519) 
35 7 9 1 9 Pentobarbital Zuppa et al.(2011)(520) 
                      NA, not available 
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                       Table 6. 11 Continued: Blood samples in mixed age groups (2005-2014) 
Number of 
patients 
Mean 
weight 
(kg) 
No. of 
samples 
Vol of 
blood (ml) 
Total vol 
of blood 
(ml) 
Drug 
Study 
(2005-2014) 
195 NA 7 NA NA Atazanavir 
Kiser et al.(2011) 
(521) 
94 NA 5 NA NA Busulfan 
Trame et al.(2011) 
(352) 
23 NA 8 NA NA Sunitinib 
DuBois et al.(2012) 
(522) 
38 NA 7 NA NA Plitidepsin 
Geoerger et al.(2012) 
(523) 
 
50 
 
37 
14 
 
0.6 8.4 Esomeprazole 
Sandstorm et al. 
(2012)(524) 
24 71 7 1 7 Olmesartan 
Wells et al.(2012) 
(525) 
48 NA 5 2 10 Lorazepam 
Chamberlain et al. 
(2012) (526) 
67 15* 2-6 NA NA Busulfan 
Michel et al. (2012) 
(353) 
47 NA 6 NA NA Cixutumumab 
Malempati et al. 
(2012) (527) 
237 11 3 1 3 Glycopeptide Ito et al.(2013)(528) 
41 36 9 2 18 Doxylamine 
Balan et 
al.(2013)(529) 
126 31 10 0.2 2 Raltegravir 
Nachman et 
al.(2013)(530) 
28 36 8 1 8 Telbivudine 
Stein et 
al.(2013)(531) 
38 12 15 NA NA Tacrolimus Min et al.(2013)(532) 
36 63 10 1 10 Aliskiren 
Sullivan et al. 
(2013)(533) 
6 24 7 NA NA Busulfan 
Okamoto et al. 
(2014)(534) 
32 20 11 2.5 27.5 Famotidine 
Madani et al. 
(2014)(535) 
              *Median, NA, not available             
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                       Figure 6. 7: Number of samples collected during two periods 
in mixed age groups (p=0.384) 
 
 
6.5.6. Summary of all paediatric studies 
There were 234 studies involving 9,806 patients, with more studies 
involving children than any other age groups. The median number of 
blood samples collected over all age groups was significantly higher in 
old decade (median: 8 [IQR: 6-11] compared to 7 [IQR: 5-
9](p=0.013) (Table 6.12  and Figure 6.7). There were no significant 
differences in blood volume collected at a single time point or overall 
between the periods. The total volume of blood samples was 
significantly higher in old decade (median: 16 [IQR: 6-27]) than new 
(median:10 [IQR: 5.6-17.5]). 
Thirty five of the new studies used population PK method. There was 
significant difference in the frequency of blood of sampling between 
population PK studies (median 6, IQR [4-9]) and non-population PK 
studies (median 8, IQR [6-10] (p=0.007) (Figure 6.2).  
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            Table 6. 12: Summary of all paediatric studies 
Number of blood samples 
Age group  
(No of studies) 
Old studies 
Median [IQR] 
 
Range  
New studies 
Median [IQR] 
 
Range 
     
P value 
Neonates (23) 7 [5-8]  3-10 4.5 [3-7]  2-9 0.054 
Infants  (17) 7 [5.5-7.5]  3-10 7 [4-8]  4-10 0.999 
Children (114) 9 [7-12] 4-20 8 [5-9.5]  1-13 0.006 
Adolescents (8) 7.5 [5-9]  5-9 9 [5-11] 4-11 0.571 
Mixed age (72) 8 [6-11] 2-18 7 [6-9]  1-15 0.384 
Total 8 [6-11] 2-20 7 [5-9] 1-15 0.013 
Volume of blood samples 
Neonates  (23) 0.7 [0.2-1]  0.2-2 0.3 [0.2-0.8]  0.15-1.4 0.283 
Infants  (17) NA NA 2 [1.5-2] 0.5-2.5 NA 
Children (114) 2 [1-3] 0.4-5 2 [1.5-3] 0.2-7 0.942 
Adolescents (8) NA NA NA NA NA 
Mixed age  (72) 1.7 [1-3] 0.7-3 1 [0.5-2] 0.1-5 0.234 
Total 2 [0.7-3] 0.2-5 1.5 [1-2.5] 0.1-7 0.889                                  
Total volume of blood samples 
Neonates (23) 4 [1.5-7] 1.4-16 2 [0.8-4] 0.6-7 0.117 
Infants (17) NA NA 10 [6-16]  5-16 NA 
Children (114) 24 [12-33] 2.8-55 15 [8-18] 2-77 0.014 
Adolescents (8) NA NA NA NA NA 
Mixed age (72) 16.5 [11-25]  8-27 9.5 [3-15] 0.4-75 0.062 
Total 16 [6-27] 1.4-55 10 [5.6-17.5] 0.4-77 0.025 
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                                 Figure 6. 8: Number of blood samples collected in all paediatric 
age groups during two periods (p=0.013) 
 
6.6. Discussion  
We have performed a systematic review to determine the 
invasiveness of pharmacokinetic studies in children over two separate 
decades.  
Both the number of blood samples and their total volume were 
significantly greater in the old decade than new. The dangers of 
excessive blood sampling include the increased risk of infection, 
bruising, pain and higher rates of blood transfusion (122). A 
correlation between the blood volume sampled and transfusion rate 
has already been shown in neonates (536). 
Lower sampling frequency and volume in recent studies may be due 
to the development of new techniques which minimise the 
requirement of blood for PK studies. This study showed that fewer 
blood samples are utilised in population PK studies than non-
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population. Population PK studies have been discussed in chapter 
one. They involve PK parameter estimation by collecting samples 
from a number of subjects taking different doses over different 
periods of time (104). There are currently no guidelines on the 
frequency of blood sampling in children.  For population PK studies, it 
has been suggested that no more than 6 samples need to be 
collected (537) and for neonates, 3 samples are thought to be 
optimal for the estimation of PK parameters (538). In this review the 
frequency of blood sampling in neonates was between 2-10. Despite 
the recommendations for less frequent blood sampling, Reed showed 
in his study that the greater the number of blood samples taken, the 
better the estimation of PK parameters (127). This conclusion was 
reached after comparing PK parameters obtained from 5 and 12 
sampling time points (127).  Therefore, this accuracy may need to be 
balanced against the need to limit the number of samples depending 
on the patient’s age and disease.  
The available guidelines on the volume of blood samples for PK 
studies in children are highly varied with most recommendations 
suggesting a range between 1 and 5% of TBV within 24 hours and 
not more than 10% of TBV within 8 weeks (125)(Table 1.4).  
Children’s TBV can be estimated from their weight (70 ml/kg), 
preterm neonates 90 ml/kg and term neonates 80 ml/kg. This 
suggests that a three kilogram neonate will have a TBV of about 240 
ml. We found the largest total blood volume drawn from preterm 
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neonates to be 4ml, in a PK study of cefoperazone (356). The weights 
of neonates in this study were not reported; hence it could not be 
exactly determined whether the maximum allowable total blood 
volume draw based on EMA recommendations for total volume of 
blood was exceeded. It would have represented approximately 1.5% 
of the TBV of a 3kg term baby, which is within the recommended 
limits (123). In another study of midazolam in term neonates, a 
sample volume of 0.5 ml was taken on nine occasions, total volume 
4.5ml in 24 hours (182). Therefore each individual sample and total 
volume did not exceed 1% (2.4ml single draw) and 3% (7.2ml total) 
per EMA guideline for a 3kg baby.  
The maximum recommended allowable blood draw is a percentage of 
blood volume per body weight. It is often difficult to ascertain 
whether the studies involving children and adolescents exceeded 
these recommendations, as they may have wide age ranges and only 
quote a mean or median weight. Two Canadian studies involved the 
collection of 77 and 65 ml respectively over a 24 hour period in 
children (386, 439). The maximum recommended volumes would 
have been exceeded in the lightest children recruited in one of these 
studies (386). The second study of temozolomide, however did not 
specify the patient’s weight. It is therefore very important to look at 
the whole age and weight ranges of children taking part in PK studies, 
when deciding the blood volumes to be collected. Protocols may need 
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to have different regimens for different ages/weights if the population 
studied is wide. 
Blood samples were collected mainly from a catheter or by venous 
sampling. Catheter sampling is the most convenient method when 
repeated blood collection is required and minimises the distress of 
repeated blood sampling.  However, a catheter requires nursing care 
and monitoring, also it may not always continue to sample for the 
whole duration of the study (539, 540). The other sampling method 
identified was arterial sampling. Unlike venous sampling, it requires 
greater expertise and may result in bleeding. Venous sampling is also 
generally preferred to heel pricks in neonates, because it is less 
painful and more likely to provide the required volume (120).  
In conclusion, definitive evidence guidelines should be developed 
regarding the maximum volume and number of samples that should 
be collected in children of various ages. There is presently no 
guideline on frequency of blood sampling and the guidelines on 
volume are variable.  More attention needs to be given to reducing 
both the number of blood samples and the total volume of blood 
collected in an individual patient, by using micro analytical techniques 
and population PK methods. Consideration should be given by 
researchers to all ages/weights of potential children within the study, 
as to whether the single volume or total volume of blood exceeds 
current guidance. 
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 CHAPTER SEVEN                                                                              
GENERAL DISCUSSION AND CONCLUSION 
7.1. General discussion  
From the preceding chapters it is clear that age is a major 
determinant of midazolam, theophylline and morphine clearance in 
paediatric patients. Critical illness was a significant predictor of 
midazolam and theophylline clearance, but not morphine. This effect, 
however, was not observed after adjusting for age and weight. There 
were, however, very few midazolam, morphine and theophylline PK 
studies conducted in non-critically ill subjects.   
It was also shown that significantly fewer blood samples were being 
utilised in population PK studies than non-population PK studies in 
children. Population PK methods are increasingly being utilised in 
children in the last 10 years and new studies are less invasive in 
paediatrics. 
7.1.1. Age and variability of drug clearance 
The metabolism and consequently clearance of midazolam, 
theophylline and morphine is low at birth before progressively rising 
to adult levels during infancy (28, 34, 57).  The ontogeny of the 
different metabolizing enzymes have been described in the 
introductory chapter and further discussed in the individual chapters. 
Drug clearance is generally more variable during neonatal life than in 
late childhood. Hattis et al. (2003) evaluated the PK characteristics of 
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45 different drugs from published literature and compared PK 
parameters between different age groups. They reported a higher 
inter-individual variability in drug half-life and clearance in the first 
week of life than late neonatal period (2-8 weeks). They also reported 
lower variability in children and adolescents (541). Their findings 
reflect the impact of the rapid changes to drug elimination systems 
that occur during the neonatal period. Differences in drug 
pharmacokinetics between children and adults are mainly due to 
physiological differences and also as a result of differences in the 
maturity of the enzyme systems and clearance mechanisms. 
Variability in PK characteristics makes it necessary to titrate the drug 
dose according to individual requirements and also where applicable 
monitor therapeutic drug concentration.   
In this thesis, midazolam clearance in neonates was found to be 
much lower in neonates than children and adolescents.  Clearance 
ranged between 0.78 and 1.7 ml/min/kg in preterm neonates and 
between 1.17 and 3.5 ml/min/kg in term neonates. In children 
however, midazolam clearance was higher, ranging between 1.1and 
15 ml/min/kg.  This trend has also been  previously reported in a 
previous study (198). However, a study by de Wildt et al. (2001) 
reported no significant relationship between age (gestational, 
postnatal, or postconceptional) and midazolam clearance (542). 
Higher clearance levels in children than neonates are reflective of the 
developmental changes in CYP3A4 activity, which has been shown to 
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increase with postnatal age (28).  During the immediate postnatal 
period, there is a shift from CYP3A7 predominance to a progressive 
rise in CYP3A4 activity. Thus the contribution of CYP3A7 to 
midazolam metabolism becomes marginal (28, 542). These highly 
dynamic changes in CYP activity in early neonatal life may therefore 
contribute to the higher CV observed in preterm neonates than 
children.  
A morphine clearance ranging from up to 10ml/kg/min in preterm 
neonates to 52 ml/kg/min in children was found. However, evidence 
from limited data showed no significant difference in CV of morphine 
clearance between neonates and infants. There was insufficient data 
for comparison of CV between children and adolescents. Morphine is 
metabolised by glucuronidation and complete UGT expression occurs 
over the first six months of life (43). During this period, especially the 
neonatal period, rapid maturation may cause variable expression of 
UGT (5). Morphine is also metabolised by sulphation which is 
decreased after neonatal period (543).  
In neonates, theophylline clearance varied between 0.2 and 0.9 
ml/min/kg; while clearance ranging between 1 and 2 ml/min/kg was 
reported in children. This age related increase in theophylline 
clearance has been similarly described by Tanaka (1998). In our 
findings, the CV of theophylline was not significantly different 
between neonates and children. However, Milsap et al.(1994) 
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reported a significant inter-individual variability of theophylline 
clearance in a review of several clinical studies involving premature 
neonates, full-term neonates, and infants (544). Theophylline is 
metabolised in the liver by CYP1A and CYP1A2. CYP1A activity level 
increases during the first three months, which may result in 
variability of clearance (249). 
7.1.2. Critical illness and variability of drug clearance 
Although no significant difference in CV of clearance was observed for 
midazolam, theophylline or morphine, critically ill subjects showed 
comparatively lower clearance than non-critically ill. We were unable 
to perform a subgroup analysis for the different age groups due to 
insufficient number of studies. For all of the drugs, very few studies 
were conducted in non-critically ill subjects. Critical illness alters PK in 
different ways. Some of this has been discussed in the different 
chapters for the respective drugs. The capacity of the liver to 
metabolise drugs and renal function are often compromised during 
critical illness.  
Stress and infection, which are commonly associated with critical 
illness cause a spike in inflammatory mediators, such as IL-6 and 
nitric oxide (NO), causing changes in drug clearance (545). The 
expression of these mediators has been shown to downregulate the 
expression of cytochrome P450 enzymes in the liver (546) following a 
decline in mRNA transcription and protein translation (547). Children 
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with severe sepsis are reported to have as much as 2 fold reduction 
in drug clearance and up to four fold decline when they have multiple 
organ failure (548). A study by Haas et al. (2003) showed a 
statistically significant decline in the expression of CYP3A4 in 
immediate post-operative patients compared with baseline levels. The 
CYP3A4 level in their study was negatively correlated with IL-6 
concentration (545). An inverse relationship between clearance and 
IL-6 and NO has also been reported in children (548). 
Reduced organ perfusion also occurs in severely ill patients. Reduced 
liver perfusion and subsequent oxygen deprivation can result in 
reduction in enzyme activity in the liver cells (549). Renal hypo 
perfusion can cause renal failure leading to poor drug clearance (12). 
Mechanical ventilation is an important part of the management of 
severely ill children. This can reduce cardiac output with eventual 
liver and kidney damage (550). 
7.2. Implication of this research  
 Age has been shown to be the most important determinant of PK 
studies in children. Age appropriate dosing is an important aspect of 
treatment in paediatrics. For several drugs, including those evaluated 
in this thesis, there are dosing guidelines specifically for neonates, 
children and adolescents. It is however unclear how rapidly age 
related changes in PK occur during childhood. Therefore, more 
studies evaluating the effect of age on the variability of PK 
168 
 
parameters are required. Furthermore, there were very few studies 
comparing of the effect of critical illness on clearance. Critical illness 
is a very heterogeneous classification and it is important that future 
research should focus on how specific illnesses and their affects 
influence drug clearance.  Understanding the relationship between 
critical illness and drug pharmacokinetics can help clinicians to 
optimise treatment in these children.  
One of the reasons sighted for the very few PK studies in children is 
the ethics of conducting such studies in this age group. It is therefore 
important to adopt less invasive PK techniques for future research in 
children. Raising awareness on the use of available minimally invasive 
techniques is important. Evidence based guidance is needed for the 
determination of the ideal frequency of blood samples for PK studies 
in different age groups. Finally, a standardisation of the maximum 
volume of blood samples collected in children of various ages is 
required. 
7.3. Limitations 
These systematic reviews are limited by the inconsistent reporting 
styles of the authors. While some provided the range and the SD 
which are measures of variability, some provided neither. Therefore, 
valuable data was lost because such results could not be included for 
interpretation. Additionally, some studies did not report the results 
for different paediatric age groups. There were very few PK studies 
169 
 
conducted in non-critically ill subjects. Therefore, comparison 
between critically ill and non-critically ill patients was impossible.  A 
further limitation is the inability to determine the CV of the drug 
clearance in some studies because the individual patient data were 
not provided. Hence, comparison of the CV between different age 
groups was inadequate, because of small datasets. Furthermore, 
there were extensive variation in the number of participants in each 
PK studies and some of the studies were old, especially theophylline 
PK studies. Predominantly old studies made it impossible to 
determine the effect of population PK methods on clearance 
determination.  
When examining invasiveness, this was limited by the lack of data on 
weight of patients. Therefore compliance of studies with current 
guidelines could not be determined. Furthermore, an accurate 
comparison within the paediatric age group is difficult because of the 
wide age range in the ICH age paediatric catagory. Finally some 
studies did not provide information on volume of blood sampled and 
methods used. 
7.4. Final conclusion  
Age is a major risk factor for inter-individual variation of PK 
parameters of midazolam, theophylline and morphine. It is also an 
important predictor of drug clearance in children. Therefore, age 
appropriate dosing of these drugs is important. Furthermore, 
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significantly less numbers and volume of blood samples are utilised in 
new PK studies than old studies. This trend is particularly influenced 
by the increasing utilisation recently of population PK studies. 
Population PK method should be encouraged to minimise invasiveness 
of PK studies. New methodologies for reducing sample volumes and 
frequency should be considered for all studies.  
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